

# APPENDIX

## 2012 Reporting Experience Including Trends (2009-2013)

---

Physician Quality Reporting System and  
Electronic Prescribing (eRx) Incentive Program

## APPENDIX TABLE OF CONTENTS

Data and methods.....	5
Data Sources .....	5
Unit of Analysis .....	5
Outcomes .....	6
Key Variables.....	13
Data Analysis.....	14
2012 Physician Quality reporting system appendix tables .....	15
2012 eRx Incentive Program Appendix Tables .....	217
Abbreviations .....	237

## LIST OF TABLES

Table A1. List of Individual Measure Numbers and Descriptions for the Physician Quality Reporting System (2012).....	15
Table A2. Distribution of Incentive Amounts by Specialty for the Physician Quality Reporting System, excluding MOCP (2012).....	23
Table A3. Potential Incentives and Participation Information for the Physician Quality Reporting System, excluding MOCP (2012).....	26
Table A4. Eligible Professional Characteristics for the Physician Quality Reporting System (2012).....	28
Table A5. Eligible Professional Characteristics (2012) for the Physician Quality Reporting System.....	29
Table A6. Number of Eligible Professionals by Specialty for the Physician Quality Reporting System (2009 to 2012).....	31
Table A7. Participation Information by Submission Mechanism/Option for the Physician Quality Reporting System (2009 to 2012).....	33
Table A8. Eligible Professionals who Participated in the Physician Quality Reporting System, by Specialty (2009 to 2012).....	34
Table A9. Eligible Professionals who Participated by Reporting Individual Measures through the Claims Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	37
Table A10. Eligible Professionals who Participated by Reporting Measures Groups through the Claims Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	40
Table A11. Eligible Professionals who Participated in Individual Measures through the Registry Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	43
Table A12. Eligible Professionals who Participated in the Measures Groups through the Registry Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	46
Table A13. Eligible Professionals who Participated through the EHR Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2010 to 2012) .....	49
Table A14. Eligible Professionals who Participated in the Physician Quality Reporting System by the Number of Medicare Beneficiaries, by Specialty (2012) .....	52
Table A15. Eligible Professionals, Participation, and Incentive Information for the Physician Quality Reporting System, by State (2012).....	55
Table A16. Submission Information for Individual Measures submitted through the Claims Mechanism for the Physician Quality Reporting System (2012) .....	57
Table A17. Individual Measures Submitted through the Claims Mechanism for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Diagnosis Code (2012).....	72
Table A18. Individual Measures Submitted through the Claims Mechanism for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Procedure Code (2012).....	73
Table A19. Individual Measures Submitted through the Claims Mechanism for the Physician Quality Reporting System Where More than 20% of Reported Instances were for a Patient Without the Necessary Age Range (2012) .....	74

Table A20. Incentive Eligibility Information for the Physician Quality Reporting System, by Reporting Option/Mechanism (2009 to 2012).....	75
Table A21. Eligible Professionals who Received an Incentive from Individual Measures through the Claims Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	76
Table A22. Eligible Professionals who Received an Incentive from Measures Groups through the Claims Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	79
Table A23. Eligible Professionals who Received an Incentive from Individual Measures through the Registry Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	82
Table A24. Eligible Professionals who Received an Incentive from Measures Groups through the Registry Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).....	85
Table A25. Eligible Professionals who Received an Incentive from Individual Measures through the EHR Mechanism for the Physician Quality Reporting System, by Specialty (2010 to 2012).....	88
Table A26. Eligible Professional Eligibility and Participation Information by Individual Measures for the Physician Quality Reporting System (2009 to 2012) .....	91
Table A27. Reporting and Performance Information by Individual Measure for the Physician Quality Reporting System (2009 to 2012).....	117
Table A28. Eligible Professional Individual Measure Reporting Consistency Across Program Years for the Physician Quality Reporting System (2009 to 2012) .....	142
Table A29. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Four Years for the Physician Quality Reporting System (2009 to 2012).....	161
Table A30. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Three Years for the Physician Quality Reporting System (2010 to 2012).....	172
Table A31. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Two Years for the Physician Quality Reporting System (2011 to 2012).....	183
Table A32. Percent of Eligible Professionals who Participated by Individual Measures for the Physician Quality Reporting System and had at Least a 90% Performance Rate (2012).....	195
Table A33. Performance Information for Measures Reported by Practices Participating in the Small Group Practice Reporting Option for the Physician Quality Reporting System (2012).....	205
Table A34. Performance Information for Measures Reported by Practices Participating in the Large Group Practice Reporting Option for the Physician Quality Reporting System (2012).....	209
Table A35. Performance Information for Measures Reported by ACOs Reporting Under the Medicare Shared Savings Program and Pioneer ACO Model (2012) .....	213
Table A36. Physician Quality Reporting System Incentive Eligibility and Incentive Payments for Group Reporting, Including ACOs Reporting Under the Medicare Shared Savings Program and Pioneer ACO Model (2012) .....	216
Table A37. Distribution of Incentive Amounts for the eRx Incentive Program, by Specialty (2012).....	217

Table A38. Potential Incentives and Participation Information for the eRx Incentive Program, by Specialty (2012).....	220
Table A39. Eligible Professional Information for the eRx Incentive Program, by Specialty (2011 to 2012).....	222
Table A40. Eligible Professionals who Qualified for an Incentive from the eRx Incentive Program, by Specialty (2011 to 2012).....	225
Table A41. Eligible Professional Characteristics for the eRx Incentive Program (2012).....	227
Table A42. Eligible Professional Information for the eRx Incentive Program, by State (2012)	229
Table A43. Eligible Professionals who Successfully met Reporting Criteria but did not Receive an Incentive Because they did not have at Least 10% of their MPFS Charges from Instances for the eRx Measure (i.e., Incentive Eligibility Threshold) for the eRx Incentive Program (2011 to 2012).....	231
Table A44. Eligible Professionals Subject to the 2012 and 2013 eRx Payment Adjustment, by Specialty .....	234
Table A45. GPRO Incentive Eligibility and Incentive Payments for the eRx Incentive Program, by GPRO Size (2012) .....	236
Table A46. Abbreviations.....	237

## DATA AND METHODS

This section describes the data and methods used in the “2012 Physician Quality Reporting System and Electronic Prescribing (eRx) Incentive Program Reporting Experience Including Trends (2007-2013)” report.

### Data Sources

The report used multiple sources of data: (1) Medicare Part B claims data, (2) data submitted by qualified registries, (3) data submitted by qualified Electronic Health Records (EHR) vendors, and (4) Physician Quality Reporting System (PQRS) measure data submitted through an online web interface by practices that were approved to participate in the Physician Quality Reporting System Group Practice Reporting Option and by eligible professionals participating in Medicare Accountable Care Organizations (ACOs) through the Medicare Shared Savings Program and the Pioneer ACO Model. In addition, the report uses Maintenance of Certification Program (MOCP) data reported by participating specialty boards for the 2012 program year. Data on the 2013 eRx payment adjustment were from the eRx Payment Adjustment File dated September 9, 2013.

Claims data encompassed services within the respective program years and must have been processed by the last Friday in February of the following year to be included in analyses. For example, the analysis of the 2012 program year—for both the Physician Quality Reporting System and the eRx Incentive Program—encompassed claims with service dates from January 1, 2012 through December 31, 2012 and processed no later than February 22, 2013. To provide preliminary information for the 2013 program year, the available information encompassed only service dates from January 1, 2013 through June 28, 2013 from claims processed no later than June 28, 2013. Similar to claims data, data collected from the registry and EHR mechanisms as well as the GPRO web interface (used for the Physician Quality Reporting System GPRO and for eligible professionals participating in Medicare ACOs for purposes of Physician Quality Reporting System reporting through the Medicare Shared Savings Program and the Pioneer ACO Model) aligns with the program year and must have been received by CMS by the established deadline for the reporting option. No preliminary information was available for the 2013 program year from the registry and EHR mechanisms, the group reporting option, or ACO reporting under the Medicare Shared Savings Program and Pioneer ACO models; that is, preliminary information for the 2013 program year included claims information only (individual measures and measures groups).

Information on physician specialty and location was obtained from the National Plan and Provider Enumeration System (NPPES), which is publicly available data and downloadable from the NPPES website.<sup>1</sup>

### Unit of Analysis

The most common unit of analysis for the Physician Quality Reporting System and eRx Incentive Program was the individual eligible professional. The National Provider Identifier number (NPI) within a billing unit (i.e., the Taxpayer Identification Number [TIN]) defined an

---

<sup>1</sup> [http://nppes.viva-it.com/NPI\\_Files.html](http://nppes.viva-it.com/NPI_Files.html)

eligible professional; the NPI was the *performing* NPI.<sup>2</sup> All analyses regarding individual eligibility, participation, and incentive eligibility were performed at the NPI level within a TIN (referred to as TIN/NPI). Consequently, a single eligible professional could be counted more than once if he/she worked for multiple practices (i.e., single NPI and more than one TIN).

An additional unit of analysis was at the group practice level, which was defined by a TIN. Practices that participated under the GPRO were analyzed at the practice (i.e., TIN) level. In addition to summarizing GPRO information at the TIN level, this report also aggregates information from individual eligible professionals to the practice (TIN) level for descriptive purposes. For these descriptions, a practice was defined as eligible, participated, or incentive eligible if at least one eligible professional associated with that practice was eligible, participated, or incentive eligible.

This report also describes counts of individual eligible professionals who belong to a practice that participated under the GPRO (and eligible professionals within Medicare ACOs reporting Physician Quality Reporting System data under the Medicare Shared Savings Program or Pioneer ACO model<sup>3</sup>). For example, unless otherwise noted, tables and figures that describe results for individual eligible professionals also include the number of eligible professionals within practices participating under group reporting options. For the purposes of summarizing participation and incentive eligibility, all eligible professionals that are part of a practice that participates or is incentive eligible under a group reporting option are assumed to have participated or been incentive eligible.

## Outcomes

The report summarized the following outcomes:

1. *Program eligibility.* A professional was defined as eligible to participate individually in the Physician Quality Reporting System or the eRx Incentive Program if he/she had at least one Medicare Part B Physician Fee Schedule (MPFS) professional services claim that contained the denominator criteria of the applicable quality measure for any Physician Quality Reporting System measure or the eRx measure, respectively. In addition, anyone who participated through the registry or EHR reporting options was defined as eligible to participate—regardless of whether they had a qualifying claim—because eligibility information was not available from registry or EHR data. These reporting options can use clinical information to identify eligible instances that is not available in and, therefore, cannot be verified by claims information.

---

<sup>2</sup> There are multiple NPIs associated with a service (performing, referring, and ordering); the performing NPI identifies the eligible professional who actually performed the service.

<sup>3</sup> As part of their quality reporting requirements, practices within Medicare ACOs reporting Physician Quality Reporting System data under the Medicare Shared Savings Program and Pioneer ACO models submitted data on 22 measures via the GPRO web interface.

Eligible practices (TINs) that chose to report under the GPRO applied and met requirements for participation.<sup>4</sup> A practice could participate under the GPRO under the Physician Quality Reporting System and the eRx Incentive Program. However, a practice could not participate under the GPRO in the eRx Incentive Program alone; they were also required to participate in the Physician Quality Reporting System under the GPRO.<sup>5</sup> A practice could participate in the Physician Quality Reporting System alone. Eligible professionals were not eligible to participate individually in the Physician Quality Reporting System (or the eRx Incentive Program) if they participated as a group practice under the GPRO in the same program. All eligible professionals that were part of a practice self-nominating to participate via the GPRO or that were part of an ACO that reported for PQRS under the Shared Savings Program or Pioneer ACO model were considered eligible under those reporting options only.

2. *Program participation.*<sup>6</sup> Eligible professionals were defined as participating in the Physician Quality Reporting System or eRx Incentive Program if they had a complete and valid submission of data on quality measures through claims or a valid submission from a qualified registry or EHR (via direct submission or the new data submission vendor mechanism). To participate through the claims reporting mechanism, eligible professionals submitted the specified Quality Data Code(s) (QDC) for a given measure on a Medicare Part B professional services claim that met the denominator criteria for that measure. QDCs indicate that a specific quality action or outcome was or was not met, or that exclusion criteria for the measure were met. QDCs are entered on a line item on the claim, similar to procedure codes. A QDC for a given quality measure must be entered on a claim that also has all the required denominator criteria for that measure. For example, a measure could require a specific combination of diagnosis, procedure codes, and beneficiary age to be an ‘eligible instance’ for a certain measure; to report the measure validly, the eligible professional had to submit the required QDC(s) on line items for that claim. If an eligible professional submitted only one valid QDC for a measure that required two QDCs, that eligible professional does not count as participating.<sup>7</sup>

---

<sup>4</sup> GPRO eligibility criteria varied by program year. In 2010, practices with at least 200 NPIs could participate in the GPRO option; in 2011, practices with 200+ NPIs could participate in “GPRO I” and those with 2-199 NPIs could participate in the GPRO II option; in 2012, practices with 25-99 NPIs could participate in the “Small GPRO” option, while practices with 100+ NPIs could participate in the “Large GPRO” option; and in 2013, Small GPRO (2-24 NPIs), Medium GPRO (25-99 NPIs), and Large GPRO (100+ NPIs) were available.

<sup>5</sup> There was one exception to this statement; several practices that were part of a pilot program participated through the GPRO in the eRx Incentive Program and not the Physician Quality Reporting System.

<sup>6</sup> In some places we have included results related to the Medicare Shared Savings Program and the Pioneer ACO Model given that eligible professionals within ACOs may report through those programs/models for purposes of earning a Physician Quality Reporting System incentive. However, such eligible professionals participating in such initiatives outside the traditional Physician Quality Reporting System are subject to reporting, participation, and program requirements specific to the Shared Savings Program and Pioneer ACO Model. Unless otherwise indicated, the program requirements discussed below (i.e. reporting options, mechanisms, periods, criteria and measures, participation rules, etc.) generally pertain to the traditional Physician Quality Reporting System.

<sup>7</sup> Please note, the program defined participation slightly differently in the 2007 and 2008 program years; an eligible professional was defined as participating in those years if they submitted at least one QDC for the measure.



To report measures groups through the claims reporting mechanism, eligible professionals submitted a specified procedure code (referred to as an intent G-code) indicating intent to submit measures group information on one claim during the reporting period. In order to be considered participating, the eligible professional had then to report the specified QDCs for each applicable measure in the specific measures group. Alternatively, an eligible professional could submit one ‘composite’ G-code specified for that measures group indicating that all quality actions in the measures group had been performed for that patient.

To report measures through the registry and EHR reporting mechanisms, eligible professionals submitted performance data for each measure—such as number of eligible instances (denominator), instances of quality service performed (numerator), number of performance exclusions, reporting rates, and performance rates—in a file format specified by CMS.

A practice was defined as participating in the Physician Quality Reporting System GPRO or participating in an ACO under the Medicare Shared Savings Program or Pioneer ACO Model for purposes of the Physician Quality Reporting System reporting if the practice submitted data for an assigned sample of patients through a web interface provided by CMS. A practice was defined as participating in the GPRO option for the eRx Incentive Program if they had a valid submission of the eRx quality code through claims, or the required summary information through a registry or EHR.

3. *Incentive eligibility.*<sup>8</sup> An individual eligible professional was defined as incentive eligible for the 2012 Physician Quality Reporting System if they met the criteria for incentive eligibility through at least one individual reporting option. The three basic criteria were:

- Percentage Method:

- Fifty percent of patients, individual measures option: An eligible professional must report at least 50 percent of eligible instances for at least three measures; this criterion applied to the individual measures option for the claims mechanism only. An eligible professional could qualify for an incentive by reporting at least 50 percent of eligible instances on one or two measures (i.e. less than three) if the Measure Applicability Validation (MAV) process was passed; the MAV process checked to ensure it was acceptable for an eligible professional to report less than three measures. Eligible professionals could report using this option for a 12-month period (January 1 through December 31, 2012).

---

<sup>8</sup> In some places we have included results related to the Medicare Shared Savings Program and the Pioneer ACO Model given that eligible professionals within ACOs may report through those programs/models for purposes of earning a Physician Quality Reporting System incentive. However, such eligible professionals participating in such initiatives outside the traditional Physician Quality Reporting System are subject to reporting, participation, and program requirements specific to the Shared Savings Program and Pioneer ACO Model. Unless otherwise indicated, the program requirements discussed below (i.e. reporting options, mechanisms, periods, criteria and measures, participation rules, etc.) generally pertain to the traditional Physician Quality Reporting System.

- Eighty percent of patients, individual measures option: An eligible professional must report at least 80 percent of eligible instances for at least three measures; this criterion applied to the individual measures option for the registry and EHR reporting mechanisms. Eligible professionals could report using this option for a 12-month period (January 1 through December 31, 2012).
- Fifty percent of patients, measures groups option: An eligible professional must report all applicable measures for at least one measures group among the 12 available for claims reporting provided they reported at least 50 percent of all applicable Medicare Part B FFS patients. They could choose to report for a 12-month period (January 1 through December 31, 2012) for a minimum of 15 patients.
- Eighty percent of patients, measures groups option: An eligible professional must report all applicable measures for at least one measures group among the 22 available for registry reporting provided they reported for at least 80 percent of applicable Medicare Part B FFS patients. They could choose to report for a 12-month period (January 1 through December 31, 2012) for a minimum of 15 patients; they could also choose to report for a 6-month period (July 1 through December 31, 2012) for a minimum of eight patients.
- 30 Patient Method: An eligible professional must report at least one measures group for at least 30 patients; this criterion applied to the claims and registry mechanisms. The option required all Medicare Part B FFS patients for both claims- and registry-reporting. Participants using the 30-patient reporting criterion for the claims or registry reporting mechanisms were required to use a 12-month reporting period (January 1, 2011 through December 31, 2012).
- Align with EHR Meaningful Use: For EHR only, an eligible professional must report on all three Medicare EHR Incentive Program core measures (or, if the denominator for one or more of the Medicare EHR Incentive Program core measures is zero, the eligible professional must report on up to three Medicare EHR Incentive Program alternate core measures) AND report on three additional measures available for the Medicare EHR Incentive Program.

A group practice that participated under the GPRO and eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model for the 2012 Physician Quality Reporting System were defined as incentive eligible if they met the satisfactory reporting criteria. The Large GPRO option required a practice to report on the first 411 patients from a preselected sample of Medicare patients for each of the 29 GPRO measures or on all eligible patients for a measure where fewer than 411 patients were available. The Small GPRO option required a practice to report on the first 218 preselected sample of Medicare patients for each GPRO measure or on all eligible patients for a measure where fewer than 218 patients were available. ACOs were required to report on the first 411 preselected Medicare patients for each of the 22 ACO Physician Quality Reporting System measures or on all eligible patients for a measure where fewer than 411 patients were available.

An eligible professional was defined as incentive eligible for the 2012 eRx Incentive Program if: 1) they correctly reported the eRx quality measure in at least 25 instances; and 2) during the reporting period, the allowed charges for Medicare Part B covered professional services furnished by the eligible professional for the codes that appear in the eRx quality measure denominator were at least 10 percent of the total allowed Medicare Part B charges for all such covered professional services furnished by the eligible professional. A practice that participated in the Large GPRO option for the 2012 eRx Incentive Program was defined as incentive eligible if: 1) they correctly reported at least 2,500 instances; and 2) during the reporting period, the allowed charges for Medicare Part B covered professional services furnished by the practice for the codes that appear in the eRx quality measure denominator were at least 10 percent of the total allowed Medicare Part B charges (referred to as the 10 percent threshold limitation). A practice that participated in the Small GPRO option for the 2012 eRx Incentive Program was defined as incentive eligible if: 1) they correctly reported at least 625 instances; and 2) they met the same 10 percent limitation threshold as above.

The above incentive eligibility criteria applied to the 2012 program year; criteria for preceding program years differed for some reporting options. When comparing results across years, it is important to note the incentive eligibility requirements can be different in different years. See Table 7 of the main text for a summary of the Physician Quality Reporting incentive eligibility criteria across the years.

Finally, eligible professionals who met incentive eligibility criteria under the Physician Quality Reporting System but had no Part B MPFS allowed charges on which to calculate an incentive payment had an incentive amount of \$0.00; these participants are not included in the counts of eligible professionals who were incentive eligible. Potentially, this was because an eligible professional or the vendor submitting data on behalf of the eligible professional provided an incorrect TIN or NPI.

4. *Incentive amounts.* For 2012 Physician Quality Reporting System and eRx Incentive Program, eligible professionals (or group practices) who were incentive eligible qualified for an incentive payment equal to a percentage of their estimated Part B MPFS allowed charges for covered professional services furnished by the eligible professional (or group practice) during the reporting period. The applicable incentive percentage varied across program years. The applicable percentage was one-half percent for the 2012 Physician Quality Reporting System. It was one percent for the 2012 eRx Incentive Program and the 2011 Physician Quality Reporting System and eRx Incentive Programs, and two percent for both programs for the 2010 and 2009 program years. The applicable quality incentive percentage was 1.5 percent for the Physician Quality Reporting System in 2007 and 2008.

For the eRx Incentive Program, counts of individually-participating incentive-eligible professionals and incentive dollar amounts for both eligible professionals and group practices participating under the GPRO shown in this report include those receiving an incentive through the Medicare EHR Incentive Program; see the eRx Incentive Program section (Section IV) of the main body of this report for more details.

5. *Measure performance*<sup>9</sup>. For the Physician Quality Reporting System, performance on a measure was calculated as the number of times the eligible professional reported that the recommended quality action for that measure was performed (numerator), divided by the number of instances they could have performed the quality action (denominator), multiplied by 100. For example, under claims-based reporting options, the numerator was the number of times the eligible professional reported the measure-specific QDC indicating the quality action was met and the denominator was the number of eligible instances for that measure identified through claims. Instances that did not apply (i.e., reported as exclusions) were excluded from performance. The following hierarchy was used if an eligible professional participated through more than one reporting mechanisms: EHR, claims, and then registry. Applying the hierarchy ensured only one performance rate for each measure for an eligible professional; information could not be combined across reporting methods.

Due to differences in the methodology for calculating performance rates, the performance rates displayed in the 2012 Quality Resource Use Reports (QRURs) may differ from the rates displayed in the 2012 PQRS/eRx Experience Report in the following ways: (1) when an eligible professional (EP) reports via multiple reporting methods, the QRURs report the rate for the one which gives the highest rate/denominator, compared to the hierarchy described above; (2) this report excludes measures group measures from average performance rates while the QRURs include measures groups measures. For more information on the methodology used for the 2012 QRURs, please see the following link: <http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeedbackProgram/Downloads/PY2012-Detailed-Methods.pdf>.

Please note, multiple factors should be considered when interpreting performance trends. For example, there have been many changes within the Physician Quality Reporting System across program years that include changes in participation methods, measures, and the eligible professionals who participated. As a result, it is unclear the extent that any observed changes in performance were genuine or artifacts of the aforementioned changes.

6. *2013 eRx Payment Adjustment*. Section 1848(a)(5) of the Social Security Act requires payment adjustments under the eRx Incentive Program for eligible professionals who were not successful electronic prescribers. The 2013 eRx payment adjustment, a reduction of 1.5 percent, applies to the MPFS amounts for Medicare Part B services furnished by the eligible professional between January 1 and December 31, 2013, for those eligible professionals who are not successful electronic prescribers under the 2011 eRx Incentive program or did not report on the required number of claims for the period January 1 through June 30, 2012 and did not otherwise qualify for an exception from the payment adjustment. Certain types of individually-participating eligible professionals were not subject to the adjustment:
- Those that were not physicians (MD, DO, or podiatrist), nurse practitioners, or physician assistants as of April 2012, based on primary taxonomy code in the National Plan and Provider Enumeration System (NPPES).

---

<sup>9</sup> EHR performance rates of zero percent have been excluded from results.

- Those that did not have at least 100 eligible claims containing an encounter code in the measure denominator during the period from January 1, 2012 to June 30, 2012.
- Those that did not meet the 10 percent limitation threshold were not subject to the adjustment.

To avoid the payment adjustment for 2013, eligible professionals who did not meet any of these automatic exclusion criteria, had to report the G8553 code via claims on at least 10 Medicare billable services during the six-month period January 1, 2012 through June 30, 2012, or have been a successful 2011 electronic prescriber. Minimum reporting criteria to avoid the payment adjustment for practices reporting via GPRO were 2,500 instances for Large GPRO and 625 for Small GPRO.

Alternatively, eligible professionals and practices could avoid the payment adjustment if one of the following applied:

- Reporting a G-code G8644 (to indicate a lack of prescribing privileges) at least one time on an eligible claim between January 1 and June 30, 2012.
- Requesting (by reporting the applicable G-code via claims between January 1, 2012 and June 30, 2012) and being granted a significant hardship exemption for the following reasons:
  - G8642: The eligible professional practices in a rural area without sufficient high-speed internet.
  - G8643: The eligible professional practices in an area without sufficient available pharmacies for electronic prescribing.
- For practices reporting under the GPRO, indicating a hardship or lack of prescribing privileges to CMS during self-nomination.
- Requesting (by June 30, 2012 through the Communication Support Page (CSP), or via mail for group practices) and being granted a significant hardship exemption for the following reasons:
  - Inability to prescribe electronically due to local, state, or federal law or regulation (e.g., controlled substances).
  - Limited prescribing activity.
  - Insufficient opportunities to report the electronic prescribing measure due to limitations of the measure's denominator.

The results in this report reflect that some eligible professionals had their payment adjustment overturned based on informal review and re-analysis by CMS. These included eligible professionals participating individually and GPROs whose circumstances qualified them for exemption from the 2013 payment adjustment. For example, an incorrect TIN/NPI had been submitted into the CSP when they requested a hardship exemption. In addition, eligible professionals who achieved Meaningful Use during January 1, 2011 through June 30, 2012 and attested to this by January 31, 2013 and eligible professionals who demonstrated intent to participate in the EHR Incentive

Program and adopted Certified EHR Technology by registering for the EHR Incentive Program by January 31, 2013 were exempt from the 2013 eRx payment adjustment.

## Key Variables

The analysis examined outcomes by several eligible professional and practice characteristics.

- *Specialty (TIN/NPI level only).* The specialty for eligible professionals was obtained from the NPPEs. Specialty in the NPPEs was self-designated by the professionals and could contain multiple specialties for the same professional. The primary specialty was used in cases where the professional designated it. If there was no primary designation, the first specialty was selected to allow assigning of an eligible professional to a single specialty category. Some specialty codes were grouped for efficiency of data presentation.
- *Reporting Option (TIN and TIN/NPI levels).* There were nine individual reporting options and two group reporting options for the 2012 Physician Quality Reporting System (Small and Large GPRO).<sup>10</sup> There were three individual reporting mechanisms and two group reporting options available to report data to earn an incentive in the 2012 eRx Incentive Program. Some analyses combined reporting options such as individual measures or measures group options).
- *State and Region.* The state for eligible professionals was obtained from NPPEs. Region was based on CMS carrier regions on claims. In most tables, information on the Railroad Retirement Board (RRB) carrier is not provided. This is due to the RRB not being based on geographical location of the eligible professional.
- *Practice Size (TIN/NPI level only).* This variable was the number of eligible professionals within the practice who were defined as eligible based on data submitted through Medicare claims and therefore could have participated in the Physician Quality Reporting System or the eRx Incentive Program.
- *Beneficiary Volume (TIN and TIN/NPI levels).* This variable was a unique count of Medicare beneficiaries who were identified as having an eligible claim for at least one Physician Quality Reporting System measure on which an eligible professional could have reported or who had at least one eligible claim on which an eligible professional could have reported the eRx measure for the eRx Incentive Program. A Health Insurance Claim (HIC) number identified beneficiaries. Beneficiary information was not available from the registry or EHR methods. Registry information was reported to CMS aggregated to individual eligible professionals and the patient identifier available in the EHR reporting method was not linkable to the claims-based HIC number.
- *Eligible Measures (TIN/NPI level only).* The number of measures the eligible professional could have reported (i.e., treated at least one beneficiary who qualified for the measure). Participation in registry-only measures was summed with claims-

---

<sup>10</sup> This report also presents data separately for eligible professionals within ACOs reporting under the Medicare Shared Savings Program and the Pioneer ACO Model for the purposes of earning the Physician Quality Reporting System incentive.

based eligibility counts to estimate the count of measures for which an eligible professional could have reported; eligibility information was not available for registry or EHR.

## **Data Analysis**

Cross-tabulations were used to illustrate bivariate relationships between eligible professional or practice characteristics and the key outcomes of interest (e.g., eligibility, participation, and incentive eligibility). Tables commonly presented frequencies (i.e., counts) and percents. Note that summing counts across participation options or across tables do not equal unduplicated totals due to eligible professionals who participated through multiple options.

## 2012 PHYSICIAN QUALITY REPORTING SYSTEM APPENDIX TABLES

**Table A1. List of Individual Measure Numbers and Descriptions for the Physician Quality Reporting System (2012)**

Measure Number	Measure Description
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>e</sup>
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>
6	Coronary Artery Disease (CAD): Antiplatelet Therapy
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) <sup>a, b, c, d</sup>
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge <sup>a, b, c, d</sup>
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered



Measure Number	Measure Description
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility <sup>d</sup>
47	Advance Care Plan
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy
53	Asthma: Pharmacologic Therapy for Persistent Asthma
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic
64	Asthma: Assessment of Asthma Control
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use
66	Appropriate Testing for Children with Pharyngitis
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute <sup>a, b, c, d</sup>

Measure Number	Measure Description
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute <sup>a, b, c, d</sup>
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia <sup>a, b, c</sup>
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment
85	Hepatitis C: HCV Genotype Testing Prior to Treatment
86	Hepatitis C: Antiviral Treatment Prescribed
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy
91	Acute Otitis Externa (AOE): Topical Therapy
92	Acute Otitis Externa (AOE): Pain Assessment
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy
106	Major Depressive Disorder (MDD): Diagnostic Evaluation
107	Major Depressive Disorder (MDD): Suicide Risk Assessment
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
109	Osteoarthritis (OA): Function and Pain Assessment
110	Preventive Care and Screening: Influenza Immunization
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
112	Preventive Care and Screening: Screening Mammography
113	Preventive Care and Screening: Colorectal Cancer Screening
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)

Measure Number	Measure Description
122	Adult Kidney Disease: Blood Pressure Management
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>e</sup>
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up
130	Documentation of Current Medications in the Medical Record
131	Pain Assessment and Follow-Up
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan
137	Melanoma: Continuity of Care – Recall System <sup>a, b, c</sup>
138	Melanoma: Coordination of Care <sup>a, b, c</sup>
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications
143	Oncology: Medical and Radiation – Pain Intensity Quantified <sup>a, b, c</sup>
144	Oncology: Medical and Radiation – Plan of Care for Pain <sup>a, b, c</sup>
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>e</sup>
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy
154	Falls: Risk Assessment
155	Falls: Plan of Care
156	Oncology: Radiation Dose Limits to Normal Tissues
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage <sup>a, b, c, d</sup>
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis <sup>a, b, c, d</sup>
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy <sup>a, b, c, d</sup>
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy <sup>a, b, c, d</sup>
163	Diabetes Mellitus: Foot Exam
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a, b, c, d, e</sup>
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a, b, c, d, e</sup>

Measure Number	Measure Description
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a, b, c, d, e</sup>
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a, b, c, d, e</sup>
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a, b, c, d, e</sup>
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge <sup>a, b, c, d</sup>
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge <sup>a, b, c, d</sup>
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge <sup>a, b, c, d</sup>
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening
176	Rheumatoid Arthritis (RA): Tuberculosis Screening
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity
178	Rheumatoid Arthritis (RA): Functional Status Assessment
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis
180	Rheumatoid Arthritis (RA): Glucocorticoid Management
181	Elder Maltreatment Screen and Follow-Up Plan
182	Functional Outcome Assessment
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy <sup>a, b, c</sup>
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery <sup>a, b, c</sup>
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a, b, c, e</sup>
193	Perioperative Temperature Management
194	Oncology: Cancer Stage Documented
195	Radiology: Stenosis Measurement in Carotid Imaging Reports
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment <sup>a, b, c</sup>
197	Coronary Artery Disease (CAD): Lipid Control <sup>a, b, c</sup>
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment <sup>a, b, c</sup>

Measure Number	Measure Description
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation <sup>a, b, c</sup>
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea <sup>a, b, c</sup>
206	HIV/AIDS: Screening for High Risk Sexual Behaviors <sup>a, b, c</sup>
207	HIV/AIDS: Screening for Injection Drug Use <sup>a, b, c</sup>
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis <sup>a, b, c</sup>
209	Functional Communication Measure - Spoken Language Comprehension <sup>a, b, c</sup>
210	Functional Communication Measure - Attention <sup>a, b, c</sup>
211	Functional Communication Measure - Memory <sup>a, b, c</sup>
212	Functional Communication Measure - Motor Speech <sup>a, b, c</sup>
213	Functional Communication Measure - Reading <sup>a, b, c</sup>
214	Functional Communication Measure - Spoken Language Expression <sup>a, b, c</sup>
215	Functional Communication Measure - Writing <sup>a, b, c</sup>
216	Functional Communication Measure - Swallowing <sup>a, b, c</sup>
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments <sup>a, b</sup>
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments <sup>a, b</sup>
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments <sup>a, b</sup>
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments <sup>a, b</sup>
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments <sup>a, b</sup>
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments <sup>a, b</sup>
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments <sup>a, b</sup>
224	Melanoma: Overutilization of Imaging Studies in Melanoma <sup>a, b</sup>
225	Radiology: Reminder System for Mammograms
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing <sup>a, b</sup>
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection <sup>a, b</sup>

Measure Number	Measure Description
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy) <sup>a, b</sup>
235	Hypertension (HTN): Plan of Care
236	Hypertension (HTN): Controlling High Blood Pressure <sup>a, b</sup>
237	Hypertension (HTN): Blood Pressure Measurement <sup>a, b</sup>
238	Drugs to be Avoided in the Elderly <sup>a, b, e</sup>
239	Weight Assessment and Counseling for Children and Adolescents <sup>a, b</sup>
240	Childhood Immunization Status <sup>a, b</sup>
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control
242	Coronary Artery Disease (CAD): Symptom Management <sup>a</sup>
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting <sup>a</sup>
244	Hypertension: Blood Pressure Management <sup>a</sup>
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence
249	Barrett's Esophagus
250	Radical Prostatectomy Pathology Reporting
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients
252	Anticoagulation for Acute Pulmonary Embolus Patients
253	Pregnancy Test for Female Abdominal Pain Patients
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR) <sup>a</sup>
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB) <sup>a</sup>
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) <sup>a</sup>
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2) <sup>a</sup>
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2) <sup>a</sup>

Measure Number	Measure Description
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness
262	Image Confirmation of Successful Excision of Image–Localized Breast Lesion
263	Preoperative Diagnosis of Breast Cancer
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer <sup>a</sup>
265	Biopsy Follow-Up <sup>a</sup>
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy
303	Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery <sup>a</sup>
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery <sup>a</sup>
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement <sup>a</sup>
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) <sup>a</sup>
307	Prenatal Care: Anti-D Immune Globulin <sup>a</sup>
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies <sup>a</sup>
309	Cervical Cancer Screening <sup>a</sup>
310	Chlamydia Screening for Women <sup>a</sup>
311	Use of Appropriate Medications for Asthma <sup>a</sup>
312	Low Back Pain: Use of Imaging Studies <sup>a</sup>
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%) <sup>a</sup>
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL <sup>a</sup>
317	Preventive Care and Screening: Screening for High Blood Pressure

<sup>a</sup> Measure was not reportable via claims during the 2012 program year.

<sup>b</sup> Measure was not reportable via claims during the 2011 program year.

<sup>c</sup> Measure was not reportable via claims (e.g., registry only) during the 2010 program year.

<sup>d</sup> Measure was not reportable via claims (e.g., registry only) during the 2009 program year.

<sup>e</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

**Table A2. Distribution of Incentive Amounts by Specialty for the Physician Quality Reporting System, excluding MOCP (2012)**

Specialty	Eligible Professionals who Received Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount	Percent of National Total Incentive Amount
<b>MD/DO</b>	<b>269,935</b>	<b>85.6%</b>	<b>38.2%</b>	<b>\$0.01</b>	<b>\$294</b>	<b>\$548</b>	<b>\$110,586</b>	<b>\$147,864,792</b>	<b>88.1%</b>
Allergy/Immunology	875	85.5%	23.1%	\$0.11	\$125	\$239	\$5,362	\$208,964	0.1%
Anesthesiology	23,461	82.8%	50.8%	\$0.04	\$182	\$212	\$8,153	\$4,972,335	3.0%
Cardiology	12,860	89.6%	47.9%	\$0.04	\$922	\$1,215	\$110,586	\$15,625,988	9.3%
Colon/Rectal Surgery	434	81.9%	34.7%	\$0.38	\$456	\$526	\$2,284	\$228,188	0.1%
Critical Care	782	82.7%	29.1%	\$0.33	\$351	\$539	\$18,448	\$421,543	0.3%
Dermatology	3,602	93.5%	31.4%	\$0.11	\$887	\$1,532	\$43,649	\$5,519,077	3.3%
Emergency Medicine	36,262	92.7%	63.0%	\$0.04	\$219	\$278	\$5,412	\$10,098,440	6.0%
Endocrinology	2,563	86.1%	43.0%	\$0.18	\$228	\$351	\$4,804	\$898,833	0.5%
Family Practice	35,341	84.3%	34.7%	\$0.04	\$207	\$314	\$7,389	\$11,096,015	6.6%
Gastroenterology	4,891	83.3%	36.2%	\$0.05	\$520	\$621	\$7,903	\$3,037,614	1.8%
General Practice	841	80.5%	13.8%	\$0.18	\$159	\$330	\$7,871	\$277,776	0.2%
General Surgery	7,254	83.7%	30.0%	\$0.05	\$350	\$464	\$17,633	\$3,362,448	2.0%
Geriatrics	1,574	85.5%	34.6%	\$0.05	\$361	\$555	\$9,347	\$873,815	0.5%
Hand Surgery	470	85.3%	26.2%	\$0.04	\$473	\$580	\$4,552	\$272,806	0.2%
Infectious Disease	1,943	90.1%	31.8%	\$0.10	\$217	\$423	\$4,412	\$821,951	0.5%
Internal Medicine	38,560	84.6%	36.4%	\$0.01	\$314	\$482	\$24,080	\$18,577,374	11.1%
Interventional Radiologist	919	83.9%	48.8%	\$0.05	\$552	\$984	\$52,231	\$904,084	0.5%
Nephrology	3,308	75.0%	35.6%	\$0.10	\$938	\$1,185	\$31,125	\$3,921,182	2.3%
Neurology	5,160	85.8%	35.4%	\$0.13	\$265	\$426	\$6,888	\$2,199,839	1.3%
Neurosurgery	1,632	81.7%	32.9%	\$0.05	\$557	\$685	\$5,420	\$1,117,878	0.7%
Nuclear Medicine	272	90.4%	38.6%	\$0.76	\$305	\$654	\$5,832	\$177,881	0.1%
Obstetrics/Gynecology	8,205	84.4%	24.4%	\$0.05	\$41	\$101	\$3,561	\$831,569	0.5%
Oncology/Hematology	5,391	87.5%	42.2%	\$0.11	\$448	\$844	\$13,674	\$4,551,315	2.7%



Specialty	Eligible Professionals who Received Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount	Percent of National Total Incentive Amount
Ophthalmology	9,216	82.8%	45.5%	\$0.14	\$1,304	\$1,728	\$20,336	\$15,921,621	9.5%
Oral/Maxillofacial Surgery	60	85.7%	14.4%	\$0.33	\$52	\$89	\$584	\$5,325	0.0%
Orthopaedic Surgery	6,932	83.7%	30.5%	\$0.13	\$644	\$813	\$8,272	\$5,636,468	3.4%
Other MD/DO	3,181	83.6%	26.6%	\$0.02	\$275	\$419	\$6,942	\$1,332,471	0.8%
Otolaryngology	2,892	84.3%	30.7%	\$0.06	\$425	\$535	\$5,081	\$1,546,659	0.9%
Pathology	6,192	87.8%	60.6%	\$0.06	\$318	\$398	\$26,505	\$2,466,498	1.5%
Pediatrics	2,723	90.0%	30.4%	\$0.03	\$3	\$41	\$3,468	\$111,947	0.1%
Physical Medicine	1,897	84.4%	21.4%	\$0.20	\$342	\$542	\$5,525	\$1,027,914	0.6%
Plastic Surgery	878	87.3%	18.5%	\$0.17	\$233	\$323	\$7,724	\$283,537	0.2%
Psychiatry	3,562	89.3%	11.0%	\$0.03	\$63	\$139	\$4,047	\$495,532	0.3%
Pulmonary Disease	4,060	85.3%	37.5%	\$0.05	\$573	\$816	\$7,602	\$3,314,392	2.0%
Radiation Oncology	1,818	82.1%	36.0%	\$0.26	\$817	\$2,157	\$28,488	\$3,921,651	2.3%
Radiologist	20,063	83.4%	49.4%	\$0.04	\$484	\$640	\$17,573	\$12,848,483	7.7%
Rheumatology	2,144	87.0%	44.8%	\$0.38	\$362	\$600	\$11,154	\$1,286,466	0.8%
Thoracic/Cardiac Surgery	1,929	82.5%	47.2%	\$0.06	\$675	\$827	\$4,632	\$1,594,859	1.0%
Urology	4,438	82.9%	43.2%	\$0.04	\$852	\$962	\$12,294	\$4,270,832	2.5%
Vascular Surgery	1,350	81.8%	37.7%	\$0.12	\$901	\$1,336	\$20,392	\$1,803,222	1.1%
<b>Other Eligible Professionals</b>	<b>97,111</b>	<b>80.8%</b>	<b>19.7%</b>	<b>\$0.01</b>	<b>\$80</b>	<b>\$205</b>	<b>\$58,803</b>	<b>\$19,919,461</b>	<b>11.9%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	480	77.0%	1.5%	\$0.18	\$167	\$626	\$58,803	\$300,272	0.2%
Audiologist	838	74.0%	12.1%	\$0.09	\$27	\$42	\$326	\$35,247	0.0%
Certified Nurse Midwives	539	89.5%	29.8%	\$0.10	\$2	\$7	\$148	\$3,895	0.0%
Chiropractor	643	39.5%	1.3%	\$0.12	\$54	\$88	\$1,011	\$56,422	0.0%
Clinical Nurse Specialists	528	85.4%	20.6%	\$0.12	\$54	\$109	\$1,521	\$57,592	0.0%
Counselor/Psychologist	1,630	82.3%	4.9%	\$0.09	\$45	\$103	\$3,198	\$167,174	0.1%

Specialty	Eligible Professionals who Received Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount	Percent of National Total Incentive Amount
Dentist	217	92.3%	6.8%	\$0.18	\$22	\$55	\$769	\$11,849	0.0%
Dietitian/Nutritionist	607	90.5%	21.0%	\$0.11	\$10	\$24	\$488	\$14,542	0.0%
Nurse Anesthetist	18,215	83.2%	37.3%	\$0.05	\$77	\$100	\$1,124	\$1,829,004	1.1%
Nurse Practitioner	19,761	85.8%	28.0%	\$0.01	\$50	\$105	\$2,798	\$2,065,837	1.2%
Optometry	6,824	62.9%	20.1%	\$0.05	\$160	\$265	\$6,082	\$1,810,832	1.1%
Other Eligible Professional	12,072	82.1%	26.8%	\$0.04	\$260	\$627	\$27,753	\$7,565,785	4.5%
Physical/Occupational Therapy	9,435	75.9%	19.5%	\$0.10	\$162	\$251	\$4,442	\$2,368,327	1.4%
Physician Assistant	20,552	88.7%	34.7%	\$0.04	\$54	\$97	\$3,484	\$1,983,849	1.2%
Podiatrist	2,651	63.0%	14.5%	\$0.25	\$435	\$565	\$5,992	\$1,498,990	0.9%
Registered Nurse	1,036	84.1%	26.7%	\$0.16	\$60	\$100	\$1,785	\$103,641	0.1%
Social Worker	1,083	87.1%	3.3%	\$0.07	\$25	\$43	\$586	\$46,203	0.0%
Unknown/Missing	182	64.5%	15.7%	\$0.09	\$62	\$170	\$2,350	\$30,940	0.0%
<b>Total (Unduplicated)</b>	<b>367,228</b>	<b>84.3%</b>	<b>30.6%</b>	<b>\$0.01</b>	<b>\$209</b>	<b>\$457</b>	<b>\$110,586</b>	<b>\$167,815,193</b>	<b>100.0%</b>

*Notes for Table A2: Results include eligible professionals who were part of a practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program and the Pioneer ACO Model.*

**Table A3. Potential Incentives and Participation Information for the Physician Quality Reporting System, excluding MOCP (2012)**

Specialty	Average Potential Incentive per Eligible Professional	Percent of Eligible Professionals who Participated
<b>MD/DO</b>	<b>\$485</b>	<b>44.6%</b>
Allergy/Immunology	\$274	27.0%
Anesthesiology	\$223	61.3%
Cardiology	\$1,122	53.5%
Colon/Rectal Surgery	\$526	42.4%
Critical Care	\$489	35.2%
Dermatology	\$1,225	33.6%
Emergency Medicine	\$242	68.0%
Endocrinology	\$380	50.0%
Family Practice	\$287	41.1%
Gastroenterology	\$644	43.5%
General Practice	\$255	17.1%
General Surgery	\$419	35.8%
Geriatrics	\$535	40.5%
Hand Surgery	\$559	30.7%
Infectious Disease	\$518	35.3%
Internal Medicine	\$456	43.0%
Interventional Radiologist	\$848	58.1%
Nephrology	\$1,151	47.5%
Neurology	\$467	41.3%
Neurosurgery	\$661	40.3%
Nuclear Medicine	\$665	42.7%
Obstetrics/Gynecology	\$92	29.0%
Oncology/Hematology	\$705	48.3%
Ophthalmology	\$1,319	55.0%
Oral/Maxillofacial Surgery	\$88	16.8%
Orthopaedic Surgery	\$728	36.5%
Other MD/DO	\$429	31.9%
Otolaryngology	\$512	36.4%
Pathology	\$419	69.0%
Pediatrics	\$35	33.8%
Physical Medicine	\$565	25.3%
Plastic Surgery	\$320	21.2%
Psychiatry	\$165	12.3%
Pulmonary Disease	\$785	44.0%
Radiation Oncology	\$1,784	43.8%
Radiologist	\$589	59.3%
Rheumatology	\$553	51.5%
Thoracic/Cardiac Surgery	\$728	57.2%
Urology	\$816	52.0%
Vascular Surgery	\$1,171	46.0%

Specialty	Average Potential Incentive per Eligible Professional	Percent of Eligible Professionals who Participated
<b>Other Eligible Professionals</b>	<b>\$166</b>	<b>24.4%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	\$82	1.9%
Audiologist	\$42	16.3%
Certified Nurse Midwives	\$8	33.3%
Chiropractor	\$72	3.4%
Clinical Nurse Specialists	\$103	24.1%
Counselor/Psychologist	\$96	5.9%
Dentist	\$52	7.4%
Dietitian/Nutritionist	\$23	23.2%
Nurse Anesthetist	\$93	44.8%
Nurse Practitioner	\$100	32.6%
Optometry	\$154	32.0%
Other Eligible Professional	\$571	32.6%
Physical/Occupational Therapy	\$252	25.7%
Physician Assistant	\$92	39.1%
Podiatrist	\$534	23.1%
Registered Nurse	\$98	31.8%
Social Worker	\$44	3.7%
Unknown/Missing	\$162	24.4%
<b>Total (Unduplicated)</b>	<b>\$353</b>	<b>36.3%</b>

*Notes for Table A3: Results include eligible professionals who were part of a practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program and the Pioneer ACO Model.*

**Table A4. Eligible Professional Characteristics for the Physician Quality Reporting System (2012)**

Eligible Professional (EP) Characteristics	Eligible EPs (TIN/NPI)	Participating EPs	Participation Rate	Incentive Eligible EPs	Incentive Eligibility Rate
Individual Participants (TIN/NPI)	1,066,852	301,874	28.3%	233,749	77.4%
Claims	1,066,852	249,492	23.4%	182,352	73.1%
Individual Measures (12 mo.)	1,066,852	248,206	23.3%	180,450	72.7%
Measures Groups	1,066,852	4,776	0.4%	2,619	54.8%
Patient Count (12 mo.)	1,066,852	4,776	0.4%	2,129	44.6%
Patient Percent (12 mo.)	1,066,852	4,762	0.4%	1,259	26.4%
Registry	1,066,852	46,642	4.4%	39,905	85.6%
Individual Measures (12 mo.)	1,066,852	36,473	3.4%	31,068	85.2%
Measures Groups	1,066,852	10,478	1.0%	8,993	85.8%
Patient Count (12 mo.)	1,066,852	9,891	0.9%	8,536	86.3%
Patient Percent (12 mo.)	1,066,852	531	0.0%	415	78.2%
Patient Percent (6 mo.)	1,066,852	57	0.0%	42	73.7%
EHR	1,066,852	19,817	1.9%	18,570	93.7%
Direct Submission	1,066,852	3,726	0.3%	3,283	88.1%
Data Submission Vendor	1,066,852	16,304	1.5%	15,496	95.0%
Group Reporting	134,510	133,997	99.6%	133,479	99.6%
Small GPRO	868	766	88.2%	766	100.0%
Large GPRO	43,641	43,290	99.2%	43,290	100.0%
ACO – MSSP	40,145	40,085	99.9%	39,694	99.0%
ACO – Pioneer	49,856	49,856	100.0%	49,729	99.7%
<b>Total Eligible Professionals (Unduplicated)</b>	<b>1,201,362</b>	<b>435,871</b>	<b>36.3%</b>	<b>367,228</b>	<b>84.3%</b>

Notes for Table A4: (1) Eligible professional-level results in this table include EPs who were part of a practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program and the Pioneer ACO Model. (2) Sums across participation methods do not equal totals due to participation in multiple methods.

**Table A5. Eligible Professional Characteristics (2012) for the Physician Quality Reporting System**

Eligible Professional (EP) Characteristics	Eligible EPs (TIN/NPI)	Participating EPs	Participation Rate	Incentive Eligible EPs	Incentive Eligibility Rate
Geography (Regions)	--	--	--	--	--
1 – Boston	83,002	34,653	41.7%	31,269	90.2%
2 - New York	137,429	39,064	28.4%	33,147	84.9%
3 - Philadelphia	124,094	42,683	34.4%	34,490	80.8%
4 – Atlanta	217,976	79,652	36.5%	64,385	80.8%
5 - Chicago	217,880	96,488	44.3%	84,143	87.2%
6 – Dallas	130,167	42,848	32.9%	36,206	84.5%
7 - Kansas City	54,458	20,944	38.5%	18,067	86.3%
8 – Denver	40,617	13,404	33.0%	11,168	83.3%
9 - San Francisco	136,477	43,048	31.5%	36,707	85.3%
10 - Seattle	50,334	15,274	30.3%	13,150	86.1%
Unknown	10,045	10,029	99.8%	6,282	62.6%
Number of Measures for which EP was Eligible	--	--	--	--	--
1 to 5	268,989	70,014	26.0%	55,390	79.1%
6 to 15	257,384	66,486	25.8%	56,142	84.4%
16 to 30	242,215	53,199	22.0%	40,326	75.8%
>30	295,239	109,153	37.0%	81,780	74.9%
Unknown	3,025	3,022	99.9%	111	3.7%
Practice Size (# of NPIs)	--	--	--	--	--
Individual Participants	--	--	--	--	--
1	210,113	16,982	8.1%	9,406	55.4%
2 to 4	130,179	26,038	20.0%	16,215	62.3%
5 to 10	115,079	30,451	26.5%	22,018	72.3%
11 to 24	129,843	47,160	36.3%	37,864	80.3%
25 to 50	120,574	50,039	41.5%	40,974	81.9%
51 to 99	95,070	40,153	42.2%	32,413	80.7%
100 to 199	86,217	32,679	37.9%	26,247	80.3%
200+	179,777	58,372	32.5%	48,612	83.3%
Group Participants	--	--	--	--	--
1 to 24	58	58	100.0%	58	100.0%
25 to 50	593	533	89.9%	531	99.6%
51 to 99	2,233	2,233	100.0%	1,980	88.7%
100 to 199	2,892	2,790	96.5%	2,760	98.9%
200+	128,734	128,383	99.7%	128,150	99.8%
Beneficiary Volume	--	--	--	--	--
Individual Participants	--	--	--	--	--
1 to 25	323,739	36,299	11.2%	30,005	82.7%
26 to 100	264,650	62,183	23.5%	47,873	77.0%
101 to 200	169,011	59,198	35.0%	45,366	76.6%
201+	305,824	140,569	46.0%	110,383	78.5%
Unknown	3,628	3,625	99.9%	122	3.4%

Eligible Professional (EP) Characteristics	Eligible EPs (TIN/NPI)	Participating EPs	Participation Rate	Incentive Eligible EPs	Incentive Eligibility Rate
Group Participants	--	--	--	--	--
1 to 25	28,949	28,814	99.5%	28,765	99.8%
26 to 100	31,822	31,676	99.5%	31,638	99.9%
101 to 200	26,094	25,959	99.5%	25,915	99.8%
201+	41,183	41,099	99.8%	40,979	99.7%
Unknown	6,462	6,449	99.8%	6,182	95.9%
Specialty	--	--	--	--	--
<b>MD/DO</b>	--	--	--	--	--
Primary Care	222,934	91,548	41.1%	77,465	84.6%
Surgery	67,760	25,085	37.0%	20,939	83.5%
Other Specialties	416,064	198,701	47.8%	171,531	86.3%
<b>Other Eligible Professionals</b>	--	--	--	--	--
Physicians	103,855	16,924	16.3%	10,335	61.1%
Physician Assistant	59,312	23,179	39.1%	20,552	88.7%
Nurses	127,722	47,377	37.1%	40,079	84.6%
Other Eligible Professionals	203,589	32,987	16.2%	26,321	79.8%
<b>Unknown/Missing</b>	126	70	55.6%	6	8.6%
<b>Total (Unduplicated)</b>	<b>1,201,362</b>	<b>435,871</b>	<b>36.3%</b>	<b>367,228</b>	<b>84.3%</b>

Notes for Table A5: (1) Eligible professional-level results in this table include EPs who were part of a practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program or Pioneer ACO Model. (2) Sums across participation methods do not equal totals due to participation in multiple methods. (3) EPs in the Unknown categories include Registry and EHR data where a match in claims was not found.

**Table A6. Number of Eligible Professionals by Specialty for the Physician Quality Reporting System (2009 to 2012)**

Specialty	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012
<b>MD/DO</b>	<b>621,051</b>	<b>642,615</b>	<b>665,234</b>	<b>706,758</b>
Allergy/ Immunology	3,463	3,418	3,468	3,789
Anesthesiology	42,360	43,173	43,510	46,195
Cardiology	23,287	23,768	24,118	26,834
Colon/Rectal Surgery	1,077	1,069	1,110	1,251
Critical Care	2,452	2,422	2,488	2,687
Dermatology	10,332	10,234	10,466	11,457
Emergency Medicine	49,508	49,278	51,428	57,538
Endocrinology	5,055	6,087	6,278	5,960
Family Practice	90,787	93,052	98,388	101,941
Gastroenterology	11,824	12,265	13,210	13,499
General Practice	5,759	5,883	5,942	6,104
General Surgery	21,871	21,595	21,941	24,208
Geriatrics	4,044	4,055	4,080	4,545
Hand Surgery	1,434	1,530	1,594	1,795
Infectious Disease	5,082	5,084	5,313	6,116
Internal Medicine	92,373	100,777	102,364	105,943
Interventional Radiologist	1,373	1,364	1,578	1,885
Nephrology	7,790	8,301	8,685	9,290
Neurology	12,434	15,544	13,433	14,564
Neurosurgery	4,541	4,452	4,476	4,955
Nuclear Medicine	713	703	683	705
Obstetrics/ Gynecology	29,592	30,000	31,262	33,569
Oncology/ Hematology	10,864	10,762	11,153	12,762
Ophthalmology	18,990	18,917	18,992	20,243
Oral/Maxillofacial Surgery	376	370	377	417
Orthopaedic Surgery	20,644	20,662	21,365	22,708
Other MD/DO	8,143	8,978	11,492	11,946
Otolaryngology	8,448	8,374	8,666	9,426
Pathology	7,705	9,109	10,814	10,223
Pediatrics	5,840	5,816	6,656	8,946
Physical Medicine	7,680	7,859	8,176	8,883
Plastic Surgery	4,250	4,630	4,694	4,752
Psychiatry	30,273	30,269	32,868	32,430
Pulmonary Disease	8,763	9,100	9,646	10,819
Radiation Oncology	4,491	4,448	4,498	5,054
Radiologist	37,242	38,236	38,503	40,576
Rheumatology	4,207	4,116	4,291	4,786



Specialty	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012
Thoracic/Cardiac Surgery	3,576	4,526	4,601	4,089
Urology	9,380	9,233	9,422	10,283
Vascular Surgery	3,028	3,156	3,205	3,585
<b>Other Eligible Professionals</b>	<b>383,690</b>	<b>399,000</b>	<b>435,572</b>	<b>493,447</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	3,130	3,262	3,080	32,783
Audiologist	5,923	6,073	6,481	6,928
Certified Nurse Midwives	1,136	1,166	1,392	1,810
Chiropractor	47,362	47,494	47,819	48,531
Clinical Nurse Specialists	1,967	2,074	2,253	2,567
Counselor/ Psychologist	31,189	31,287	31,984	33,441
Dentist	3,349	3,281	3,232	3,173
Dietitian/Nutritionist	2,303	2,298	2,472	2,892
Nurse Anesthetist	40,314	42,437	45,448	48,857
Nurse Practitioner	44,309	50,645	64,210	70,615
Optometry	29,979	31,377	32,796	33,923
Other Eligible Professional	46,537	44,292	49,080	45,049
Physical/ Occupational Therapy	37,794	39,769	44,085	48,292
Physician Assistant	38,638	43,059	48,766	59,312
Podiatrist	17,408	17,442	17,809	18,228
Registered Nurse	4,176	3,806	3,679	3,873
Social Worker	28,176	29,238	30,986	33,173
Unknown/Missing	2,092	980	967	1,157
<b>Total (Unduplicated)</b>	<b>1,006,833</b>	<b>1,042,595</b>	<b>1,101,773</b>	<b>1,201,362</b>

*Note for Table A6: Results include data for eligible professionals who belong to a group practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program or Pioneer ACO Model.*

**Table A7. Participation Information by Submission Mechanism/Option for the Physician Quality Reporting System (2009 to 2012)**

Reporting Options	Eligible Professionals who Participated in 2009	Percent of Eligible Professionals in 2009	Eligible Professionals who Participated in 2010	Percent of Eligible Professionals in 2010	Eligible Professionals who Participated in 2011	Percent of Eligible Professionals in 2011	Eligible Professionals who Participated in 2012	Percent of Eligible Professionals in 2012
Claims Individual Measures	185,154	18.4%	200,517	19.7%	229,282	21.6%	248,206	23.3%
Claims Measures Groups	3,649	0.4%	4,151	0.4%	4,472	0.4%	4,776	0.4%
Registry Individual Measures	22,750	2.3%	39,255	3.9%	50,215	4.7%	36,473	3.4%
Registry Measures Groups	10,356	1.0%	17,133	1.7%	12,894	1.2%	10,478	1.0%
EHR	N/A	N/A	14	0.0%	560	0.1%	19,817	1.9%
Group Practice Reporting Option (GPRO) I	N/A	N/A	24,931	100.0%	39,404	96.4%	N/A	N/A
Group Practice Reporting Option (GPRO) II	N/A	N/A	N/A	N/A	789	1.9%	N/A	N/A
Small GPRO	N/A	N/A	N/A	N/A	N/A	N/A	766	88.2%
Large GPRO	N/A	N/A	N/A	N/A	N/A	N/A	43,290	99.2%
MSSP ACO	N/A	N/A	N/A	N/A	N/A	N/A	40,085	99.9%
Pioneer ACO	N/A	N/A	N/A	N/A	N/A	N/A	49,856	100.0%
<b>Total (Unduplicated)</b>	<b>210,559</b>	<b>20.9%</b>	<b>269,076</b>	<b>25.8%</b>	<b>320,422</b>	<b>29.1%</b>	<b>435,871</b>	<b>36.3%</b>

Notes for Table A7: (1) Sums across participation methods do not equal totals due to participation in multiple methods. (2) Results included the claims, registry, EHR, and Group Practice Reporting Option methods. (3) The EHR mechanism and GPRO options were not available before the 2010 program year. (4) Participation within ACOs under the Medicare Shared Savings Program and Pioneer ACO Model was not an option until the 2012 program year.

**Table A8. Eligible Professionals who Participated in the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
<b>MD/DO</b>	<b>157,194</b>	<b>25.3%</b>	<b>201,080</b>	<b>31.3%</b>	<b>229,484</b>	<b>34.5%</b>	<b>315,334</b>	<b>44.6%</b>
Allergy/Immunology	313	9.0%	376	11.0%	532	15.3%	1,023	27.0%
Anesthesiology	17,485	41.3%	21,205	49.1%	23,747	54.6%	28,318	61.3%
Cardiology	7,083	30.4%	8,729	36.7%	9,430	39.1%	14,354	53.5%
Colon/Rectal Surgery	243	22.6%	268	25.1%	313	28.2%	530	42.4%
Critical Care	362	14.8%	437	18.0%	535	21.5%	946	35.2%
Dermatology	2,104	20.4%	1,725	16.9%	2,310	22.1%	3,853	33.6%
Emergency Medicine	31,215	63.1%	32,327	65.6%	34,690	67.5%	39,132	68.0%
Endocrinology	1,291	25.5%	2,414	39.7%	2,820	44.9%	2,978	50.0%
Family Practice	20,551	22.6%	25,445	27.3%	30,259	30.8%	41,912	41.1%
Gastroenterology	1,805	15.3%	2,918	23.8%	4,240	32.1%	5,875	43.5%
General Practice	387	6.7%	493	8.4%	545	9.2%	1,045	17.1%
General Surgery	3,142	14.4%	3,819	17.7%	4,393	20.0%	8,666	35.8%
Geriatrics	770	19.0%	882	21.8%	978	24.0%	1,841	40.5%
Hand Surgery	168	11.7%	248	16.2%	290	18.2%	551	30.7%
Infectious Disease	595	11.7%	816	16.1%	999	18.8%	2,157	35.3%
Internal Medicine	19,206	20.8%	31,068	30.8%	32,286	31.5%	45,565	43.0%
Interventional Radiologist	448	32.6%	537	39.4%	707	44.8%	1,096	58.1%
Nephrology	1,984	25.5%	2,699	32.5%	2,987	34.4%	4,413	47.5%
Neurology	1,580	12.7%	5,295	34.1%	3,450	25.7%	6,016	41.3%
Neurosurgery	721	15.9%	864	19.4%	959	21.4%	1,997	40.3%
Nuclear Medicine	117	16.4%	167	23.8%	173	25.3%	301	42.7%
Obstetrics/Gynecology	2,558	8.6%	3,726	12.4%	4,892	15.6%	9,722	29.0%
Oncology/Hematology	3,066	28.2%	3,258	30.3%	3,684	33.0%	6,163	48.3%
Ophthalmology	7,363	38.8%	8,144	43.1%	8,844	46.6%	11,135	55.0%
Oral/Maxillofacial Surgery	13	3.5%	14	3.8%	22	5.8%	70	16.8%
Orthopaedic Surgery	4,013	19.4%	4,746	23.0%	5,482	25.7%	8,278	36.5%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Other MD/DO	1,087	13.3%	1,438	16.0%	3,029	26.4%	3,807	31.9%
Otolaryngology	1,060	12.5%	1,477	17.6%	1,852	21.4%	3,429	36.4%
Pathology	4,539	58.9%	6,136	67.4%	8,007	74.0%	7,050	69.0%
Pediatrics	499	8.5%	628	10.8%	991	14.9%	3,026	33.8%
Physical Medicine	645	8.4%	789	10.0%	1,004	12.3%	2,248	25.3%
Plastic Surgery	296	7.0%	692	14.9%	760	16.2%	1,006	21.2%
Psychiatry	686	2.3%	825	2.7%	3,148	9.6%	3,989	12.3%
Pulmonary Disease	1,475	16.8%	1,958	21.5%	2,532	26.2%	4,759	44.0%
Radiation Oncology	919	20.5%	995	22.4%	1,291	28.7%	2,215	43.8%
Radiologist	11,889	31.9%	15,796	41.3%	18,543	48.2%	24,065	59.3%
Rheumatology	1,152	27.4%	1,386	33.7%	1,586	37.0%	2,465	51.5%
Thoracic/Cardiac Surgery	1,419	39.7%	2,523	55.7%	2,703	58.7%	2,338	57.2%
Urology	2,174	23.2%	2,888	31.3%	3,432	36.4%	5,351	52.0%
Vascular Surgery	771	25.5%	929	29.4%	1,039	32.4%	1,650	46.0%
<b>Other Eligible Professionals</b>	<b>53,029</b>	<b>13.8%</b>	<b>67,863</b>	<b>17.0%</b>	<b>90,781</b>	<b>20.8%</b>	<b>120,255</b>	<b>24.4%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	228	7.3%	283	8.7%	338	11.0%	623	1.9%
Audiologist	138	2.3%	212	3.5%	259	4.0%	1,132	16.3%
Certified Nurse Midwives	101	8.9%	125	10.7%	182	13.1%	602	33.3%
Chiropractor	477	1.0%	563	1.2%	860	1.8%	1,626	3.4%
Clinical Nurse Specialists	187	9.5%	221	10.7%	265	11.8%	618	24.1%
Counselor/Psychologist	494	1.6%	534	1.7%	685	2.1%	1,980	5.9%
Dentist	22	0.7%	29	0.9%	50	1.5%	235	7.4%
Dietitian/Nutritionist	190	8.3%	187	8.1%	221	8.9%	671	23.2%
Nurse Anesthetist	11,800	29.3%	15,532	36.6%	18,510	40.7%	21,883	44.8%
Nurse Practitioner	7,391	16.7%	11,139	22.0%	18,798	29.3%	23,042	32.6%
Optometry	5,925	19.8%	7,459	23.8%	9,372	28.6%	10,852	32.0%
Other Eligible Professional	8,535	18.3%	9,991	22.6%	13,980	28.5%	14,697	32.6%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Physical/Occupational Therapy	5,770	15.3%	6,391	16.1%	8,378	19.0%	12,429	25.7%
Physician Assistant	9,599	24.8%	12,375	28.7%	15,098	31.0%	23,179	39.1%
Podiatrist	1,175	6.7%	1,823	10.5%	2,629	14.8%	4,211	23.1%
Registered Nurse	724	17.3%	777	20.4%	821	22.3%	1,232	31.8%
Social Worker	273	1.0%	222	0.8%	335	1.1%	1,243	3.7%
Unknown/Missing	336	16.1%	133	13.6%	157	16.2%	282	24.4%
<b>Total (Unduplicated)</b>	<b>210,559</b>	<b>20.9%</b>	<b>269,076</b>	<b>25.8%</b>	<b>320,422</b>	<b>29.1%</b>	<b>435,871</b>	<b>36.3%</b>

*Notes for Table A8: Results include EPs who were part of a practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO model.*

**Table A9. Eligible Professionals who Participated by Reporting Individual Measures through the Claims Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
<b>MD/DO</b>	<b>135,778</b>	<b>21.9%</b>	<b>145,047</b>	<b>23.3%</b>	<b>162,557</b>	<b>25.4%</b>	<b>171,222</b>	<b>28.3%</b>
Allergy/Immunology	191	5.5%	232	6.8%	341	9.8%	347	10.5%
Anesthesiology	17,372	41.0%	20,040	47.6%	23,070	53.7%	24,317	57.4%
Cardiology	5,756	24.7%	5,331	22.4%	5,159	21.4%	4,673	21.8%
Colon/Rectal Surgery	192	17.8%	213	19.9%	238	21.4%	246	23.5%
Critical Care	319	13.0%	353	14.6%	392	16.0%	399	17.8%
Dermatology	1,878	18.2%	538	5.3%	675	6.4%	771	7.7%
Emergency Medicine	31,000	62.6%	32,030	65.0%	33,976	66.6%	33,880	64.4%
Endocrinology	899	17.8%	866	17.2%	1,042	20.1%	1,139	24.2%
Family Practice	14,557	16.0%	14,778	16.1%	16,944	17.9%	18,745	21.3%
Gastroenterology	1,414	12.0%	1,820	15.2%	2,202	18.1%	2,544	22.6%
General Practice	308	5.3%	370	6.3%	433	7.3%	586	10.2%
General Surgery	2,593	11.9%	2,879	13.3%	3,198	14.6%	3,704	17.8%
Geriatrics	562	13.9%	569	14.0%	615	15.1%	676	18.2%
Hand Surgery	139	9.7%	186	12.2%	221	13.9%	235	14.9%
Infectious Disease	383	7.5%	452	8.9%	543	10.2%	684	13.6%
Internal Medicine	14,231	15.4%	14,427	15.6%	17,110	17.7%	17,477	20.3%
Interventional Radiologist	433	31.5%	522	38.3%	657	41.6%	822	49.6%
Nephrology	1,157	14.9%	1,050	13.1%	1,106	13.2%	1,236	16.1%
Neurology	1,241	10.0%	1,484	12.1%	1,879	14.9%	2,142	18.5%
Neurosurgery	590	13.0%	634	14.2%	692	15.5%	900	21.6%
Nuclear Medicine	110	15.4%	138	19.6%	126	18.4%	147	25.3%
Obstetrics/Gynecology	1,771	6.0%	2,238	7.5%	2,697	8.8%	3,323	11.5%
Oncology/Hematology	2,629	24.2%	2,649	24.6%	2,770	24.9%	2,765	27.0%
Ophthalmology	7,044	37.1%	7,555	39.9%	8,087	42.6%	8,133	44.9%
Oral/Maxillofacial Surgery	13	3.5%	12	3.2%	13	3.4%	31	8.2%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Orthopaedic Surgery	3,321	16.1%	3,687	17.8%	3,851	18.3%	4,138	20.7%
Other MD/DO	908	11.2%	1,037	11.6%	1,327	13.0%	1,480	14.7%
Otolaryngology	778	9.2%	905	10.8%	1,117	12.9%	1,303	16.2%
Pathology	4,529	58.8%	4,733	61.3%	4,814	63.0%	5,144	61.7%
Pediatrics	319	5.5%	302	5.2%	414	6.5%	553	8.2%
Physical Medicine	505	6.6%	553	7.0%	686	8.4%	896	11.4%
Plastic Surgery	202	4.8%	246	5.7%	291	6.7%	327	7.7%
Psychiatry	540	1.8%	674	2.2%	738	2.4%	901	3.0%
Pulmonary Disease	1,184	13.5%	1,433	15.7%	1,778	18.4%	1,948	21.9%
Radiation Oncology	789	17.6%	755	17.0%	996	22.1%	1,047	24.7%
Radiologist	11,730	31.5%	14,554	38.8%	17,012	45.4%	18,333	51.7%
Rheumatology	721	17.1%	789	19.2%	840	19.8%	899	23.2%
Thoracic/Cardiac Surgery	1,079	30.2%	1,037	29.3%	1,069	30.3%	977	29.5%
Urology	1,744	18.6%	2,252	24.4%	2,641	28.0%	2,508	29.6%
Vascular Surgery	647	21.4%	724	22.9%	797	24.9%	846	27.8%
<b>Other Eligible Professionals</b>	<b>49,086</b>	<b>12.8%</b>	<b>55,378</b>	<b>14.1%</b>	<b>66,610</b>	<b>15.9%</b>	<b>76,855</b>	<b>16.7%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	203	6.5%	233	7.1%	279	9.1%	295	0.9%
Audiologist	112	1.9%	171	2.8%	232	3.6%	392	6.3%
Certified Nurse Midwives	67	5.9%	72	6.2%	105	7.5%	160	11.1%
Chiropractor	460	1.0%	546	1.1%	853	1.8%	1,493	3.1%
Clinical Nurse Specialists	157	8.0%	179	8.6%	195	8.7%	238	10.6%
Counselor/Psychologist	413	1.3%	461	1.5%	581	1.8%	598	1.9%
Dentist	16	0.5%	20	0.6%	29	0.9%	30	1.0%
Dietitian/Nutritionist	149	6.5%	136	5.9%	176	7.1%	137	5.8%
Nurse Anesthetist	11,781	29.2%	14,274	34.6%	17,130	38.8%	18,669	41.0%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Nurse Practitioner	6,064	13.7%	6,721	13.8%	8,115	14.3%	10,136	16.6%
Optometry	5,837	19.5%	6,949	22.4%	8,811	27.2%	9,969	30.0%
Other Eligible Professional	7,655	16.4%	7,595	17.4%	8,307	19.0%	8,596	21.0%
Physical/Occupational Therapy	5,693	15.1%	6,081	15.3%	7,310	16.8%	9,246	19.8%
Physician Assistant	8,623	22.3%	9,529	22.8%	11,093	23.7%	12,953	25.2%
Podiatrist	970	5.6%	1,499	8.6%	2,359	13.2%	2,828	16.5%
Registered Nurse	677	16.2%	707	18.6%	746	20.3%	787	22.5%
Social Worker	209	0.7%	205	0.7%	289	0.9%	328	1.0%
Unknown/Missing	290	13.9%	92	9.4%	115	11.9%	129	12.0%
<b>Total (Unduplicated)</b>	<b>185,154</b>	<b>18.4%</b>	<b>200,517</b>	<b>19.7%</b>	<b>229,282</b>	<b>21.6%</b>	<b>248,206</b>	<b>23.3%</b>

*Notes for Table A9: Eligible professionals who were part of a practice that participated under the GPRO and eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO model are excluded.*



**Table A10. Eligible Professionals who Participated by Reporting Measures Groups through the Claims Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
<b>MD/DO</b>	<b>3,155</b>	<b>0.5%</b>	<b>3,487</b>	<b>0.6%</b>	<b>3,758</b>	<b>0.6%</b>	<b>3,861</b>	<b>0.6%</b>
Allergy/Immunology	4	0.1%	0	0.0%	6	0.2%	4	0.1%
Anesthesiology	37	0.1%	38	0.1%	58	0.1%	61	0.1%
Cardiology	42	0.2%	559	2.4%	635	2.6%	549	2.6%
Colon/Rectal Surgery	8	0.7%	16	1.5%	4	0.4%	6	0.6%
Critical Care	9	0.4%	5	0.2%	6	0.2%	7	0.3%
Dermatology	6	0.1%	12	0.1%	1	0.0%	1	0.0%
Emergency Medicine	6	0.0%	47	0.1%	7	0.0%	144	0.3%
Endocrinology	71	1.4%	50	1.0%	66	1.3%	72	1.5%
Family Practice	928	1.0%	759	0.8%	826	0.9%	880	1.0%
Gastroenterology	29	0.2%	18	0.2%	23	0.2%	25	0.2%
General Practice	14	0.2%	12	0.2%	18	0.3%	12	0.2%
General Surgery	145	0.7%	140	0.6%	125	0.6%	104	0.5%
Geriatrics	31	0.8%	36	0.9%	32	0.8%	27	0.7%
Hand Surgery	3	0.2%	4	0.3%	11	0.7%	12	0.8%
Infectious Disease	2	0.0%	2	0.0%	2	0.0%	3	0.1%
Internal Medicine	997	1.1%	895	1.0%	966	1.0%	823	1.0%
Interventional Radiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nephrology	117	1.5%	91	1.1%	84	1.0%	121	1.6%
Neurology	19	0.2%	10	0.1%	8	0.1%	7	0.1%
Neurosurgery	59	1.3%	71	1.6%	75	1.7%	75	1.8%
Nuclear Medicine	0	0.0%	1	0.1%	1	0.1%	1	0.2%
Obstetrics/Gynecology	41	0.1%	29	0.1%	49	0.2%	112	0.4%
Oncology/Hematology	22	0.2%	24	0.2%	14	0.1%	16	0.2%
Ophthalmology	16	0.1%	1	0.0%	1	0.0%	9	0.0%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Orthopaedic Surgery	245	1.2%	285	1.4%	349	1.7%	381	1.9%
Other MD/DO	46	0.6%	41	0.5%	48	0.5%	50	0.5%
Otolaryngology	6	0.1%	4	0.0%	2	0.0%	5	0.1%
Pathology	0	0.0%	0	0.0%	0	0.0%	1	0.0%
Pediatrics	2	0.0%	2	0.0%	4	0.1%	6	0.1%
Physical Medicine	28	0.4%	45	0.6%	63	0.8%	64	0.8%
Plastic Surgery	3	0.1%	0	0.0%	0	0.0%	1	0.0%
Psychiatry	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pulmonary Disease	24	0.3%	34	0.4%	38	0.4%	69	0.8%
Radiation Oncology	4	0.1%	0	0.0%	1	0.0%	0	0.0%
Radiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rheumatology	149	3.5%	204	5.0%	183	4.3%	188	4.8%
Thoracic/Cardiac Surgery	9	0.3%	9	0.3%	9	0.3%	13	0.4%
Urology	17	0.2%	30	0.3%	35	0.4%	6	0.1%
Vascular Surgery	16	0.5%	13	0.4%	8	0.2%	6	0.2%
<b>Other Eligible Professionals</b>	<b>490</b>	<b>0.1%</b>	<b>664</b>	<b>0.2%</b>	<b>713</b>	<b>0.2%</b>	<b>912</b>	<b>0.2%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	2	0.1%	1	0.0%	3	0.1%	3	0.0%
Audiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Certified Nurse Midwives	0	0.0%	0	0.0%	2	0.1%	2	0.1%
Chiropractor	11	0.0%	0	0.0%	0	0.0%	0	0.0%
Clinical Nurse Specialists	3	0.2%	9	0.4%	8	0.4%	13	0.6%
Counselor/Psychologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dentist	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Dietitian/Nutritionist	0	0.0%	0	0.0%	3	0.1%	4	0.2%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nurse Practitioner	164	0.4%	153	0.3%	183	0.3%	268	0.4%
Optometry	20	0.1%	0	0.0%	0	0.0%	5	0.0%
Other Eligible Professional	152	0.3%	222	0.5%	201	0.5%	202	0.5%
Physical/Occupational Therapy	0	0.0%	158	0.4%	179	0.4%	232	0.5%
Physician Assistant	113	0.3%	109	0.3%	121	0.3%	145	0.3%
Podiatrist	19	0.1%	7	0.0%	12	0.1%	35	0.2%
Registered Nurse	6	0.1%	5	0.1%	1	0.0%	3	0.1%
Social Worker	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Unknown/Missing	4	0.2%	0	0.0%	1	0.1%	3	0.3%
<b>Total (Unduplicated)</b>	<b>3,649</b>	<b>0.4%</b>	<b>4,151</b>	<b>0.4%</b>	<b>4,472</b>	<b>0.4%</b>	<b>4,776</b>	<b>0.4%</b>

*Notes for Table A10: Eligible professionals who were part of a practice that participated under the GPRO and eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model are excluded.*

**Table A11. Eligible Professionals who Participated in Individual Measures through the Registry Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012).**

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
<b>MD/DO</b>	<b>19,054</b>	<b>3.1%</b>	<b>32,532</b>	<b>5.2%</b>	<b>41,587</b>	<b>6.5%</b>	<b>28,832</b>	<b>4.8%</b>
Allergy/Immunology	81	2.3%	105	3.1%	215	6.2%	120	3.6%
Anesthesiology	112	0.3%	172	0.4%	164	0.4%	194	0.5%
Cardiology	1,358	5.8%	2,199	9.3%	2,949	12.2%	1,531	7.1%
Colon/Rectal Surgery	27	2.5%	51	4.8%	93	8.4%	51	4.9%
Critical Care	43	1.8%	83	3.4%	115	4.7%	93	4.1%
Dermatology	257	2.5%	1,311	12.8%	1,834	17.5%	1,700	16.9%
Emergency Medicine	366	0.7%	475	1.0%	489	1.0%	319	0.6%
Endocrinology	383	7.6%	467	9.3%	650	12.6%	355	7.5%
Family Practice	4,509	5.0%	7,059	7.7%	8,663	9.1%	4,921	5.6%
Gastroenterology	337	2.9%	613	5.1%	1,008	8.3%	727	6.5%
General Practice	50	0.9%	80	1.4%	83	1.4%	66	1.1%
General Surgery	557	2.5%	881	4.1%	1,278	5.8%	1,092	5.3%
Geriatrics	192	4.7%	268	6.6%	319	7.8%	208	5.6%
Hand Surgery	23	1.6%	62	4.1%	71	4.5%	69	4.4%
Infectious Disease	219	4.3%	346	6.8%	478	9.0%	279	5.5%
Internal Medicine	4,505	4.9%	7,239	7.8%	8,901	9.2%	5,538	6.4%
Interventional Radiologist	26	1.9%	50	3.7%	81	5.1%	66	4.0%
Nephrology	269	3.5%	397	5.0%	618	7.4%	476	6.2%
Neurology	387	3.1%	627	5.1%	829	6.6%	588	5.1%
Neurosurgery	139	3.1%	203	4.6%	249	5.6%	210	5.0%
Nuclear Medicine	14	2.0%	26	3.7%	51	7.5%	20	3.4%
Obstetrics/Gynecology	833	2.8%	1,276	4.3%	1,707	5.6%	886	3.1%
Oncology/Hematology	328	3.0%	655	6.1%	1,073	9.6%	662	6.5%
Ophthalmology	441	2.3%	1,061	5.6%	1,395	7.4%	1,301	7.2%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Oral/Maxillofacial Surgery	0	0.0%	2	0.5%	9	2.4%	1	0.3%
Orthopaedic Surgery	563	2.7%	842	4.1%	1,106	5.3%	1,015	5.1%
Other MD/DO	140	1.7%	372	4.1%	465	4.5%	487	4.8%
Otolaryngology	227	2.7%	490	5.9%	687	7.9%	514	6.4%
Pathology	13	0.2%	29	0.4%	24	0.3%	168	2.0%
Pediatrics	193	3.3%	348	6.0%	343	5.4%	214	3.2%
Physical Medicine	98	1.3%	182	2.3%	271	3.3%	207	2.6%
Plastic Surgery	90	2.1%	114	2.6%	147	3.4%	103	2.4%
Psychiatry	176	0.6%	184	0.6%	229	0.7%	194	0.7%
Pulmonary Disease	254	2.9%	471	5.2%	798	8.3%	467	5.3%
Radiation Oncology	212	4.7%	327	7.4%	387	8.6%	410	9.7%
Radiologist	383	1.0%	1,710	4.6%	1,537	4.1%	1,541	4.3%
Rheumatology	218	5.2%	289	7.0%	389	9.2%	250	6.4%
Thoracic/Cardiac Surgery	493	13.8%	647	18.3%	755	21.4%	659	19.9%
Urology	399	4.3%	626	6.8%	875	9.3%	916	10.8%
Vascular Surgery	139	4.6%	193	6.1%	252	7.9%	214	7.0%
<b>Other Eligible Professionals</b>	<b>3,660</b>	<b>1.0%</b>	<b>6,699</b>	<b>1.7%</b>	<b>8,601</b>	<b>2.1%</b>	<b>7,581</b>	<b>1.6%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	14	0.4%	42	1.3%	46	1.5%	47	0.1%
Audiologist	32	0.5%	60	1.0%	36	0.6%	20	0.3%
Certified Nurse Midwives	34	3.0%	53	4.5%	83	6.0%	43	3.0%
Chiropractor	12	0.0%	11	0.0%	9	0.0%	4	0.0%
Clinical Nurse Specialists	30	1.5%	47	2.3%	71	3.2%	31	1.4%
Counselor/Psychologist	106	0.3%	98	0.3%	124	0.4%	79	0.2%
Dentist	4	0.1%	11	0.3%	21	0.6%	22	0.7%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Dietitian/Nutritionist	46	2.0%	54	2.3%	49	2.0%	24	1.0%
Nurse Anesthetist	19	0.0%	17	0.0%	60	0.1%	107	0.2%
Nurse Practitioner	1,261	2.8%	2,237	4.6%	2,992	5.3%	1,961	3.2%
Optometry	100	0.3%	215	0.7%	268	0.8%	296	0.9%
Other Eligible Professional	632	1.4%	1,332	3.0%	1,524	3.5%	1,413	3.4%
Physical/Occupational Therapy	142	0.4%	446	1.1%	734	1.7%	1,765	3.8%
Physician Assistant	942	2.4%	1,714	4.1%	2,171	4.6%	1,499	2.9%
Podiatrist	154	0.9%	260	1.5%	273	1.5%	185	1.1%
Registered Nurse	47	1.1%	67	1.8%	74	2.0%	54	1.5%
Social Worker	85	0.3%	35	0.1%	66	0.2%	31	0.1%
Unknown/Missing	36	1.7%	24	2.4%	27	2.8%	60	5.6%
<b>Total (Unduplicated)</b>	<b>22,750</b>	<b>2.3%</b>	<b>39,255</b>	<b>3.9%</b>	<b>50,215</b>	<b>4.7%</b>	<b>36,473</b>	<b>3.4%</b>

*Notes for Table A11: Eligible professionals who are part of a practice that participated under the GPRO and eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model are excluded.*

**Table A12. Eligible Professionals who Participated in the Measures Groups through the Registry Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
<b>MD/DO</b>	<b>9,135</b>	<b>1.5%</b>	<b>15,006</b>	<b>2.4%</b>	<b>11,392</b>	<b>1.8%</b>	<b>9,192</b>	<b>1.5%</b>
Allergy/Immunology	64	1.8%	70	2.0%	10	0.3%	9	0.3%
Anesthesiology	34	0.1%	31	0.1%	30	0.1%	19	0.0%
Cardiology	651	2.8%	2,279	9.6%	2,039	8.5%	1,672	7.8%
Colon/Rectal Surgery	42	3.9%	31	2.9%	7	0.6%	3	0.3%
Critical Care	16	0.7%	26	1.1%	10	0.4%	10	0.4%
Dermatology	63	0.6%	48	0.5%	19	0.2%	8	0.1%
Emergency Medicine	28	0.1%	61	0.1%	74	0.1%	28	0.1%
Endocrinology	130	2.6%	182	3.6%	151	2.9%	113	2.4%
Family Practice	2,891	3.2%	4,042	4.4%	2,800	3.0%	1,923	2.2%
Gastroenterology	141	1.2%	340	2.8%	171	1.4%	132	1.2%
General Practice	40	0.7%	77	1.3%	53	0.9%	37	0.6%
General Surgery	156	0.7%	350	1.6%	176	0.8%	100	0.5%
Geriatrics	99	2.4%	150	3.7%	134	3.3%	97	2.6%
Hand Surgery	10	0.7%	24	1.6%	13	0.8%	12	0.8%
Infectious Disease	47	0.9%	89	1.8%	63	1.2%	51	1.0%
Internal Medicine	1,961	2.1%	3,045	3.3%	2,433	2.5%	1,882	2.2%
Interventional Radiologist	0	0.0%	1	0.1%	1	0.1%	1	0.1%
Nephrology	755	9.7%	1,164	14.6%	1,071	12.8%	1,105	14.4%
Neurology	93	0.7%	85	0.7%	63	0.5%	127	1.1%
Neurosurgery	34	0.7%	67	1.5%	38	0.8%	35	0.8%
Nuclear Medicine	1	0.1%	15	2.1%	11	1.6%	10	1.7%
Obstetrics/Gynecology	143	0.5%	226	0.8%	124	0.4%	81	0.3%
Oncology/Hematology	242	2.2%	336	3.1%	242	2.2%	211	2.1%
Ophthalmology	133	0.7%	191	1.0%	105	0.6%	110	0.6%

Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Orthopaedic Surgery	355	1.7%	571	2.8%	426	2.0%	376	1.9%
Other MD/DO	51	0.6%	98	1.1%	74	0.7%	69	0.7%
Otolaryngology	147	1.7%	233	2.8%	179	2.1%	139	1.7%
Pathology	1	0.0%	0	0.0%	0	0.0%	0	0.0%
Pediatrics	14	0.2%	16	0.3%	7	0.1%	7	0.1%
Physical Medicine	60	0.8%	74	0.9%	46	0.6%	43	0.5%
Plastic Surgery	22	0.5%	18	0.4%	7	0.2%	2	0.0%
Psychiatry	8	0.0%	11	0.0%	4	0.0%	14	0.0%
Pulmonary Disease	138	1.6%	224	2.5%	146	1.5%	205	2.3%
Radiation Oncology	30	0.7%	26	0.6%	31	0.7%	21	0.5%
Radiologist	10	0.0%	2	0.0%	3	0.0%	1	0.0%
Rheumatology	266	6.3%	370	9.0%	367	8.7%	314	8.1%
Thoracic/Cardiac Surgery	29	0.8%	56	1.6%	41	1.2%	29	0.9%
Urology	195	2.1%	303	3.3%	172	1.8%	133	1.6%
Vascular Surgery	35	1.2%	74	2.3%	51	1.6%	63	2.1%
<b>Other Eligible Professionals</b>	<b>1,210</b>	<b>0.3%</b>	<b>2,108</b>	<b>0.5%</b>	<b>1,488</b>	<b>0.4%</b>	<b>1,279</b>	<b>0.3%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	15	0.5%	22	0.7%	23	0.7%	13	0.0%
Audiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Certified Nurse Midwives	2	0.2%	4	0.3%	0	0.0%	1	0.1%
Chiropractor	4	0.0%	9	0.0%	0	0.0%	1	0.0%
Clinical Nurse Specialists	12	0.6%	7	0.3%	7	0.3%	5	0.2%
Counselor/Psychologist	0	0.0%	0	0.0%	1	0.0%	2	0.0%
Dentist	3	0.1%	0	0.0%	0	0.0%	0	0.0%



Specialty	Eligible Professionals Participating in 2009	Percent of Eligible Professionals Participating in 2009	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Dietitian/Nutritionist	2	0.1%	5	0.2%	3	0.1%	2	0.1%
Nurse Anesthetist	0	0.0%	11	0.0%	0	0.0%	0	0.0%
Nurse Practitioner	344	0.8%	598	1.2%	503	0.9%	470	0.8%
Optometry	44	0.1%	63	0.2%	14	0.0%	4	0.0%
Other Eligible Professional	480	1.0%	866	2.0%	598	1.4%	490	1.2%
Physical/Occupational Therapy	5	0.0%	58	0.1%	30	0.1%	8	0.0%
Physician Assistant	214	0.6%	311	0.7%	240	0.5%	228	0.4%
Podiatrist	79	0.5%	144	0.8%	59	0.3%	48	0.3%
Registered Nurse	6	0.1%	10	0.3%	10	0.3%	7	0.2%
Social Worker	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Unknown/Missing	11	0.5%	19	1.9%	14	1.4%	7	0.6%
<b>Total (Unduplicated)</b>	<b>10,356</b>	<b>1.0%</b>	<b>17,133</b>	<b>1.7%</b>	<b>12,894</b>	<b>1.2%</b>	<b>10,478</b>	<b>1.0%</b>

*Notes for Table A12: Eligible professionals who are part of a practice that participated under the GPRO and eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model are excluded.*

**Table A13. Eligible Professionals who Participated through the EHR Reporting Mechanism for the Physician Quality Reporting System, by Specialty (2010 to 2012)**

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
<b>MD/DO</b>	<b>10</b>	<b>0.0%</b>	<b>440</b>	<b>0.1%</b>	<b>16,152</b>	<b>2.7%</b>
Allergy/Immunology	0	0.0%	0	0.0%	65	2.0%
Anesthesiology	0	0.0%	0	0.0%	82	0.2%
Cardiology	0	0.0%	40	0.2%	1,560	7.3%
Colon/Rectal Surgery	0	0.0%	0	0.0%	39	3.7%
Critical Care	0	0.0%	0	0.0%	27	1.2%
Dermatology	0	0.0%	5	0.0%	167	1.7%
Emergency Medicine	0	0.0%	2	0.0%	194	0.4%
Endocrinology	0	0.0%	1	0.0%	236	5.0%
Family Practice	7	0.0%	174	0.2%	4,539	5.2%
Gastroenterology	0	0.0%	7	0.1%	410	3.6%
General Practice	1	0.0%	9	0.2%	69	1.2%
General Surgery	0	0.0%	10	0.0%	660	3.2%
Geriatrics	0	0.0%	2	0.0%	108	2.9%
Hand Surgery	0	0.0%	2	0.1%	32	2.0%
Infectious Disease	0	0.0%	5	0.1%	178	3.5%
Internal Medicine	2	0.0%	78	0.1%	3,215	3.7%
Interventional Radiologist	0	0.0%	0	0.0%	11	0.7%
Nephrology	0	0.0%	5	0.1%	183	2.4%
Neurology	0	0.0%	11	0.1%	422	3.6%
Neurosurgery	0	0.0%	0	0.0%	91	2.2%
Nuclear Medicine	0	0.0%	0	0.0%	14	2.4%
Obstetrics/Gynecology	0	0.0%	9	0.0%	1,003	3.5%
Oncology/Hematology	0	0.0%	5	0.0%	260	2.5%
Ophthalmology	0	0.0%	0	0.0%	89	0.5%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	1	0.3%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Orthopaedic Surgery	0	0.0%	24	0.1%	528	2.6%
Other MD/DO	0	0.0%	3	0.0%	100	1.0%
Otolaryngology	0	0.0%	7	0.1%	185	2.3%
Pathology	0	0.0%	0	0.0%	6	0.1%
Pediatrics	0	0.0%	2	0.0%	108	1.6%
Physical Medicine	0	0.0%	3	0.0%	129	1.6%
Plastic Surgery	0	0.0%	0	0.0%	76	1.8%
Psychiatry	0	0.0%	0	0.0%	190	0.6%
Pulmonary Disease	0	0.0%	9	0.1%	420	4.7%
Radiation Oncology	0	0.0%	0	0.0%	35	0.8%
Radiologist	0	0.0%	0	0.0%	51	0.1%
Rheumatology	0	0.0%	5	0.1%	165	4.3%
Thoracic/Cardiac Surgery	0	0.0%	0	0.0%	101	3.1%
Urology	0	0.0%	17	0.2%	317	3.7%
Vascular Surgery	0	0.0%	5	0.2%	86	2.8%
<b>Other Eligible Professionals</b>	<b>4</b>	<b>0.0%</b>	<b>119</b>	<b>0.0%</b>	<b>3,653</b>	<b>0.8%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	0	0.0%	1	0.0%	25	0.1%
Audiologist	0	0.0%	0	0.0%	14	0.2%
Certified Nurse Midwives	0	0.0%	1	0.1%	36	2.5%
Chiropractor	0	0.0%	0	0.0%	7	0.0%
Clinical Nurse Specialists	0	0.0%	1	0.0%	31	1.4%
Counselor/Psychologist	0	0.0%	0	0.0%	45	0.1%
Dentist	0	0.0%	0	0.0%	1	0.0%
Dietitian/Nutritionist	0	0.0%	0	0.0%	9	0.4%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%
Nurse Practitioner	2	0.0%	41	0.1%	1,588	2.6%
Optometry	0	0.0%	0	0.0%	24	0.1%

Specialty	Eligible Professionals Participating in 2010	Percent of Eligible Professionals Participating in 2010	Eligible Professionals Participating in 2011	Percent of Eligible Professionals Participating in 2011	Eligible Professionals Participating in 2012	Percent of Eligible Professionals Participating in 2012
Other Eligible Professional	1	0.0%	22	0.1%	534	1.3%
Physical/Occupational Therapy	0	0.0%	0	0.0%	35	0.1%
Physician Assistant	1	0.0%	39	0.1%	1,098	2.1%
Podiatrist	0	0.0%	12	0.1%	150	0.9%
Registered Nurse	0	0.0%	2	0.1%	27	0.8%
Social Worker	0	0.0%	0	0.0%	29	0.1%
Unknown/Missing	0	0.0%	1	0.1%	12	1.1%
<b>Total (Unduplicated)</b>	<b>14</b>	<b>0.0%</b>	<b>560</b>	<b>0.1%</b>	<b>19,817</b>	<b>1.9%</b>

*Notes for Table A13: Eligible professionals who are part of a practice that participated under the GPRO and eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model are excluded.*

**Table A14. Eligible Professionals who Participated in the Physician Quality Reporting System by the Number of Medicare Beneficiaries, by Specialty (2012)**

Specialty	Number EPs with 25 or fewer patients participating	Participation Rate for EPs with 25 or fewer patients participating	Number EPs with 26-100 patients	Participation Rate for EPs with 26-100 patients participating	Number EPs with 101-200 patients	Participation Rate for EPs with 101-200 patients participating	Number EPs with more than 200 patients	Participation Rate for EPs with more than 200 patients participating	Total EPs	Overall Participation Rate
<b>MD/DO</b>	<b>37,911</b>	<b>25.3%</b>	<b>57,794</b>	<b>38.9%</b>	<b>59,933</b>	<b>47.8%</b>	<b>152,443</b>	<b>55.3%</b>	<b>315,334</b>	<b>44.6%</b>
Allergy/Immunology	193	22.6%	390	27.5%	257	27.9%	167	28.8%	1,023	27.0%
Anesthesiology	3,304	40.4%	6,208	58.2%	8,605	67.9%	10,143	69.3%	28,318	61.3%
Cardiology	698	22.7%	1,070	37.8%	1,382	47.1%	10,294	60.2%	14,354	53.5%
Colon/Rectal Surgery	35	24.3%	105	43.0%	187	48.6%	202	42.3%	530	42.4%
Critical Care	122	24.7%	197	29.9%	214	34.0%	393	44.4%	946	35.2%
Dermatology	239	18.3%	342	27.0%	437	31.1%	2,781	37.5%	3,853	33.6%
Emergency Medicine	3,839	36.3%	6,523	64.1%	5,813	72.3%	22,880	79.8%	39,132	68.0%
Endocrinology	268	33.0%	530	49.3%	574	54.3%	1,558	52.5%	2,978	50.0%
Family Practice	3,518	18.6%	8,253	35.2%	10,835	47.1%	18,577	51.8%	41,912	41.1%
Gastroenterology	367	25.3%	772	43.8%	1,104	49.0%	3,535	44.5%	5,875	43.5%
General Practice	129	6.1%	242	15.2%	231	23.4%	426	30.7%	1,045	17.1%
General Surgery	1,041	21.0%	2,240	33.5%	2,635	43.1%	2,561	40.9%	8,665	35.8%
Geriatrics	132	20.6%	277	33.7%	312	36.8%	1,095	49.5%	1,841	40.5%
Hand Surgery	31	14.8%	77	26.0%	125	31.6%	311	35.1%	551	30.7%
Infectious Disease	284	24.4%	590	38.4%	502	43.7%	752	33.6%	2,157	35.3%
Internal Medicine	3,822	22.1%	7,603	36.9%	9,204	45.0%	24,016	51.5%	45,565	43.0%
Interventional Radiologist	153	31.2%	159	48.5%	229	64.3%	532	77.3%	1,096	58.1%
Nephrology	212	20.7%	453	35.9%	579	45.4%	3,127	55.0%	4,413	47.5%
Neurology	739	27.0%	1,161	40.7%	1,211	46.1%	2,726	44.2%	6,016	41.3%
Neurosurgery	188	23.5%	476	40.4%	554	44.6%	756	44.2%	1,997	40.3%
Nuclear Medicine	50	24.5%	81	38.6%	56	46.7%	94	62.3%	301	42.7%
Obstetrics/Gynecology	3,110	24.2%	4,040	30.8%	1,379	29.1%	770	31.6%	9,722	29.0%

Specialty	Number EPs with 25 or fewer patients participating	Participation Rate for EPs with 25 or fewer patients participating	Number EPs with 26-100 patients	Participation Rate for EPs with 26-100 patients participating	Number EPs with 101-200 patients	Participation Rate for EPs with 101-200 patients participating	Number EPs with more than 200 patients	Participation Rate for EPs with more than 200 patients participating	Total EPs	Overall Participation Rate
Oncology/Hematology	484	28.8%	997	40.3%	1,218	48.5%	3,401	56.4%	6,163	48.3%
Ophthalmology	623	24.0%	885	37.5%	822	44.9%	8,726	65.2%	11,135	55.0%
Oral/Maxillofacial Surgery	27	10.9%	26	20.0%	10	45.5%	2	16.7%	70	16.8%
Orthopaedic Surgery	569	17.5%	969	28.5%	1,552	37.0%	5,055	43.1%	8,278	36.5%
Other MD/DO	554	19.1%	850	32.7%	775	35.8%	1,548	36.8%	3,807	31.9%
Otolaryngology	285	20.4%	434	35.9%	570	39.3%	2,102	39.4%	3,429	36.4%
Pathology	3,605	59.7%	2,593	79.8%	81	57.4%	26	50.0%	7,050	69.0%
Pediatrics	1,781	25.5%	239	35.2%	132	44.1%	131	57.0%	3,026	33.8%
Physical Medicine	241	14.9%	411	19.8%	544	30.5%	1,035	30.6%	2,248	25.3%
Plastic Surgery	214	13.5%	432	22.8%	233	29.7%	100	21.6%	1,006	21.2%
Psychiatry	1,479	10.7%	1,313	12.3%	638	14.2%	448	13.3%	3,989	12.3%
Pulmonary Disease	304	23.3%	619	37.3%	734	43.4%	2,978	49.3%	4,759	44.0%
Radiation Oncology	301	27.8%	693	44.1%	718	51.0%	460	48.5%	2,215	43.8%
Radiologist	4,079	35.3%	3,897	55.4%	3,599	65.8%	11,558	74.2%	24,065	59.3%
Rheumatology	155	26.6%	365	47.4%	453	51.1%	1,467	58.2%	2,465	51.5%
Thoracic/Cardiac Surgery	316	36.6%	745	57.0%	685	65.9%	472	62.3%	2,338	57.2%
Urology	318	19.5%	364	39.5%	484	47.7%	4,141	62.0%	5,351	52.0%
Vascular Surgery	102	21.4%	173	32.7%	260	45.5%	1,097	55.1%	1,650	46.0%
<b>Other Eligible Professionals</b>	<b>27,148</b>	<b>13.4%</b>	<b>36,006</b>	<b>24.4%</b>	<b>25,169</b>	<b>36.2%</b>	<b>29,190</b>	<b>41.0%</b>	<b>120,255</b>	<b>24.4%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	141	0.8%	151	1.3%	101	3.6%	155	11.7%	623	1.9%
Audiologist	208	10.7%	390	16.9%	302	20.1%	226	19.2%	1,132	16.3%
Certified Nurse Midwives	488	30.7%	44	31.0%	5	38.5%	2	40.0%	602	33.3%
Chiropractor	445	2.1%	800	3.7%	298	6.1%	80	7.2%	1,626	3.4%
Clinical Nurse Specialists	159	16.5%	208	24.2%	122	30.0%	110	34.4%	618	24.1%

Specialty	Number EPs with 25 or fewer patients participating	Participation Rate for EPs with 25 or fewer patients participating	Number EPs with 26-100 patients	Participation Rate for EPs with 26-100 patients participating	Number EPs with 101-200 patients	Participation Rate for EPs with 101-200 patients participating	Number EPs with more than 200 patients	Participation Rate for EPs with more than 200 patients participating	Total EPs	Overall Participation Rate
Counselor/Psychologist	1,070	4.2%	587	9.9%	144	11.1%	57	7.4%	1,980	5.9%
Dentist	139	6.4%	53	6.4%	14	13.6%	4	10.5%	235	7.4%
Dietitian/Nutritionist	380	19.6%	224	29.7%	52	34.7%	10	21.7%	671	23.2%
Nurse Anesthetist	4,104	33.6%	6,832	44.7%	7,358	53.4%	3,567	47.2%	21,883	44.8%
Nurse Practitioner	5,436	22.7%	6,799	31.5%	4,864	38.6%	5,128	43.8%	23,042	32.6%
Optometry	1,005	12.6%	2,341	24.1%	2,488	37.3%	5,005	52.4%	10,852	32.0%
Other Eligible Professional	2,190	19.2%	3,040	30.4%	2,374	34.2%	6,623	40.9%	14,697	32.6%
Physical/Occupational Therapy	4,814	21.2%	6,308	29.8%	887	25.6%	142	20.9%	12,429	25.7%
Physician Assistant	5,204	25.3%	7,032	40.1%	5,109	48.3%	5,109	51.5%	23,179	39.1%
Podiatrist	217	10.4%	452	17.3%	701	21.6%	2,785	27.2%	4,211	23.1%
Registered Nurse	284	22.1%	402	34.1%	331	38.9%	185	35.0%	1,232	31.8%
Social Worker	864	3.1%	343	7.1%	19	5.4%	2	5.3%	1,243	3.7%
Unknown/Missing	54	11.1%	59	19.6%	55	35.0%	35	26.1%	282	24.4%
<b>Total (Unduplicated)</b>	<b>65,113</b>	<b>18.5%</b>	<b>93,859</b>	<b>31.7%</b>	<b>85,157</b>	<b>43.6%</b>	<b>181,668</b>	<b>52.4%</b>	<b>435,871</b>	<b>36.3%</b>

Notes for Table A14: (1) Results include eligible professionals who belong to a practice that reported under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) There were 10,085 eligible professionals for whom we could not obtain beneficiary counts that are not included in this table.

**Table A15. Eligible Professionals, Participation, and Incentive Information for the Physician Quality Reporting System, by State (2012)**

State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received an Incentive	Incentive Eligibility Rate
Alaska	2,712	452	16.7%	315	69.7%
Alabama	15,697	4,676	29.8%	3,559	76.1%
Arkansas	9,246	3,676	39.8%	3,132	85.2%
Arizona	22,699	7,595	33.5%	6,495	85.5%
California	103,626	32,472	31.3%	27,820	85.7%
Colorado	18,815	5,860	31.1%	4,603	78.5%
Connecticut	18,167	4,538	25.0%	3,518	77.5%
District of Columbia	3,993	1,376	34.5%	1,232	89.5%
Delaware	4,028	1,255	31.2%	979	78.0%
Florida	69,787	24,873	35.6%	19,634	78.9%
Georgia	31,363	12,371	39.4%	10,321	83.4%
Hawaii	4,244	974	23.0%	587	60.3%
Iowa	12,057	5,482	45.5%	4,973	90.7%
Idaho	5,683	1,352	23.8%	1,101	81.4%
Illinois	50,462	20,691	41.0%	17,409	84.1%
Indiana	23,959	10,007	41.8%	8,492	84.9%
Kansas	11,692	3,447	29.5%	2,674	77.6%
Kentucky	17,227	5,689	33.0%	4,091	71.9%
Louisiana	16,894	5,048	29.9%	3,850	76.3%
Massachusetts	42,236	20,907	49.5%	19,371	92.7%
Maryland	24,844	6,832	27.5%	5,233	76.6%
Maine	8,313	3,857	46.4%	3,635	94.2%
Michigan	47,116	19,710	41.8%	17,541	89.0%
Minnesota	28,453	14,718	51.7%	13,103	89.0%
Missouri	23,329	9,587	41.1%	8,159	85.1%
Mississippi	9,769	2,748	28.1%	2,288	83.3%
Montana	3,945	911	23.1%	698	76.6%
North Carolina	36,744	16,038	43.6%	13,463	83.9%
North Dakota	3,864	1,841	47.6%	1,739	94.5%
Nebraska	7,937	2,493	31.4%	2,096	84.1%
New Hampshire	7,104	3,554	50.0%	3,273	92.1%
New Jersey	38,724	11,496	29.7%	9,386	81.6%
New Mexico	6,877	2,668	38.8%	2,394	89.7%
Nevada	7,242	2,577	35.6%	2,029	78.7%
New York	95,095	29,399	30.9%	25,260	85.9%
Ohio	48,250	20,757	43.0%	17,744	85.5%
Oklahoma	12,721	3,706	29.1%	2,969	80.1%
Oregon	15,073	4,737	31.4%	4,062	85.8%
Pennsylvania	58,389	20,981	35.9%	17,014	81.1%
Puerto Rico	7,133	140	2.0%	67	47.9%
Rhode Island	5,650	1,536	27.2%	1,134	73.8%



State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received an Incentive	Incentive Eligibility Rate
South Carolina	15,830	4,833	30.5%	3,803	78.7%
South Dakota	4,255	1,355	31.8%	1,085	80.1%
Tennessee	26,349	9,344	35.5%	7,316	78.3%
Texas	71,167	27,708	38.9%	23,572	85.1%
Utah	8,411	3,256	38.7%	2,886	88.6%
Virginia	27,547	10,809	39.2%	8,907	82.4%
Virgin Islands	193	30	15.5%	21	70.0%
Vermont	3,175	1,065	33.5%	952	89.4%
Washington	27,497	8,786	32.0%	7,698	87.6%
Wisconsin	24,833	12,575	50.6%	11,256	89.5%
West Virginia	7,371	2,336	31.7%	1,785	76.4%
Wyoming	2,041	371	18.2%	239	64.4%
Other	377	94	24.9%	83	88.3%
Unknown/ Missing	1,157	282	24.4%	182	64.5%
<b>Total (Unduplicated)</b>	<b>1,201,362</b>	<b>435,871</b>	<b>36.3%</b>	<b>367,228</b>	<b>84.3%</b>

*Notes for Table A15: Results include eligible professionals who were part of a practice that participated under the GPRO as well as eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A16. Submission Information for Individual Measures submitted through the Claims Mechanism for the Physician Quality Reporting System (2012)**

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	309,621	22,127	7.1%	15,586	70.4%	59.2%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	309,621	20,211	6.5%	14,408	71.3%	59.5%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	309,621	21,006	6.8%	14,936	71.1%	59.8%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	205,609	7,011	3.4%	5,151	73.5%	70.9%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	252,877	1,862	0.7%	750	40.3%	36.7%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	29,184	13,119	45.0%	10,919	83.2%	72.9%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	47,873	13,506	28.2%	10,275	76.1%	76.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	75,404	13,873	18.4%	10,205	73.6%	77.9%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	47,340	9,993	21.1%	7,453	74.6%	73.3%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	47,340	5,944	12.6%	4,126	69.4%	69.0%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	87,813	4,956	5.6%	3,914	79.0%	71.4%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	64,040	5,348	8.4%	4,182	78.2%	72.4%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	81,092	4,358	5.4%	3,285	75.4%	70.4%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	70,012	4,928	7.0%	3,834	77.8%	71.1%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	204,324	754	0.4%	414	54.9%	33.8%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	38,006	22,386	58.9%	21,070	94.1%	84.2%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	82,842	43,502	52.5%	38,770	89.1%	83.9%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	127,928	4,832	3.8%	3,246	67.2%	53.0%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	108,374	3,308	3.1%	2,038	61.6%	52.7%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	125,481	5,583	4.4%	4,755	85.2%	64.3%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	104,026	3,022	2.9%	1,783	59.0%	49.7%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	503,166	9,019	1.8%	4,030	44.7%	41.0%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	204,324	1,507	0.7%	458	30.4%	24.3%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	159,837	2,903	1.8%	1,640	56.5%	48.0%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	3,302	689	20.9%	643	93.3%	86.6%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported ≥1 Valid QDC	% of Eligible Professionals who Reported ≥1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	3,302	480	14.5%	443	92.3%	85.5%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	3,605	197	5.5%	153	77.7%	68.9%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	467,597	1,436	0.3%	181	12.6%	16.3%
47	Advance Care Plan	616,621	11,147	1.8%	6,385	57.3%	50.4%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	511,112	6,328	1.2%	2,060	32.6%	31.8%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	114,273	1,944	1.7%	1,219	62.7%	61.0%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	114,273	2,038	1.8%	1,259	61.8%	61.1%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	199,877	3,079	1.5%	1,756	57.0%	53.2%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	199,877	2,099	1.1%	1,174	55.9%	48.7%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
53	Asthma: Pharmacologic Therapy for Persistent Asthma	76,119	708	0.9%	547	77.3%	51.7%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	70,810	43,646	61.6%	40,850	93.6%	86.7%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	54,158	27,318	50.4%	23,606	86.4%	74.1%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	191,845	41,714	21.7%	38,379	92.0%	84.5%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	191,845	41,945	21.9%	39,391	93.9%	87.6%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	191,845	38,703	20.2%	36,390	94.0%	87.5%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	191,845	31,277	16.3%	27,608	88.3%	79.5%
64	Asthma: Assessment of Asthma Control	76,119	360	0.5%	286	79.4%	54.2%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	164	1	0.6%	1	100.0%	100.0%
66	Appropriate Testing for Children with Pharyngitis	129	0	0.0%	0	0.0%	0.0%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported ≥1 Valid QDC	% of Eligible Professionals who Reported ≥1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	28,808	1,144	4.0%	893	78.1%	68.5%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	23,689	835	3.5%	597	71.5%	60.2%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	35,600	1,369	3.8%	1,080	78.9%	67.3%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	35,747	1,344	3.8%	1,129	84.0%	74.3%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	104,961	1,673	1.6%	1,110	66.3%	62.0%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	72,660	1,302	1.8%	883	67.8%	58.0%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	84,243	17,480	20.7%	15,560	89.0%	80.1%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	38,874	395	1.0%	252	63.8%	59.6%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	38,874	335	0.9%	231	69.0%	63.7%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
86	Hepatitis C: Antiviral Treatment Prescribed	38,874	312	0.8%	193	61.9%	54.3%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	38,874	220	0.6%	134	60.9%	55.3%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	66,951	703	1.1%	456	64.9%	48.5%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	28,149	98	0.3%	61	62.2%	42.6%
91	Acute Otitis Externa (AOE): Topical Therapy	97,641	2,413	2.5%	2,164	89.7%	55.7%
92	Acute Otitis Externa (AOE): Pain Assessment	97,641	2,075	2.1%	1,858	89.5%	57.1%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	97,641	1,995	2.0%	1,817	91.1%	57.6%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	6,747	4,582	67.9%	4,215	92.0%	82.6%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	6,337	3,750	59.2%	3,452	92.1%	82.8%



Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported ≥1 Valid QDC	% of Eligible Professionals who Reported ≥1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	9,004	429	4.8%	239	55.7%	46.7%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	3,772	417	11.1%	250	60.0%	48.0%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	3,681	517	14.0%	346	66.9%	56.3%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	114,413	700	0.6%	485	69.3%	54.8%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	114,413	943	0.8%	614	65.1%	51.9%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	140,812	1,452	1.0%	943	64.9%	54.8%
109	Osteoarthritis (OA): Function and Pain Assessment	203,691	1,507	0.7%	542	36.0%	40.6%
110	Preventive Care and Screening: Influenza Immunization	569,150	16,519	2.9%	6,526	39.5%	36.3%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	555,506	17,650	3.2%	10,252	58.1%	49.5%
112	Preventive Care and Screening: Screening Mammography	489,337	11,314	2.3%	6,055	53.5%	46.9%
113	Preventive Care and Screening: Colorectal Cancer Screening	534,237	12,823	2.4%	6,320	49.3%	44.7%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported ≥1 Valid QDC	% of Eligible Professionals who Reported ≥1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	89,185	347	0.4%	175	50.4%	28.1%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	326,158	16,783	5.1%	10,885	64.9%	64.2%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	309,621	6,715	2.2%	3,741	55.7%	42.9%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	102,980	829	0.8%	358	43.2%	45.0%
122	Adult Kidney Disease: Blood Pressure Management	9,691	474	4.9%	226	47.7%	34.9%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	113,148	413	0.4%	137	33.2%	32.7%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	747,085	57,530	7.7%	39,910	69.4%	62.3%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	323,038	4,477	1.4%	2,092	46.7%	43.6%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	323,038	2,991	0.9%	1,211	40.5%	43.4%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	680,438	18,695	2.7%	9,829	52.6%	44.7%
130	Documentation of Current Medications in the Medical Record	704,398	44,198	6.3%	28,390	64.2%	56.7%
131	Pain Assessment and Follow-Up	705,580	11,408	1.6%	7,268	63.7%	30.5%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	644,900	2,346	0.4%	650	27.7%	15.2%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	75,012	9,980	13.3%	6,755	67.7%	72.3%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	47,769	5,815	12.2%	3,688	63.4%	61.5%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	203,691	1,863	0.9%	769	41.3%	41.1%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	97,664	14,456	14.8%	12,513	86.6%	79.8%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	21,272	9,173	43.1%	8,154	88.9%	84.5%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	16,727	8,403	50.2%	7,415	88.2%	81.8%
154	Falls: Risk Assessment	589,812	11,641	2.0%	6,738	57.9%	38.4%
155	Falls: Plan of Care	8,944	6,531	73.0%	5,746	88.0%	84.2%
156	Oncology: Radiation Dose Limits to Normal Tissues	3,348	434	13.0%	332	76.5%	68.6%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	3,120	47	1.5%	29	61.7%	54.8%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	5,515	440	8.0%	380	86.4%	80.0%
163	Diabetes Mellitus: Foot Exam	309,621	7,270	2.3%	3,454	47.5%	43.5%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	4,363	236	5.4%	202	85.6%	78.3%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	640,116	7,458	1.2%	3,929	52.7%	42.9%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	140,812	487	0.3%	228	46.8%	36.9%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	140,812	551	0.4%	246	44.6%	38.6%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	140,812	653	0.5%	326	49.9%	41.1%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	140,812	411	0.3%	176	42.8%	32.8%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	140,812	492	0.3%	209	42.5%	35.3%
181	Elder Maltreatment Screen and Follow-Up Plan	589,553	268	0.0%	35	13.1%	8.7%
182	Functional Outcome Assessment	98,099	3,046	3.1%	1,420	46.6%	37.3%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	66,951	451	0.7%	296	65.6%	52.1%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	66,951	424	0.6%	275	64.9%	52.0%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	16,363	953	5.8%	698	73.2%	68.0%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	45,483	347	0.8%	172	49.6%	44.7%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	3,102	4	0.1%	3	75.0%	62.5%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	5,950	16	0.3%	11	68.8%	40.5%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported >=1 Valid QDC	% of Eligible Professionals who Reported >=1 Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	13,712	219	1.6%	58	26.5%	27.4%
193	Perioperative Temperature Management	90,065	28,642	31.8%	23,068	80.5%	76.0%
194	Oncology: Cancer Stage Documented	155,840	1,767	1.1%	1,212	68.6%	67.4%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	59,459	14,103	23.7%	12,376	87.8%	80.4%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	250,458	4,298	1.7%	2,642	61.5%	53.0%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	250,458	4,792	1.9%	2,919	60.9%	54.9%
225	Radiology: Reminder System for Mammograms	24,167	6,053	25.0%	4,976	82.2%	77.0%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	646,239	34,338	5.3%	19,750	57.5%	52.6%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	79,261	166	0.2%	110	66.3%	47.6%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	79,261	98	0.1%	65	66.3%	43.2%
235	Hypertension (HTN): Plan of Care	288,968	1,301	0.5%	135	10.4%	11.7%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	250,436	2,375	0.9%	908	38.2%	38.8%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	152,193	267	0.2%	51	19.1%	18.1%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	152,193	331	0.2%	60	18.1%	18.0%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	37,316	49	0.1%	43	87.8%	60.4%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	87,976	120	0.1%	71	59.2%	54.4%
249	Barrett's Esophagus	7,589	3,611	47.6%	3,153	87.3%	79.6%
250	Radical Prostatectomy Pathology Reporting	3,508	2,104	60.0%	1,982	94.2%	84.1%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	4,985	2,605	52.3%	2,249	86.3%	75.9%
252	Anticoagulation for Acute Pulmonary Embolus Patients	25,106	1,954	7.8%	1,865	95.4%	80.2%
253	Pregnancy Test for Female Abdominal Pain Patients	48,156	5,266	10.9%	4,845	92.0%	76.0%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	840	94	11.2%	94	100.0%	99.0%

Measure Number	Measure Description	Eligible Professionals	Eligible Professionals who Reported $\geq 1$ Valid QDC	% of Eligible Professionals who Reported $\geq 1$ Valid QDC	Eligible Professionals who Satisfactorily Reported	% of Eligible Professionals who Satisfactorily Reported	Average Reporting Rate per Eligible Professional
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	10	2	20.0%	2	100.0%	100.0%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	10,224	88	0.9%	35	39.8%	26.7%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	8,231	41	0.5%	20	48.8%	43.8%
263	Preoperative Diagnosis of Breast Cancer	8,735	48	0.5%	21	43.8%	35.7%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	78,554	281	0.4%	121	43.1%	37.3%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	78,554	208	0.3%	94	45.2%	36.3%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	18,471	55	0.3%	29	52.7%	42.0%
317	Preventive Care and Screening: Screening for High Blood Pressure	662,654	10,953	1.7%	7,039	64.3%	46.3%

*Notes for Table A16: (1) Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) Satisfactory Reporting was defined as reporting at least 50% of eligible instances. (3) The reporting rate was the percent of eligible instances on which the eligible professional reported.*



**Table A17. Individual Measures Submitted through the Claims Mechanism for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Diagnosis Code (2012)**

Measure Number	Measure Description	Number of QDCs Reported	Number of QDCs without Necessary Diagnosis Code	Percent of QDCs without Necessary Diagnosis Code
122	Adult Kidney Disease: Blood Pressure Management	190,372	129,445	68.0%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	7,463	3,784	50.7%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	39,520	19,073	48.3%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	2,020	880	43.6%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	22,201	8,325	37.5%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	548	177	32.3%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	310,730	95,237	30.6%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	13,604	3,755	27.6%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	46,968	12,149	25.9%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	23,136	5,660	24.5%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	149,945	31,366	20.9%

*Notes for Table A17: Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A18. Individual Measures Submitted through the Claims Mechanism for the Physician Quality Reporting System Where More than 20% of Reported Instances did not Include the Necessary Procedure Code (2012).**

Measure Number	Measure Description	Number of QDCs Reported	Number of QDCs without Necessary Procedure Code	Percent of QDCs without Necessary Procedure Code
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	14,548	5,471	37.6%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	20,812	7,281	35.0%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	185,359	54,135	29.2%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	5,827	1,657	28.4%
112	Preventive Care and Screening: Screening Mammography	353,796	94,827	26.8%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	188,824	49,169	26.0%
20	Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician	159,825	40,382	25.3%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	166,733	41,965	25.2%

*Notes for Table A18: Results do not include eligible professionals who are part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A19. Individual Measures Submitted through the Claims Mechanism for the Physician Quality Reporting System Where More than 20% of Reported Instances were for a Patient Without the Necessary Age Range (2012)**

Measure Number	Measure Description	Number of QDCs Reported	Number of QDCs without Necessary Age Range Code	Percent of QDCs without Necessary Age Range Code
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	208	207	99.5%
66	Appropriate Testing for Children with Pharyngitis	194	193	99.5%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	5,842	5,237	89.6%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	28,227	24,834	88.0%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	10,144	7,683	75.7%
64	Asthma: Assessment of Asthma Control	3,954	2,869	72.6%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	1,639	772	47.1%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	945,384	305,614	32.3%
163	Diabetes Mellitus: Foot Exam	224,051	54,510	24.3%
112	Preventive Care and Screening: Screening Mammography	353,796	79,202	22.4%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	567	124	21.9%

*Notes for Table A19: Results do not include eligible professionals who are part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A20. Incentive Eligibility Information for the Physician Quality Reporting System, by Reporting Option/Mechanism (2009 to 2012)**

Reporting Option/Mechanism	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Claims Individual Measures	92,147	43.8%	122,567	50.2%	176,706	63.1%	180,450	59.8%
Claims Measures Groups	603	0.3%	2,182	0.9%	2,877	1.0%	2,619	0.9%
Registry Individual Measures	20,447	9.7%	34,276	14.0%	44,333	15.8%	31,068	10.3%
Registry Measures Groups	9,790	4.6%	16,186	6.6%	11,909	4.2%	8,993	3.0%
EHR	N/A	N/A	13	0.0%	503	0.2%	18,570	6.2%
Group Practice Reporting Option (GPRO) I	N/A	N/A	24,931	100.0%	39,404	100.0%	N/A	N/A
Group Practice Reporting Option (GPRO) II	N/A	N/A	N/A	N/A	76	0.2%	N/A	N/A
Small GPRO	N/A	N/A	N/A	N/A	N/A	N/A	766	100.0%
Large GPRO	N/A	N/A	N/A	N/A	N/A	N/A	43,290	100.0%
MSSP ACO	N/A	N/A	N/A	N/A	N/A	N/A	39,694	99.0%
Pioneer ACO	N/A	N/A	N/A	N/A	N/A	N/A	49,729	99.7%
<b>Total (Unduplicated)</b>	<b>120,665</b>	<b>57.3%</b>	<b>194,278</b>	<b>72.2%</b>	<b>266,740</b>	<b>83.2%</b>	<b>367,228</b>	<b>84.3%</b>

Notes for Table A20: (1) The EHR reporting mechanism and the GPRO were not available before the 2010 program year. (2) Participation within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model was not an option before program year 2012.

**Table A21. Eligible Professionals who Received an Incentive from Individual Measures through the Claims Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
<b>MD/DO</b>	<b>68,071</b>	<b>50.1%</b>	<b>89,198</b>	<b>61.5%</b>	<b>125,300</b>	<b>77.1%</b>	<b>124,851</b>	<b>72.9%</b>
Allergy/Immunology	77	40.3%	115	49.6%	210	61.6%	205	59.1%
Anesthesiology	8,001	46.1%	12,743	63.6%	19,352	83.9%	19,464	80.0%
Cardiology	2,300	40.0%	2,600	48.8%	3,463	67.1%	3,058	65.4%
Colon/Rectal Surgery	61	31.8%	86	40.4%	152	63.9%	143	58.1%
Critical Care	103	32.3%	148	41.9%	295	75.3%	242	60.7%
Dermatology	637	33.9%	318	59.1%	457	67.7%	513	66.5%
Emergency Medicine	24,405	78.7%	27,411	85.6%	32,260	94.9%	30,970	91.4%
Endocrinology	399	44.4%	466	53.8%	709	68.0%	716	62.9%
Family Practice	6,889	47.3%	7,857	53.2%	11,424	67.4%	11,751	62.7%
Gastroenterology	437	30.9%	798	43.8%	1,375	62.4%	1,561	61.4%
General Practice	160	51.9%	206	55.7%	299	69.1%	372	63.5%
General Surgery	1,003	38.7%	1,393	48.4%	2,126	66.5%	2,300	62.1%
Geriatrics	208	37.0%	235	41.3%	351	57.1%	405	59.9%
Hand Surgery	52	37.4%	108	58.1%	154	69.7%	164	69.8%
Infectious Disease	148	38.6%	204	45.1%	345	63.5%	451	65.9%
Internal Medicine	5,721	40.2%	6,871	47.6%	11,341	66.3%	10,307	59.0%
Interventional Radiologist	156	36.0%	285	54.6%	513	78.1%	642	78.1%
Nephrology	440	38.0%	449	42.8%	627	56.7%	621	50.2%
Neurology	398	32.1%	703	47.4%	1,262	67.2%	1,290	60.2%
Neurosurgery	260	44.1%	379	59.8%	503	72.7%	529	58.8%
Nuclear Medicine	48	43.6%	97	70.3%	103	81.7%	117	79.6%
Obstetrics/Gynecology	626	35.3%	880	39.3%	1,629	60.4%	1,849	55.6%
Oncology/Hematology	841	32.0%	1,116	42.1%	1,888	68.2%	1,899	68.7%
Ophthalmology	3,269	46.4%	4,374	57.9%	6,109	75.5%	5,993	73.7%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Oral/Maxillofacial Surgery	5	38.5%	5	41.7%	7	53.8%	21	67.7%
Orthopaedic Surgery	1,392	41.9%	2,041	55.4%	2,470	64.1%	2,618	63.3%
Other MD/DO	323	35.6%	519	50.0%	968	72.9%	918	62.0%
Otolaryngology	244	31.4%	400	44.2%	720	64.5%	791	60.7%
Pathology	2,604	57.5%	3,348	70.7%	4,423	91.9%	4,217	82.0%
Pediatrics	190	59.6%	212	70.2%	348	84.1%	414	74.9%
Physical Medicine	187	37.0%	281	50.8%	462	67.3%	541	60.4%
Plastic Surgery	80	39.6%	137	55.7%	215	73.9%	207	63.3%
Psychiatry	191	35.4%	310	46.0%	511	69.2%	498	55.3%
Pulmonary Disease	425	35.9%	609	42.5%	1,148	64.6%	1,206	61.9%
Radiation Oncology	182	23.1%	283	37.5%	626	62.9%	631	60.3%
Radiologist	4,065	34.7%	8,899	61.1%	13,088	76.9%	14,098	76.9%
Rheumatology	252	35.0%	311	39.4%	507	60.4%	537	59.7%
Thoracic/Cardiac Surgery	510	47.3%	615	59.3%	755	70.6%	576	59.0%
Urology	553	31.7%	996	44.2%	1,564	59.2%	1,481	59.1%
Vascular Surgery	229	35.4%	390	53.9%	541	67.9%	535	63.2%
<b>Other Eligible Professionals</b>	<b>23,881</b>	<b>48.7%</b>	<b>33,312</b>	<b>60.2%</b>	<b>51,309</b>	<b>77.0%</b>	<b>55,505</b>	<b>72.2%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	89	43.8%	129	55.4%	207	74.2%	185	62.7%
Audiologist	64	57.1%	107	62.6%	135	58.2%	104	26.5%
Certified Nurse Midwives	35	52.2%	45	62.5%	88	83.8%	119	74.4%
Chiropractor	60	13.0%	208	38.1%	516	60.5%	511	34.2%
Clinical Nurse Specialists	72	45.9%	92	51.4%	153	78.5%	165	69.3%
Counselor/Psychologist	110	26.6%	235	51.0%	436	75.0%	335	56.0%
Dentist	6	37.5%	9	45.0%	23	79.3%	24	80.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Dietitian/Nutritionist	74	49.7%	88	64.7%	134	76.1%	78	56.9%
Nurse Anesthetist	6,319	53.6%	9,539	66.8%	14,006	81.8%	15,032	80.5%
Nurse Practitioner	3,326	54.8%	4,352	64.8%	6,314	77.8%	7,395	73.0%
Optometry	1,752	30.0%	2,864	41.2%	5,868	66.6%	5,924	59.4%
Other Eligible Professional	3,714	48.5%	4,486	59.1%	6,308	75.9%	6,189	72.0%
Physical/Occupational Therapy	1,864	32.7%	3,105	51.1%	5,637	77.1%	6,657	72.0%
Physician Assistant	5,806	67.3%	7,097	74.5%	9,569	86.3%	10,698	82.6%
Podiatrist	172	17.7%	349	23.3%	1,098	46.5%	1,278	45.2%
Registered Nurse	360	53.2%	476	67.3%	594	79.6%	619	78.7%
Social Worker	58	27.8%	131	63.9%	223	77.2%	192	58.5%
Unknown/Missing	195	67.2%	57	62.0%	97	84.3%	94	72.9%
<b>Total (Unduplicated)</b>	<b>92,147</b>	<b>49.8%</b>	<b>122,567</b>	<b>61.1%</b>	<b>176,706</b>	<b>77.1%</b>	<b>180,450</b>	<b>72.7%</b>

*Notes for Table A21: Results do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A22. Eligible Professionals who Received an Incentive from Measures Groups through the Claims Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
<b>MD/DO</b>	<b>513</b>	<b>16.3%</b>	<b>1,950</b>	<b>55.9%</b>	<b>2,518</b>	<b>67.0%</b>	<b>2,241</b>	<b>58.0%</b>
Allergy/Immunology	1	25.0%	0	0.0%	2	33.3%	4	100.0%
Anesthesiology	11	29.7%	25	65.8%	41	70.7%	43	70.5%
Cardiology	7	16.7%	431	77.1%	504	79.4%	439	80.0%
Colon/Rectal Surgery	0	0.0%	0	0.0%	1	25.0%	1	16.7%
Critical Care	1	11.1%	4	80.0%	6	100.0%	4	57.1%
Dermatology	1	16.7%	5	41.7%	1	100.0%	0	0.0%
Emergency Medicine	1	16.7%	19	40.4%	2	28.6%	58	40.3%
Endocrinology	11	15.5%	33	66.0%	50	75.8%	41	56.9%
Family Practice	110	11.9%	308	40.6%	487	59.0%	466	53.0%
Gastroenterology	5	17.2%	9	50.0%	16	69.6%	17	68.0%
General Practice	3	21.4%	6	50.0%	10	55.6%	10	83.3%
General Surgery	9	6.2%	37	26.4%	49	39.2%	31	29.8%
Geriatrics	5	16.1%	10	27.8%	17	53.1%	22	81.5%
Hand Surgery	0	0.0%	2	50.0%	4	36.4%	2	16.7%
Infectious Disease	1	50.0%	0	0.0%	2	100.0%	1	33.3%
Internal Medicine	151	15.1%	545	60.9%	687	71.1%	509	61.8%
Interventional Radiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Nephrology	16	13.7%	48	52.7%	37	44.0%	29	24.0%
Neurology	3	15.8%	5	50.0%	3	37.5%	3	42.9%
Neurosurgery	15	25.4%	36	50.7%	41	54.7%	34	45.3%
Nuclear Medicine	0	0.0%	0	0.0%	1	100.0%	0	0.0%
Obstetrics/Gynecology	2	4.9%	13	44.8%	26	53.1%	46	41.1%
Oncology/Hematology	5	22.7%	6	25.0%	9	64.3%	12	75.0%
Ophthalmology	2	12.5%	0	0.0%	1	100.0%	1	11.1%



Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Orthopaedic Surgery	91	37.1%	171	60.0%	247	70.8%	226	59.3%
Other MD/DO	6	13.0%	21	51.2%	25	52.1%	33	66.0%
Otolaryngology	2	33.3%	1	25.0%	1	50.0%	1	20.0%
Pathology	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pediatrics	0	0.0%	1	50.0%	2	50.0%	3	50.0%
Physical Medicine	9	32.1%	24	53.3%	32	50.8%	36	56.3%
Plastic Surgery	2	66.7%	0	0.0%	0	0.0%	0	0.0%
Psychiatry	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Pulmonary Disease	6	25.0%	19	55.9%	32	84.2%	31	44.9%
Radiation Oncology	2	50.0%	0	0.0%	1	100.0%	0	0.0%
Radiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Rheumatology	27	18.1%	138	67.6%	140	76.5%	123	65.4%
Thoracic/Cardiac Surgery	2	22.2%	3	33.3%	6	66.7%	8	61.5%
Urology	4	23.5%	23	76.7%	33	94.3%	6	100.0%
Vascular Surgery	2	12.5%	7	53.8%	2	25.0%	1	16.7%
<b>Other Eligible Professionals</b>	<b>90</b>	<b>18.4%</b>	<b>232</b>	<b>34.9%</b>	<b>358</b>	<b>50.2%</b>	<b>377</b>	<b>41.3%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	1	50.0%	1	100.0%	3	100.0%	1	33.3%
Audiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Certified Nurse Midwives	0	0.0%	0	0.0%	0	0.0%	1	50.0%
Chiropractor	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Clinical Nurse Specialists	1	33.3%	4	44.4%	5	62.5%	6	46.2%
Counselor/Psychologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dentist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Dietitian/Nutritionist	0	0.0%	0	0.0%	1	33.3%	2	50.0%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Nurse Practitioner	39	23.8%	51	33.3%	108	59.0%	125	46.6%
Optometry	5	25.0%	0	0.0%	0	0.0%	0	0.0%
Other Eligible Professional	20	13.2%	120	54.1%	125	62.2%	110	54.5%
Physical/Occupational Therapy	0	0.0%	13	8.2%	50	27.9%	65	28.0%
Physician Assistant	23	20.4%	38	34.9%	59	48.8%	53	36.6%
Podiatrist	0	0.0%	2	28.6%	6	50.0%	12	34.3%
Registered Nurse	1	16.7%	3	60.0%	1	100.0%	2	66.7%
Social Worker	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Unknown/Missing	0	0.0%	0	0.0%	1	100.0%	1	33.3%
<b>Total (Unduplicated)</b>	<b>603</b>	<b>16.5%</b>	<b>2,182</b>	<b>52.6%</b>	<b>2,877</b>	<b>64.3%</b>	<b>2,619</b>	<b>54.8%</b>

*Notes for Table A22: Results do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A23. Eligible Professionals who Received an Incentive from Individual Measures through the Registry Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
<b>MD/DO</b>	<b>17,458</b>	<b>91.6%</b>	<b>28,961</b>	<b>89.0%</b>	<b>37,544</b>	<b>90.3%</b>	<b>25,459</b>	<b>88.3%</b>
Allergy/Immunology	75	92.6%	96	91.4%	196	91.2%	114	95.0%
Anesthesiology	60	53.6%	136	79.1%	133	81.1%	131	67.5%
Cardiology	1,303	95.9%	2,090	95.0%	2,798	94.9%	1,409	92.0%
Colon/Rectal Surgery	23	85.2%	48	94.1%	91	97.8%	46	90.2%
Critical Care	41	95.3%	66	79.5%	86	74.8%	67	72.0%
Dermatology	240	93.4%	1,194	91.1%	1,739	94.8%	1,659	97.6%
Emergency Medicine	336	91.8%	434	91.4%	465	95.1%	285	89.3%
Endocrinology	365	95.3%	446	95.5%	602	92.6%	318	89.6%
Family Practice	4,208	93.3%	6,549	92.8%	8,120	93.7%	4,465	90.7%
Gastroenterology	327	97.0%	550	89.7%	917	91.0%	659	90.6%
General Practice	46	92.0%	72	90.0%	72	86.7%	61	92.4%
General Surgery	516	92.6%	804	91.3%	1,190	93.1%	969	88.7%
Geriatrics	179	93.2%	232	86.6%	267	83.7%	175	84.1%
Hand Surgery	18	78.3%	58	93.5%	66	93.0%	59	85.5%
Infectious Disease	195	89.0%	312	90.2%	428	89.5%	257	92.1%
Internal Medicine	4,154	92.2%	6,452	89.1%	7,873	88.5%	4,593	82.9%
Interventional Radiologist	22	84.6%	41	82.0%	74	91.4%	61	92.4%
Nephrology	253	94.1%	360	90.7%	532	86.1%	437	91.8%
Neurology	362	93.5%	529	84.4%	734	88.5%	497	84.5%
Neurosurgery	128	92.1%	189	93.1%	227	91.2%	193	91.9%
Nuclear Medicine	9	64.3%	14	53.8%	38	74.5%	16	80.0%
Obstetrics/Gynecology	756	90.8%	1,102	86.4%	1,486	87.1%	720	81.3%
Oncology/Hematology	311	94.8%	598	91.3%	959	89.4%	630	95.2%
Ophthalmology	390	88.4%	988	93.1%	1,263	90.5%	1,241	95.4%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Oral/Maxillofacial Surgery	0	0.0%	1	50.0%	6	66.7%	1	100.0%
Orthopaedic Surgery	536	95.2%	780	92.6%	1,008	91.1%	906	89.3%
Other MD/DO	119	85.0%	304	81.7%	387	83.2%	343	70.4%
Otolaryngology	213	93.8%	450	91.8%	618	90.0%	457	88.9%
Pathology	12	92.3%	7	24.1%	11	45.8%	149	88.7%
Pediatrics	96	49.7%	145	41.7%	133	38.8%	69	32.2%
Physical Medicine	93	94.9%	158	86.8%	226	83.4%	190	91.8%
Plastic Surgery	81	90.0%	105	92.1%	137	93.2%	92	89.3%
Psychiatry	128	72.7%	128	69.6%	129	56.3%	136	70.1%
Pulmonary Disease	241	94.9%	435	92.4%	721	90.4%	406	86.9%
Radiation Oncology	191	90.1%	303	92.7%	349	90.2%	386	94.1%
Radiologist	322	84.1%	1,215	71.1%	1,416	92.1%	1,458	94.6%
Rheumatology	202	92.7%	260	90.0%	336	86.4%	208	83.2%
Thoracic/Cardiac Surgery	426	86.4%	550	85.0%	632	83.7%	552	83.8%
Urology	360	90.2%	587	93.8%	851	97.3%	860	93.9%
Vascular Surgery	121	87.1%	173	89.6%	228	90.5%	184	86.0%
<b>Other Eligible Professionals</b>	<b>2,974</b>	<b>81.3%</b>	<b>5,313</b>	<b>79.3%</b>	<b>6,786</b>	<b>78.9%</b>	<b>5,600</b>	<b>73.9%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	7	50.0%	27	64.3%	27	58.7%	29	61.7%
Audiologist	7	21.9%	23	38.3%	13	36.1%	13	65.0%
Certified Nurse Midwives	17	50.0%	31	58.5%	47	56.6%	26	60.5%
Chiropractor	8	66.7%	7	63.6%	7	77.8%	3	75.0%
Clinical Nurse Specialists	24	80.0%	44	93.6%	53	74.6%	22	71.0%
Counselor/Psychologist	39	36.8%	40	40.8%	36	29.0%	10	12.7%
Dentist	3	75.0%	7	63.6%	6	28.6%	10	45.5%
Dietitian/Nutritionist	38	82.6%	44	81.5%	44	89.8%	22	91.7%
Nurse Anesthetist	19	100.0%	11	64.7%	10	16.7%	2	1.9%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Nurse Practitioner	1,084	86.0%	1,821	81.4%	2,419	80.8%	1,430	72.9%
Optometry	90	90.0%	205	95.3%	251	93.7%	269	90.9%
Other Eligible Professional	522	82.6%	1,045	78.5%	1,311	86.0%	1,131	80.0%
Physical/Occupational Therapy	55	38.7%	305	68.4%	448	61.0%	1,297	73.5%
Physician Assistant	841	89.3%	1,403	81.9%	1,801	83.0%	1,150	76.7%
Podiatrist	143	92.9%	244	93.8%	258	94.5%	155	83.8%
Registered Nurse	35	74.5%	42	62.7%	47	63.5%	23	42.6%
Social Worker	42	49.4%	14	40.0%	8	12.1%	8	25.8%
Unknown/Missing	15	41.7%	2	8.3%	3	11.1%	9	15.0%
<b>Total (Unduplicated)</b>	<b>20,447</b>	<b>89.9%</b>	<b>34,276</b>	<b>87.3%</b>	<b>44,333</b>	<b>88.3%</b>	<b>31,068</b>	<b>85.2%</b>

*Notes for Table A23: Results do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A24. Eligible Professionals who Received an Incentive from Measures Groups through the Registry Mechanism for the Physician Quality Reporting System, by Specialty (2009 to 2012)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
<b>MD/DO</b>	<b>8,701</b>	<b>95.2%</b>	<b>14,305</b>	<b>95.3%</b>	<b>10,565</b>	<b>92.7%</b>	<b>7,873</b>	<b>85.7%</b>
Allergy/Immunology	63	98.4%	69	98.6%	10	100.0%	7	77.8%
Anesthesiology	26	76.5%	28	90.3%	28	93.3%	17	89.5%
Cardiology	629	96.6%	2,184	95.8%	1,925	94.4%	1,574	94.1%
Colon/Rectal Surgery	37	88.1%	24	77.4%	7	100.0%	3	100.0%
Critical Care	14	87.5%	25	96.2%	10	100.0%	9	90.0%
Dermatology	61	96.8%	46	95.8%	17	89.5%	8	100.0%
Emergency Medicine	25	89.3%	59	96.7%	70	94.6%	28	100.0%
Endocrinology	126	96.9%	179	98.4%	138	91.4%	88	77.9%
Family Practice	2,746	95.0%	3,880	96.0%	2,639	94.3%	1,763	91.7%
Gastroenterology	130	92.2%	319	93.8%	162	94.7%	120	90.9%
General Practice	38	95.0%	72	93.5%	49	92.5%	35	94.6%
General Surgery	146	93.6%	327	93.4%	160	90.9%	90	90.0%
Geriatrics	89	89.9%	142	94.7%	101	75.4%	89	91.8%
Hand Surgery	9	90.0%	20	83.3%	13	100.0%	12	100.0%
Infectious Disease	46	97.9%	83	93.3%	57	90.5%	49	96.1%
Internal Medicine	1,898	96.8%	2,938	96.5%	2,239	92.0%	1,634	86.8%
Interventional Radiologist	0	0.0%	1	100.0%	0	0.0%	1	100.0%
Nephrology	740	98.0%	1,125	96.6%	1,030	96.2%	516	46.7%
Neurology	90	96.8%	81	95.3%	58	92.1%	116	91.3%
Neurosurgery	34	100.0%	62	92.5%	33	86.8%	33	94.3%
Nuclear Medicine	1	100.0%	14	93.3%	11	100.0%	2	20.0%
Obstetrics/Gynecology	130	90.9%	212	93.8%	116	93.5%	66	81.5%
Oncology/Hematology	239	98.8%	292	86.9%	234	96.7%	203	96.2%
Ophthalmology	125	94.0%	162	84.8%	82	78.1%	95	86.4%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Orthopaedic Surgery	324	91.3%	556	97.4%	388	91.1%	328	87.2%
Other MD/DO	45	88.2%	90	91.8%	65	87.8%	63	91.3%
Otolaryngology	140	95.2%	222	95.3%	177	98.9%	135	97.1%
Pathology	1	100.0%	0	0.0%	0	0.0%	0	0.0%
Pediatrics	13	92.9%	15	93.8%	7	100.0%	7	100.0%
Physical Medicine	52	86.7%	72	97.3%	42	91.3%	42	97.7%
Plastic Surgery	18	81.8%	16	88.9%	7	100.0%	2	100.0%
Psychiatry	6	75.0%	5	45.5%	4	100.0%	11	78.6%
Pulmonary Disease	131	94.9%	213	95.1%	140	95.9%	198	96.6%
Radiation Oncology	28	93.3%	14	53.8%	19	61.3%	20	95.2%
Radiologist	2	20.0%	2	100.0%	0	0.0%	1	100.0%
Rheumatology	250	94.0%	350	94.6%	304	82.8%	298	94.9%
Thoracic/Cardiac Surgery	29	100.0%	53	94.6%	13	31.7%	27	93.1%
Urology	189	96.9%	283	93.4%	164	95.3%	126	94.7%
Vascular Surgery	31	88.6%	70	94.6%	46	90.2%	57	90.5%
<b>Other Eligible Professionals</b>	<b>1,087</b>	<b>89.8%</b>	<b>1,877</b>	<b>89.0%</b>	<b>1,342</b>	<b>90.2%</b>	<b>1,119</b>	<b>87.5%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	6	40.0%	9	40.9%	5	21.7%	4	30.8%
Audiologist	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Certified Nurse Midwives	2	100.0%	4	100.0%	0	0.0%	1	100.0%
Chiropractor	2	50.0%	0	0.0%	0	0.0%	1	100.0%
Clinical Nurse Specialists	9	75.0%	7	100.0%	7	100.0%	4	80.0%
Counselor/Psychologist	0	0.0%	0	0.0%	0	0.0%	1	50.0%
Dentist	2	66.7%	0	0.0%	0	0.0%	0	0.0%
Dietitian/Nutritionist	2	100.0%	5	100.0%	3	100.0%	1	50.0%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%	0	0.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2009	Incentive Eligibility Rate in 2009	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Nurse Practitioner	304	88.4%	539	90.1%	460	91.5%	430	91.5%
Optometry	39	88.6%	50	79.4%	11	78.6%	3	75.0%
Other Eligible Professional	448	93.3%	807	93.2%	557	93.1%	413	84.3%
Physical/Occupational Therapy	4	80.0%	32	55.2%	29	96.7%	7	87.5%
Physician Assistant	192	89.7%	280	90.0%	210	87.5%	203	89.0%
Podiatrist	71	89.9%	135	93.8%	50	84.7%	44	91.7%
Registered Nurse	6	100.0%	9	90.0%	10	100.0%	7	100.0%
Social Worker	0	0.0%	0	0.0%	0	0.0%	0	0.0%
Unknown/Missing	2	18.2%	4	21.1%	2	14.3%	1	14.3%
<b>Total (Unduplicated)</b>	<b>9,790</b>	<b>94.5%</b>	<b>16,186</b>	<b>94.5%</b>	<b>11,909</b>	<b>92.4%</b>	<b>8,993</b>	<b>85.8%</b>

*Notes for Tables A24: Results do not include eligible professionals who are part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*



**Table A25. Eligible Professionals who Received an Incentive from Individual Measures through the EHR Mechanism for the Physician Quality Reporting System, by Specialty (2010 to 2012)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
<b>MD/DO</b>	<b>9</b>	<b>90.0%</b>	<b>412</b>	<b>93.6%</b>	<b>15,357</b>	<b>95.1%</b>
Allergy/Immunology	0	0.0%	0	0.0%	57	87.7%
Anesthesiology	0	0.0%	0	0.0%	79	96.3%
Cardiology	0	0.0%	40	100.0%	1,496	95.9%
Colon/Rectal Surgery	0	0.0%	0	0.0%	39	100.0%
Critical Care	0	0.0%	0	0.0%	26	96.3%
Dermatology	0	0.0%	5	100.0%	164	98.2%
Emergency Medicine	0	0.0%	2	100.0%	185	95.4%
Endocrinology	0	0.0%	1	100.0%	222	94.1%
Family Practice	7	100.0%	159	91.4%	4,294	94.6%
Gastroenterology	0	0.0%	7	100.0%	373	91.0%
General Practice	0	0.0%	8	88.9%	65	94.2%
General Surgery	0	0.0%	10	100.0%	615	93.2%
Geriatrics	0	0.0%	2	100.0%	101	93.5%
Hand Surgery	0	0.0%	2	100.0%	32	100.0%
Infectious Disease	0	0.0%	4	80.0%	170	95.5%
Internal Medicine	2	100.0%	68	87.2%	3,072	95.6%
Interventional Radiologist	0	0.0%	0	0.0%	11	100.0%
Nephrology	0	0.0%	5	100.0%	176	96.2%
Neurology	0	0.0%	11	100.0%	409	96.9%
Neurosurgery	0	0.0%	0	0.0%	86	94.5%
Nuclear Medicine	0	0.0%	0	0.0%	14	100.0%
Obstetrics/Gynecology	0	0.0%	9	100.0%	951	94.8%
Oncology/Hematology	0	0.0%	5	100.0%	246	94.6%
Ophthalmology	0	0.0%	0	0.0%	86	96.6%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%	1	100.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Orthopaedic Surgery	0	0.0%	24	100.0%	508	96.2%
Other MD/DO	0	0.0%	2	66.7%	97	97.0%
Otolaryngology	0	0.0%	7	100.0%	185	100.0%
Pathology	0	0.0%	0	0.0%	6	100.0%
Pediatrics	0	0.0%	2	100.0%	93	86.1%
Physical Medicine	0	0.0%	3	100.0%	127	98.4%
Plastic Surgery	0	0.0%	0	0.0%	70	92.1%
Psychiatry	0	0.0%	0	0.0%	186	97.9%
Pulmonary Disease	0	0.0%	9	100.0%	380	90.5%
Radiation Oncology	0	0.0%	0	0.0%	34	97.1%
Radiologist	0	0.0%	0	0.0%	50	98.0%
Rheumatology	0	0.0%	5	100.0%	158	95.8%
Thoracic/Cardiac Surgery	0	0.0%	0	0.0%	95	94.1%
Urology	0	0.0%	17	100.0%	312	98.4%
Vascular Surgery	0	0.0%	5	100.0%	86	100.0%
<b>Other Eligible Professionals</b>	<b>4</b>	<b>100.0%</b>	<b>91</b>	<b>76.5%</b>	<b>3,206</b>	<b>87.8%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	0	0.0%	1	100.0%	17	68.0%
Audiologist	0	0.0%	0	0.0%	13	92.9%
Certified Nurse Midwives	0	0.0%	0	0.0%	29	80.6%
Chiropractor	0	0.0%	0	0.0%	6	85.7%
Clinical Nurse Specialists	0	0.0%	0	0.0%	24	77.4%
Counselor/Psychologist	0	0.0%	0	0.0%	27	60.0%
Dentist	0	0.0%	0	0.0%	1	100.0%
Dietitian/Nutritionist	0	0.0%	0	0.0%	7	77.8%
Nurse Anesthetist	0	0.0%	0	0.0%	0	0.0%
Nurse Practitioner	2	100.0%	26	63.4%	1,384	87.2%
Optometry	0	0.0%	0	0.0%	24	100.0%

Specialty	Eligible Professionals who Qualified for an Incentive in 2010	Incentive Eligibility Rate in 2010	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligibility Rate in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligibility Rate in 2012
Other Eligible Professional	1	100.0%	21	95.5%	455	85.2%
Physical/Occupational Therapy	0	0.0%	0	0.0%	35	100.0%
Physician Assistant	1	100.0%	29	74.4%	1,000	91.1%
Podiatrist	0	0.0%	12	100.0%	135	90.0%
Registered Nurse	0	0.0%	2	100.0%	22	81.5%
Social Worker	0	0.0%	0	0.0%	27	93.1%
Unknown/Missing	0	0.0%	0	0.0%	7	58.3%
<b>Total (Unduplicated)</b>	<b>13</b>	<b>92.9%</b>	<b>503</b>	<b>89.8%</b>	<b>18,570</b>	<b>93.7%</b>

*Notes for Table A25: Results do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.*

**Table A26. Eligible Professional Eligibility and Participation Information by Individual Measures for the Physician Quality Reporting System (2009 to 2012)**

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>e</sup>	312,216	326,948	334,030	315,343	9.8%	10.1%	11.2%	13.7%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	312,292	326,622	333,895	315,106	9.6%	9.4%	10.5%	12.9%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	312,127	326,697	334,305	315,412	9.0%	9.1%	10.8%	13.4%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	235,550	3,720	4,413	3,747	4.8%	94.8%	94.3%	95.1%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	246,987	248,770	257,372	209,602	7.1%	7.2%	8.3%	10.1%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) <sup>a, b, c, d</sup>	1,953	4,172	5,961	7,455	100.0%	95.9%	96.0%	97.0%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	207,872	2,164	2,566	1,161	3.7%	96.2%	92.7%	96.6%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	252,456	255,966	264,734	253,407	0.5%	0.5%	0.8%	1.4%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	34,248	33,449	30,481	29,204	26.6%	32.4%	41.3%	46.8%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	46,188	44,213	45,691	48,642	22.5%	25.7%	29.4%	31.0%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	70,802	72,987	76,420	75,489	14.8%	16.3%	18.5%	19.2%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	45,255	45,963	48,175	50,322	18.3%	19.3%	21.3%	27.7%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	45,254	45,974	48,165	47,360	9.3%	10.7%	12.7%	13.4%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	102,657	97,559	96,538	87,861	8.5%	9.6%	5.9%	6.4%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	73,279	69,190	69,020	64,075	8.8%	9.9%	9.8%	9.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	94,892	89,935	88,932	81,114	5.1%	5.9%	5.8%	5.9%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	78,337	76,925	76,521	70,036	6.9%	7.7%	7.7%	7.5%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	115,427	101,443	224,361	204,349	1.0%	0.9%	0.4%	0.4%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	30,422	31,663	38,884	38,008	49.2%	52.3%	49.9%	59.1%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	81,831	81,075	83,398	82,850	38.1%	43.8%	49.0%	52.6%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	96,247	97,567	101,837	128,218	2.1%	3.4%	4.0%	4.6%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	92,266	101,842	103,182	108,471	3.3%	4.4%	5.4%	4.2%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge <sup>a, b, c, d</sup>	46	851	960	770	100.0%	80.7%	100.0%	99.9%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	73,658	72,590	74,997	125,699	1.4%	2.4%	3.0%	4.9%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	71,280	81,074	84,064	104,109	3.6%	4.5%	5.3%	4.0%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	522,062	532,868	538,622	505,070	2.3%	2.3%	2.6%	6.1%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	115,488	101,542	224,400	204,369	1.5%	1.4%	0.8%	0.8%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	182,957	180,391	179,379	159,993	3.0%	3.2%	3.2%	2.1%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	4,145	4,032	3,845	3,405	36.7%	37.6%	38.1%	36.9%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	4,145	4,031	3,845	3,406	29.9%	30.6%	30.8%	31.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	4,531	4,373	4,154	3,706	27.3%	28.7%	29.6%	22.4%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility <sup>d</sup>	283	498,294	501,894	467,598	100.0%	0.2%	0.3%	0.3%
47	Advance Care Plan	616,386	630,017	654,277	618,360	1.3%	1.6%	2.2%	5.3%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	527,926	539,520	546,207	512,380	1.3%	1.3%	1.5%	4.5%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	125,467	125,304	126,078	114,324	2.0%	2.0%	2.3%	2.0%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	125,347	125,325	125,992	114,283	1.8%	2.0%	2.3%	2.0%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	213,286	215,296	217,821	199,930	1.5%	1.7%	1.8%	1.7%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	213,100	215,197	217,697	199,904	1.0%	1.2%	1.1%	1.1%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	49,043	50,360	83,305	76,207	1.6%	2.3%	2.0%	1.2%



Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	65,574	69,637	72,175	70,847	57.6%	57.0%	59.5%	61.9%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	52,051	54,135	55,279	54,180	60.7%	62.0%	64.9%	50.6%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	203,661	203,053	207,255	191,853	16.1%	17.1%	18.0%	21.8%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	203,664	203,053	207,257	191,857	18.1%	19.2%	20.1%	21.9%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	203,661	203,049	207,233	191,847	16.1%	17.3%	18.2%	20.2%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	203,659	203,047	207,245	191,857	11.4%	12.4%	13.2%	16.4%
64	Asthma: Assessment of Asthma Control	48,987	50,034	83,237	78,089	1.1%	0.8%	1.2%	5.0%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	190	174	226	1,043	1.6%	4.0%	15.0%	84.3%
66	Appropriate Testing for Children with Pharyngitis	144	134	189	129	0.0%	0.7%	25.4%	0.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	26,897	28,262	30,109	28,819	5.4%	5.7%	4.7%	4.4%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	21,629	22,972	24,512	23,705	6.1%	5.7%	4.7%	4.2%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	34,311	35,484	37,308	35,615	5.7%	5.8%	5.1%	4.5%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	34,690	35,264	37,516	35,758	5.0%	5.1%	4.7%	4.3%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	104,127	131,106	134,396	104,973	1.8%	1.6%	1.5%	1.8%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	68,634	89,303	93,124	72,676	2.0%	1.9%	1.9%	2.1%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	91,089	89,791	89,550	84,284	10.1%	16.3%	19.0%	21.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute <sup>a, b, c, d</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute <sup>a, b, c, d</sup>	10	10	28	1	100.0%	100.0%	0.0%	100.0%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia <sup>a, b, c</sup>	65,824	246	252	151	0.8%	81.3%	57.5%	23.8%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	34,823	36,074	39,469	38,884	1.0%	1.3%	0.9%	1.1%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	34,821	36,074	39,468	38,884	1.0%	1.3%	0.8%	0.9%
86	Hepatitis C: Antiviral Treatment Prescribed	34,821	36,078	39,511	38,884	0.8%	1.2%	1.0%	0.9%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	34,821	36,072	39,462	38,883	0.6%	0.8%	0.5%	0.6%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	65,822	67,336	70,676	66,971	0.6%	0.8%	1.1%	1.1%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	25,205	25,973	28,327	28,149	0.5%	0.8%	0.4%	0.3%
91	Acute Otitis Externa (AOE): Topical Therapy	87,451	87,135	105,733	97,645	0.6%	0.9%	1.5%	2.6%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
92	Acute Otitis Externa (AOE): Pain Assessment	87,427	87,093	105,669	97,644	0.5%	0.5%	1.0%	2.2%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	87,449	87,128	105,720	97,645	0.5%	0.6%	1.0%	2.1%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	7,241	7,295	7,125	6,747	60.4%	62.4%	64.5%	68.1%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	6,843	6,855	6,734	6,341	61.4%	63.2%	66.1%	59.6%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	8,140	7,926	7,911	9,006	6.7%	6.7%	7.8%	6.4%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	4,118	4,057	4,128	3,775	12.0%	12.7%	14.7%	15.4%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	4,025	3,996	4,039	3,690	14.3%	15.0%	18.8%	21.3%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	104,999	108,497	115,853	114,474	0.5%	0.6%	0.7%	0.8%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	104,999	108,499	115,856	114,474	0.6%	0.7%	0.8%	1.0%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	144,600	146,599	151,136	140,859	0.9%	0.9%	1.1%	1.1%
109	Osteoarthritis (OA): Function and Pain Assessment	213,200	213,659	218,885	203,717	0.8%	0.8%	0.7%	0.8%
110	Preventive Care and Screening: Influenza Immunization	562,179	575,237	587,537	571,267	2.5%	3.1%	4.7%	7.3%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	568,953	569,825	590,388	557,747	2.7%	3.1%	4.7%	8.1%
112	Preventive Care and Screening: Screening Mammography	516,622	515,671	523,430	491,753	2.5%	2.8%	3.6%	7.2%
113	Preventive Care and Screening: Colorectal Cancer Screening	564,588	558,467	569,384	536,579	2.2%	2.7%	3.7%	7.2%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	99,564	98,605	100,215	89,194	0.3%	0.4%	0.4%	0.4%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	326,026	340,041	347,761	331,107	4.0%	4.3%	5.2%	10.4%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	222,374	1,751	2,266	719	1.7%	100.0%	96.6%	95.0%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	311,093	325,839	332,508	314,862	3.0%	3.1%	3.7%	8.0%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	46,392	53,494	61,611	103,028	3.2%	4.4%	3.7%	1.2%
122	Adult Kidney Disease: Blood Pressure Management	46,295	53,335	61,449	9,839	3.1%	4.3%	3.4%	6.8%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>e</sup>	46,026	52,359	60,684	113,152	1.6%	1.2%	0.9%	0.4%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	758,066	761,891	781,820	748,413	5.0%	6.9%	9.1%	10.2%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	357,891	338,908	345,501	323,402	0.8%	1.0%	1.4%	1.5%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	357,851	338,907	345,497	323,070	0.6%	0.7%	1.0%	0.9%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	782,405	704,404	722,617	682,207	1.1%	1.3%	2.7%	5.9%
130	Documentation of Current Medications in the Medical Record	768,837	691,221	710,120	705,256	2.1%	3.4%	6.2%	8.1%
131	Pain Assessment and Follow-Up	167,391	170,678	177,520	705,787	3.3%	3.6%	4.5%	1.8%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	116,337	117,265	120,628	644,900	0.3%	0.5%	0.6%	0.4%
137	Melanoma: Continuity of Care – Recall System <sup>a, b, c</sup>	53,101	1,595	1,902	2,036	4.1%	99.2%	97.2%	97.9%
138	Melanoma: Coordination of Care <sup>a, b, c</sup>	44,935	1,246	1,809	1,889	2.3%	99.1%	97.5%	97.8%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	70,379	72,524	75,907	75,085	7.8%	10.0%	12.5%	13.9%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	43,409	44,154	45,600	47,772	6.4%	8.7%	11.6%	12.4%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	213,059	213,553	218,874	203,908	0.5%	0.7%	0.9%	1.4%
143	Oncology: Medical and Radiation – Pain Intensity Quantified <sup>a, b, c</sup>	20,975	61	54	79	2.6%	100.0%	100.0%	88.6%
144	Oncology: Medical and Radiation – Plan of Care for Pain <sup>a, b, c</sup>	352	18	46	50	98.0%	100.0%	100.0%	100.0%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	127,907	125,169	108,364	97,696	6.1%	8.7%	12.3%	15.3%
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>e</sup>	28,703	27,027	23,526	21,310	20.2%	28.4%	39.7%	45.1%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	19,234	19,252	18,169	16,745	22.8%	33.2%	44.4%	51.5%
154	Falls: Risk Assessment	606,031	607,979	622,542	589,962	1.5%	1.4%	1.7%	2.2%
155	Falls: Plan of Care	6,854	6,688	8,268	9,453	47.5%	60.9%	70.7%	74.8%
156	Oncology: Radiation Dose Limits to Normal Tissues	3,706	3,661	3,557	3,352	8.3%	11.6%	15.2%	16.0%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	3,299	3,105	2,984	3,120	1.5%	1.5%	2.0%	1.5%



Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	6,742	6,464	6,181	5,515	4.6%	6.0%	7.8%	8.7%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage <sup>a, b, c, d</sup>	92	96	112	82	100.0%	100.0%	99.1%	100.0%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis <sup>a, b, c, d</sup>	74	87	74	40	100.0%	100.0%	94.6%	97.5%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy <sup>a, b, c, d</sup>	60	61	70	64	100.0%	100.0%	95.7%	98.4%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy <sup>a, b, c, d</sup>	69	68	85	60	100.0%	100.0%	96.5%	98.3%
163	Diabetes Mellitus: Foot Exam	310,547	324,827	331,724	314,625	1.6%	1.7%	2.6%	7.9%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a, b, c, d, e</sup>	15	16	5	8	100.0%	100.0%	80.0%	87.5%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a, b, c, d, e</sup>	11	19	5	5	100.0%	100.0%	80.0%	40.0%
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a, b, c, d, e</sup>	4	11	2	5	100.0%	100.0%	50.0%	80.0%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a, b, c, d, e</sup>	4	7	2	5	100.0%	100.0%	50.0%	80.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a, b, c, d, e</sup>	12	16	7	9	100.0%	100.0%	85.7%	66.7%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge <sup>a, b, c, d</sup>	14	16	10	9	100.0%	100.0%	90.0%	55.6%
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge <sup>a, b, c, d</sup>	13	15	2	5	100.0%	100.0%	50.0%	20.0%
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge <sup>a, b, c, d</sup>	13	14	2	5	100.0%	100.0%	50.0%	20.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	4,922	4,823	4,807	4,363	2.7%	3.7%	4.8%	5.6%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	625,600	662,216	675,446	641,652	0.3%	0.7%	1.2%	4.2%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	130,424	146,538	150,934	140,815	0.4%	0.3%	0.3%	0.4%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	130,424	146,538	150,932	140,816	0.4%	0.4%	0.3%	0.4%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	130,423	146,537	150,932	140,816	0.4%	0.4%	0.3%	0.5%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	130,423	146,537	150,932	140,813	0.3%	0.3%	0.2%	0.3%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	130,423	146,537	150,942	140,814	0.4%	0.4%	0.3%	0.4%
181	Elder Maltreatment Screen and Follow-Up Plan	65,240	66,877	69,780	589,553	0.1%	0.1%	0.1%	0.0%
182	Functional Outcome Assessment	47,529	47,621	47,966	98,125	0.3%	0.6%	1.2%	3.6%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	55,571	67,361	70,698	66,966	1.2%	0.7%	0.9%	0.8%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	55,570	67,359	70,695	66,968	1.2%	0.6%	0.8%	0.7%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	16,486	17,192	17,475	16,363	4.0%	4.8%	5.8%	6.2%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	7,851	11,493	43,358	45,487	1.1%	1.0%	0.5%	0.8%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy <sup>a, b, c</sup>	N/A	15	13	9	N/A	100.0%	100.0%	88.9%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	3,444	3,330	3,102	N/A	0.1%	0.1%	0.1%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	N/A	6,815	6,480	5,950	N/A	0.2%	0.2%	0.3%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	N/A	14,519	14,822	13,712	N/A	0.3%	0.4%	1.6%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery <sup>a, b, c</sup>	N/A	170	242	205	N/A	100.0%	94.6%	88.8%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a, b, c, e</sup>	N/A	149	226	148	N/A	99.3%	91.2%	83.8%
193	Perioperative Temperature Management	N/A	85,758	89,505	90,070	N/A	17.2%	26.6%	31.9%
194	Oncology: Cancer Stage Documented	N/A	164,235	167,770	155,882	N/A	0.7%	1.2%	1.3%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	N/A	65,456	64,773	59,471	N/A	16.9%	19.9%	24.6%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment <sup>a, b, c</sup>	N/A	596	916	709	N/A	100.0%	96.9%	96.6%
197	Coronary Artery Disease (CAD): Lipid Control <sup>a, b, c</sup>	N/A	1,778	4,329	11,545	N/A	100.0%	100.0%	99.8%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment <sup>a, b, c</sup>	N/A	927	1,246	699	N/A	100.0%	99.3%	99.9%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation <sup>a, b, c</sup>	N/A	814	1,738	4,156	N/A	100.0%	100.0%	100.0%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	N/A	264,191	272,354	253,905	N/A	1.7%	2.9%	6.7%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	264,152	272,232	254,048	N/A	1.7%	3.0%	7.2%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea <sup>a, b, c</sup>	N/A	50	30	22	N/A	100.0%	83.3%	100.0%
206	HIV/AIDS: Screening for High Risk Sexual Behaviors <sup>a, b, c</sup>	N/A	22	17	16	N/A	100.0%	70.6%	100.0%
207	HIV/AIDS: Screening for Injection Drug Use <sup>a, b, c</sup>	N/A	23	17	16	N/A	100.0%	70.6%	100.0%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis <sup>a, b, c</sup>	N/A	70	30	21	N/A	100.0%	86.7%	100.0%
209	Functional Communication Measure - Spoken Language Comprehension <sup>a, b, c</sup>	N/A	10	23	13	N/A	100.0%	100.0%	100.0%
210	Functional Communication Measure - Attention <sup>a, b, c</sup>	N/A	6	15	10	N/A	100.0%	100.0%	100.0%
211	Functional Communication Measure - Memory <sup>a, b, c</sup>	N/A	10	21	9	N/A	100.0%	100.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
212	Functional Communication Measure - Motor Speech <sup>a, b, c</sup>	N/A	6	14	9	N/A	100.0%	100.0%	100.0%
213	Functional Communication Measure - Reading <sup>a, b, c</sup>	N/A	4	8	5	N/A	100.0%	100.0%	100.0%
214	Functional Communication Measure - Spoken Language Expression <sup>a, b, c</sup>	N/A	12	25	13	N/A	100.0%	100.0%	100.0%
215	Functional Communication Measure - Writing <sup>a, b, c</sup>	N/A	3	2	3	N/A	100.0%	100.0%	100.0%
216	Functional Communication Measure - Swallowing <sup>a, b, c</sup>	N/A	10	21	10	N/A	100.0%	100.0%	100.0%
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments <sup>a, b</sup>	N/A	N/A	153	459	N/A	N/A	100.0%	100.0%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments <sup>a, b</sup>	N/A	N/A	146	444	N/A	N/A	100.0%	100.0%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments <sup>a, b</sup>	N/A	N/A	129	423	N/A	N/A	100.0%	100.0%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments <sup>a, b</sup>	N/A	N/A	172	504	N/A	N/A	100.0%	100.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments <sup>a, b</sup>	N/A	N/A	165	498	N/A	N/A	100.0%	100.0%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments <sup>a, b</sup>	N/A	N/A	91	230	N/A	N/A	100.0%	100.0%
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments <sup>a, b</sup>	N/A	N/A	155	442	N/A	N/A	100.0%	100.0%
224	Melanoma: Overutilization of Imaging Studies in Melanoma <sup>a, b</sup>	N/A	N/A	1,806	1,957	N/A	N/A	97.6%	97.8%
225	Radiology: Reminder System for Mammograms	N/A	N/A	26,858	24,176	N/A	N/A	20.3%	26.6%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	N/A	682,002	648,514	N/A	N/A	5.6%	9.7%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing <sup>a, b</sup>	N/A	N/A	213	192	N/A	N/A	30.0%	21.4%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	N/A	86,880	79,262	N/A	N/A	0.3%	0.2%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	N/A	86,846	79,261	N/A	N/A	0.1%	0.1%
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection <sup>a, b</sup>	N/A	N/A	1	2	N/A	N/A	0.0%	50.0%
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy) <sup>a, b</sup>	N/A	N/A	1	2	N/A	N/A	0.0%	50.0%
235	Hypertension (HTN): Plan of Care	N/A	N/A	308,982	289,071	N/A	N/A	0.8%	0.8%
236	Hypertension (HTN): Controlling High Blood Pressure <sup>a, b</sup>	N/A	N/A	0	11,249	N/A	N/A	0.0%	100.0%
237	Hypertension (HTN): Blood Pressure Measurement <sup>a, b</sup>	N/A	N/A	227	12,114	N/A	N/A	100.0%	100.0%
238	Drugs to be Avoided in the Elderly <sup>a, b, e</sup>	N/A	N/A	552	18,568	N/A	N/A	100.0%	100.0%
239	Weight Assessment and Counseling for Children and Adolescents <sup>a, b</sup>	N/A	N/A	52	115	N/A	N/A	100.0%	100.0%
240	Childhood Immunization Status <sup>a, b</sup>	N/A	N/A	11	5	N/A	N/A	100.0%	100.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	253,286	N/A	N/A	N/A	5.3%



Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
242	Coronary Artery Disease (CAD): Symptom Management <sup>a</sup>	N/A	N/A	N/A	510	N/A	N/A	N/A	100.0%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
244	Hypertension: Blood Pressure Management <sup>a</sup>	N/A	N/A	N/A	81	N/A	N/A	N/A	100.0%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	N/A	N/A	N/A	152,193	N/A	N/A	N/A	0.2%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	N/A	N/A	N/A	152,193	N/A	N/A	N/A	0.2%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	N/A	37,316	N/A	N/A	N/A	0.1%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	N/A	87,976	N/A	N/A	N/A	0.1%
249	Barrett's Esophagus	N/A	N/A	N/A	7,590	N/A	N/A	N/A	48.1%
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	N/A	3,516	N/A	N/A	N/A	61.3%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	N/A	4,987	N/A	N/A	N/A	52.8%
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	N/A	25,106	N/A	N/A	N/A	7.8%
253	Pregnancy Test for Female Abdominal Pain Patients	N/A	N/A	N/A	48,156	N/A	N/A	N/A	10.9%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	N/A	840	N/A	N/A	N/A	11.2%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	N/A	10	N/A	N/A	N/A	20.0%
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR) <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB) <sup>a</sup>	N/A	N/A	N/A	25	N/A	N/A	N/A	84.0%
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) <sup>a</sup>	N/A	N/A	N/A	15	N/A	N/A	N/A	100.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2) <sup>a</sup>	N/A	N/A	N/A	23	N/A	N/A	N/A	91.3%
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2) <sup>a</sup>	N/A	N/A	N/A	28	N/A	N/A	N/A	100.0%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	N/A	10,224	N/A	N/A	N/A	0.9%
262	Image Confirmation of Successful Excision of Image–Localized Breast Lesion	N/A	N/A	N/A	8,243	N/A	N/A	N/A	2.1%
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	N/A	8,747	N/A	N/A	N/A	2.1%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer <sup>a</sup>	N/A	N/A	N/A	139	N/A	N/A	N/A	100.0%
265	Biopsy Follow-Up <sup>a</sup>	N/A	N/A	N/A	389	N/A	N/A	N/A	100.0%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	N/A	78,554	N/A	N/A	N/A	0.4%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	N/A	78,554	N/A	N/A	N/A	0.3%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	N/A	18,471	N/A	N/A	N/A	0.3%
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery <sup>a</sup>	N/A	N/A	N/A	12	N/A	N/A	N/A	100.0%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement <sup>a</sup>	N/A	N/A	N/A	1,694	N/A	N/A	N/A	100.0%
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
307	Prenatal Care: Anti-D Immune Globulin <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies <sup>a</sup>	N/A	N/A	N/A	19,184	N/A	N/A	N/A	100.0%
309	Cervical Cancer Screening <sup>a</sup>	N/A	N/A	N/A	17,128	N/A	N/A	N/A	100.0%

Measure Number	Measure Description	Eligible Professionals in 2009	Eligible Professionals in 2010	Eligible Professionals in 2011	Eligible Professionals in 2012	Reporting Rate in 2009	Reporting Rate in 2010	Reporting Rate in 2011	Reporting Rate in 2012
310	Chlamydia Screening for Women <sup>a</sup>	N/A	N/A	N/A	688	N/A	N/A	N/A	100.0%
311	Use of Appropriate Medications for Asthma <sup>a</sup>	N/A	N/A	N/A	2,972	N/A	N/A	N/A	100.0%
312	Low Back Pain: Use of Imaging Studies <sup>a</sup>	N/A	N/A	N/A	3,106	N/A	N/A	N/A	100.0%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%) <sup>a</sup>	N/A	N/A	N/A	14,688	N/A	N/A	N/A	100.0%
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL <sup>a</sup>	N/A	N/A	N/A	17,369	N/A	N/A	N/A	100.0%
317	Preventive Care and Screening: Screening for High Blood Pressure	N/A	N/A	N/A	663,267	N/A	N/A	N/A	3.1%

<sup>a</sup> Measure was not reportable via claims (e.g. registry only) during the 2012 program year.

<sup>b</sup> Measure was not reportable via claims (e.g. registry only) during the 2011 program year.

<sup>c</sup> Measure was not reportable via claims (e.g., registry only) during the 2010 program year.

<sup>d</sup> Measure was not reportable via claims (e.g., registry only) during the 2009 program year.

<sup>e</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A26: (1) Eligible professional-level results in this table do not include EPs who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) We only have eligibility information in claims; participation in non-claims measures (e.g., registry only measures) was used as a proxy for eligibility, which results in artificial 100% participation rates. (3) We applied the following hierarchy if an EP participated in multiple methods: EHR, Claims 12-month, Registry 12-month, and Registry 6-month. For example, if an EP participated in both claims and registry methods, the information from claims was used.

**Table A27. Reporting and Performance Information by Individual Measure for the Physician Quality Reporting System (2009 to 2012)**

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>e</sup>	78.8%	80.6%	82.0%	82.7%	12.3%	21.9%	23.3%	21.4%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	79.1%	80.6%	82.4%	83.5%	67.0%	57.0%	55.6%	50.8%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	78.2%	79.9%	81.9%	83.4%	59.3%	58.6%	71.3%	69.7%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	68.2%	91.0%	98.0%	98.5%	94.5%	85.6%	79.7%	82.2%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	76.8%	77.1%	80.6%	88.5%	86.5%	85.3%	85.2%	69.9%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) <sup>a, b, c, d</sup>	99.8%	95.6%	97.2%	98.7%	60.9%	71.4%	82.1%	69.9%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	74.2%	91.7%	97.0%	96.9%	95.0%	82.7%	75.8%	86.8%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	66.9%	62.9%	67.8%	68.9%	60.2%	68.6%	71.4%	54.8%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	66.1%	71.5%	73.9%	74.7%	65.4%	68.0%	66.4%	64.6%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	69.4%	74.5%	74.4%	73.5%	95.9%	95.2%	95.5%	95.4%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	67.9%	70.0%	70.9%	70.0%	96.1%	95.7%	94.2%	94.4%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	66.5%	68.9%	70.1%	77.8%	96.8%	97.0%	96.3%	96.0%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	62.2%	65.8%	66.9%	67.4%	92.5%	91.5%	93.1%	92.0%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	70.9%	73.9%	73.7%	76.1%	92.4%	92.6%	93.9%	95.5%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	70.2%	73.4%	74.6%	74.2%	90.0%	89.4%	92.3%	92.9%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	69.7%	71.9%	72.1%	72.5%	94.5%	93.4%	95.0%	95.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	71.0%	72.7%	74.5%	73.9%	90.0%	91.2%	94.4%	94.4%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	66.2%	68.8%	54.0%	57.2%	49.0%	50.6%	62.4%	62.8%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	89.6%	91.4%	88.9%	88.8%	81.5%	83.5%	85.3%	85.7%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	71.8%	78.5%	82.1%	83.8%	91.4%	92.0%	93.3%	93.8%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	72.0%	77.8%	80.3%	71.0%	83.6%	78.6%	82.8%	81.5%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	70.6%	65.4%	70.5%	68.3%	85.1%	82.8%	84.6%	83.1%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge <sup>a, b, c, d</sup>	100.0%	85.3%	90.6%	93.1%	45.3%	79.4%	83.5%	90.5%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	67.1%	74.6%	77.9%	77.5%	76.7%	84.3%	90.6%	72.6%



Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	72.7%	63.1%	68.9%	65.9%	71.9%	69.7%	72.8%	79.0%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	71.3%	71.4%	69.6%	83.8%	56.1%	55.1%	61.2%	37.3%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	70.0%	76.2%	56.3%	40.8%	56.5%	46.8%	70.6%	66.1%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	76.1%	79.6%	76.1%	62.2%	74.7%	72.5%	70.2%	77.1%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	85.8%	90.1%	90.6%	92.7%	97.6%	97.9%	98.3%	99.2%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	86.4%	90.8%	91.8%	93.6%	91.0%	92.0%	94.0%	95.9%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	83.3%	87.7%	87.4%	93.5%	99.4%	99.4%	99.0%	98.9%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility <sup>d</sup>	100.0%	65.7%	49.2%	22.3%	91.6%	91.3%	95.9%	96.4%
47	Advance Care Plan	64.7%	68.2%	67.3%	85.2%	45.7%	50.7%	54.6%	58.1%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	51.5%	54.8%	52.5%	82.9%	57.3%	66.5%	76.0%	68.0%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	74.1%	71.4%	70.3%	66.4%	68.9%	82.5%	85.2%	88.4%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	71.6%	70.3%	67.7%	63.3%	76.4%	82.7%	89.8%	96.7%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	75.9%	74.0%	66.9%	58.9%	53.5%	56.0%	68.3%	69.4%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	70.1%	74.2%	62.9%	54.3%	92.7%	89.7%	73.4%	98.5%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	91.8%	94.3%	87.3%	78.1%	83.4%	81.7%	69.1%	92.9%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	85.9%	87.7%	88.8%	88.7%	94.6%	95.1%	95.0%	95.1%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	88.9%	90.6%	91.3%	78.7%	96.1%	96.4%	96.6%	96.9%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	88.6%	89.2%	90.5%	87.2%	94.0%	95.0%	95.7%	96.8%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	89.0%	89.9%	91.1%	90.1%	92.7%	94.0%	94.8%	96.0%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	89.5%	90.1%	91.4%	90.3%	95.4%	96.5%	97.7%	98.1%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	86.1%	86.5%	89.4%	83.9%	92.2%	92.4%	93.2%	94.6%
64	Asthma: Assessment of Asthma Control	92.5%	89.3%	83.1%	97.7%	34.2%	48.6%	40.6%	41.6%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	100.0%	100.0%	99.0%	100.0%	66.7%	85.7%	93.9%	60.0%
66	Appropriate Testing for Children with Pharyngitis	0.0%	100.0%	99.3%	0.0%	0.0%	100.0%	100.0%	0.0%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	66.5%	73.7%	74.0%	74.2%	90.9%	88.8%	94.6%	95.6%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	64.4%	69.3%	71.1%	71.6%	97.7%	94.7%	97.7%	95.3%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	71.3%	75.9%	76.4%	76.3%	86.1%	81.7%	89.5%	90.4%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	72.9%	77.9%	78.4%	80.2%	92.6%	88.3%	95.3%	95.4%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	61.5%	69.0%	64.6%	65.8%	96.4%	90.6%	94.0%	91.6%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	62.6%	67.6%	66.1%	66.4%	98.8%	93.2%	93.7%	94.3%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	76.1%	80.4%	82.9%	83.4%	77.2%	77.4%	81.3%	82.6%
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute <sup>a, b, c, d</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute <sup>a, b, c, d</sup>	100.0%	100.0%	0.0%	100.0%	0.0%	10.0%	0.0%	93.5%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia <sup>a, b, c</sup>	74.2%	98.7%	97.7%	92.5%	70.6%	34.8%	23.9%	95.1%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	76.3%	79.6%	68.3%	63.9%	84.5%	86.1%	89.9%	94.7%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	74.8%	77.7%	65.9%	68.5%	88.4%	88.4%	93.5%	96.2%
86	Hepatitis C: Antiviral Treatment Prescribed	77.6%	84.0%	77.0%	62.6%	46.0%	41.2%	45.8%	70.2%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	79.2%	80.2%	67.0%	61.8%	74.5%	78.5%	85.8%	93.1%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	72.4%	75.8%	75.2%	62.3%	57.6%	59.4%	60.3%	82.7%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	81.9%	83.1%	64.0%	59.5%	50.8%	70.2%	91.5%	82.4%
91	Acute Otitis Externa (AOE): Topical Therapy	81.3%	82.7%	85.1%	86.1%	72.4%	73.8%	83.7%	83.9%
92	Acute Otitis Externa (AOE): Pain Assessment	80.1%	76.3%	82.1%	86.3%	40.3%	59.4%	85.6%	87.4%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	82.0%	81.3%	85.8%	87.8%	45.5%	63.3%	78.2%	73.9%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	80.2%	80.7%	82.3%	84.4%	96.6%	97.5%	96.8%	97.4%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	87.2%	87.4%	87.6%	86.0%	97.5%	98.5%	98.0%	97.8%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	60.0%	72.8%	69.6%	66.6%	65.5%	71.6%	90.5%	92.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	54.6%	72.6%	67.6%	70.0%	75.8%	79.6%	93.5%	91.1%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	62.5%	70.9%	69.3%	75.7%	82.4%	94.7%	98.6%	99.2%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	72.2%	69.6%	74.9%	73.7%	68.0%	77.3%	78.4%	72.3%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	66.2%	72.0%	73.8%	70.0%	69.0%	80.8%	82.3%	77.0%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	80.9%	70.2%	76.1%	65.3%	66.5%	79.9%	70.2%	74.9%
109	Osteoarthritis (OA): Function and Pain Assessment	73.6%	63.9%	40.0%	38.4%	41.3%	51.7%	80.1%	84.1%
110	Preventive Care and Screening: Influenza Immunization	72.6%	72.2%	76.9%	77.6%	50.9%	51.2%	50.4%	43.9%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	76.7%	75.8%	80.8%	82.8%	52.8%	54.5%	58.1%	53.4%
112	Preventive Care and Screening: Screening Mammography	76.4%	76.6%	78.0%	84.6%	56.1%	53.5%	58.2%	55.0%
113	Preventive Care and Screening: Colorectal Cancer Screening	73.9%	73.0%	76.4%	83.4%	50.5%	52.0%	53.9%	49.8%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	90.6%	81.7%	67.6%	52.4%	55.3%	42.3%	44.1%	42.3%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	65.9%	66.9%	65.8%	80.9%	73.0%	79.7%	80.3%	85.9%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	72.4%	90.3%	97.1%	93.9%	73.2%	67.2%	63.5%	64.0%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	79.2%	78.5%	77.5%	88.0%	72.7%	74.0%	78.7%	81.0%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	84.7%	89.3%	87.1%	61.9%	35.2%	40.0%	45.3%	66.6%
122	Adult Kidney Disease: Blood Pressure Management	78.9%	84.3%	80.1%	63.9%	68.9%	58.2%	65.6%	87.2%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>e</sup>	61.0%	54.1%	53.6%	43.3%	96.0%	94.8%	95.0%	20.9%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	74.9%	78.5%	78.0%	73.6%	99.1%	99.2%	99.5%	99.7%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	66.2%	59.5%	55.0%	51.6%	52.8%	74.2%	86.6%	84.1%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	67.3%	54.7%	53.3%	42.1%	43.9%	66.9%	69.2%	88.7%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	54.5%	55.0%	65.5%	76.9%	49.6%	60.2%	59.9%	57.5%
130	Documentation of Current Medications in the Medical Record	69.9%	69.2%	70.5%	68.9%	68.4%	74.7%	85.7%	85.6%
131	Pain Assessment and Follow-Up	65.6%	73.5%	73.6%	63.2%	97.4%	97.3%	94.8%	86.9%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	64.3%	73.0%	79.5%	31.2%	67.2%	84.2%	82.6%	65.2%
137	Melanoma: Continuity of Care – Recall System <sup>a, b, c</sup>	72.7%	99.9%	99.8%	99.9%	90.8%	78.2%	96.0%	97.3%
138	Melanoma: Coordination of Care <sup>a, b, c</sup>	65.7%	99.9%	99.5%	100.0%	87.2%	87.7%	94.0%	93.8%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	60.1%	63.0%	64.9%	65.3%	92.0%	92.1%	91.3%	91.6%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	57.1%	58.6%	60.8%	60.4%	93.4%	94.2%	95.8%	95.8%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	71.3%	61.1%	44.1%	59.7%	41.9%	61.6%	82.7%	69.1%



Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
143	Oncology: Medical and Radiation – Pain Intensity Quantified <sup>a, b, c</sup>	65.2%	99.9%	99.1%	99.0%	66.8%	31.8%	79.2%	81.6%
144	Oncology: Medical and Radiation – Plan of Care for Pain <sup>a, b, c</sup>	91.3%	100.0%	100.0%	99.6%	91.2%	90.0%	91.2%	92.1%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	65.4%	77.7%	78.3%	81.6%	41.6%	48.1%	54.1%	57.6%
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>e</sup>	75.1%	83.3%	85.5%	86.2%	2.7%	1.1%	1.5%	0.9%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	77.3%	82.3%	83.9%	84.5%	57.3%	54.8%	56.2%	59.0%
154	Falls: Risk Assessment	55.9%	62.7%	61.3%	59.2%	87.1%	91.9%	81.9%	85.5%
155	Falls: Plan of Care	83.4%	87.0%	86.8%	85.5%	86.6%	88.0%	87.2%	91.2%
156	Oncology: Radiation Dose Limits to Normal Tissues	70.5%	73.9%	72.9%	76.1%	89.2%	93.2%	95.8%	96.6%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	73.9%	80.9%	73.9%	64.4%	77.7%	81.6%	88.0%	92.6%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	75.1%	81.2%	83.0%	82.2%	91.5%	93.8%	94.4%	94.8%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage <sup>a, b, c, d</sup>	100.0%	99.6%	98.2%	99.5%	76.7%	83.9%	92.2%	95.8%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis <sup>a, b, c, d</sup>	100.0%	99.6%	99.2%	98.9%	61.5%	75.8%	75.8%	80.1%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy <sup>a, b, c, d</sup>	100.0%	97.7%	98.9%	98.6%	90.3%	97.2%	96.4%	99.3%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy <sup>a, b, c, d</sup>	100.0%	98.5%	98.9%	98.7%	76.6%	75.5%	88.3%	95.1%
163	Diabetes Mellitus: Foot Exam	68.8%	59.0%	62.9%	85.2%	51.7%	72.1%	77.0%	67.3%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a, b, c, d, e</sup>	100.0%	100.0%	100.0%	100.0%	73.8%	93.9%	10.0%	9.6%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a, b, c, d, e</sup>	100.0%	99.8%	100.0%	70.0%	100.0%	78.9%	7.5%	8.3%
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a, b, c, d, e</sup>	100.0%	99.7%	100.0%	100.0%	100.0%	63.6%	33.3%	4.2%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a, b, c, d, e</sup>	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	60.0%	5.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a, b, c, d, e</sup>	100.0%	100.0%	100.0%	86.7%	92.3%	94.1%	3.3%	2.3%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge <sup>a, b, c, d</sup>	100.0%	91.3%	100.0%	100.0%	7.1%	37.5%	97.2%	100.0%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge <sup>a, b, c, d</sup>	100.0%	88.3%	100.0%	100.0%	0.0%	33.2%	57.1%	100.0%
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge <sup>a, b, c, d</sup>	100.0%	93.1%	100.0%	100.0%	0.0%	28.4%	71.4%	100.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	64.1%	71.2%	76.6%	79.1%	91.2%	94.6%	95.9%	95.8%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	78.4%	50.3%	58.2%	86.8%	31.0%	63.2%	86.6%	74.5%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	74.8%	56.9%	52.4%	51.2%	90.0%	85.7%	75.7%	81.1%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	74.7%	59.7%	50.3%	47.3%	38.2%	61.6%	91.3%	92.4%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	75.7%	60.9%	49.8%	50.1%	38.4%	62.2%	89.8%	92.8%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	75.2%	59.9%	43.1%	44.5%	33.2%	55.5%	88.0%	89.6%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	76.8%	60.8%	58.8%	45.9%	90.3%	95.9%	96.0%	99.9%
181	Elder Maltreatment Screen and Follow-Up Plan	75.4%	74.0%	69.7%	14.8%	50.9%	55.3%	96.7%	90.8%
182	Functional Outcome Assessment	31.0%	50.2%	54.7%	52.9%	85.0%	76.6%	78.7%	80.9%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	90.1%	83.3%	78.7%	66.5%	39.4%	47.3%	54.6%	62.7%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	90.2%	83.4%	78.7%	65.1%	41.0%	51.6%	61.6%	67.4%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	72.0%	73.5%	72.3%	71.1%	87.0%	92.5%	96.1%	97.3%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	81.4%	80.0%	62.0%	54.8%	83.4%	80.4%	91.7%	94.8%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy <sup>a, b, c</sup>	N/A	100.0%	100.0%	100.0%	N/A	83.3%	100.0%	100.0%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	74.4%	66.7%	70.8%	N/A	100.0%	78.6%	100.0%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	N/A	70.3%	59.4%	65.2%	N/A	87.5%	85.7%	95.8%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	N/A	40.3%	42.5%	31.8%	N/A	88.7%	86.5%	90.3%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery <sup>a, b, c</sup>	N/A	98.5%	99.2%	100.0%	N/A	90.6%	94.8%	92.0%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a, b, c, e</sup>	N/A	100.0%	99.1%	100.0%	N/A	3.4%	4.4%	5.2%
193	Perioperative Temperature Management	N/A	67.0%	73.0%	77.9%	N/A	85.3%	87.9%	90.4%
194	Oncology: Cancer Stage Documented	N/A	71.6%	68.8%	68.2%	N/A	85.6%	86.3%	93.2%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	N/A	75.3%	79.9%	82.7%	N/A	59.5%	61.7%	66.1%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment <sup>a, b, c</sup>	N/A	99.7%	99.9%	99.9%	N/A	47.1%	65.9%	24.8%
197	Coronary Artery Disease (CAD): Lipid Control <sup>a, b, c</sup>	N/A	97.9%	99.8%	99.7%	N/A	75.3%	82.2%	42.7%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment <sup>a, b, c</sup>	N/A	99.1%	99.6%	98.3%	N/A	45.6%	61.1%	38.3%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation <sup>a, b, c</sup>	N/A	100.0%	100.0%	100.0%	N/A	72.1%	52.4%	63.4%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	N/A	86.1%	82.4%	89.5%	N/A	76.1%	77.7%	70.8%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	83.7%	79.9%	88.9%	N/A	74.7%	79.6%	63.2%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea <sup>a, b, c</sup>	N/A	96.4%	94.5%	90.1%	N/A	32.4%	79.0%	68.3%
206	HIV/AIDS: Screening for High Risk Sexual Behaviors <sup>a, b, c</sup>	N/A	98.5%	97.0%	97.8%	N/A	28.6%	87.0%	76.2%
207	HIV/AIDS: Screening for Injection Drug Use <sup>a, b, c</sup>	N/A	96.8%	96.0%	97.5%	N/A	32.3%	86.0%	71.2%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis <sup>a, b, c</sup>	N/A	96.2%	95.5%	96.1%	N/A	50.3%	79.3%	52.3%
209	Functional Communication Measure - Spoken Language Comprehension <sup>a, b, c</sup>	N/A	80.8%	100.0%	100.0%	N/A	58.8%	70.8%	73.6%
210	Functional Communication Measure - Attention <sup>a, b, c</sup>	N/A	88.9%	100.0%	100.0%	N/A	58.3%	56.6%	79.3%
211	Functional Communication Measure - Memory <sup>a, b, c</sup>	N/A	83.0%	100.0%	100.0%	N/A	55.5%	69.0%	73.0%
212	Functional Communication Measure - Motor Speech <sup>a, b, c</sup>	N/A	81.5%	100.0%	100.0%	N/A	66.7%	77.4%	92.5%
213	Functional Communication Measure - Reading <sup>a, b, c</sup>	N/A	87.5%	100.0%	100.0%	N/A	58.3%	95.0%	100.0%
214	Functional Communication Measure - Spoken Language Expression <sup>a, b, c</sup>	N/A	77.6%	100.0%	100.0%	N/A	45.8%	77.4%	63.1%
215	Functional Communication Measure - Writing <sup>a, b, c</sup>	N/A	80.0%	100.0%	100.0%	N/A	16.7%	83.3%	83.3%
216	Functional Communication Measure - Swallowing <sup>a, b, c</sup>	N/A	84.7%	100.0%	100.0%	N/A	73.6%	72.7%	58.3%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	71.7%	71.5%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	68.8%	60.6%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	61.2%	48.9%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	67.0%	57.4%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	68.9%	59.3%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	69.7%	56.6%
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	63.7%	52.7%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
224	Melanoma: Overutilization of Imaging Studies in Melanoma <sup>a, b</sup>	N/A	N/A	100.0%	99.9%	N/A	N/A	95.0%	99.2%
225	Radiology: Reminder System for Mammograms	N/A	N/A	74.5%	80.4%	N/A	N/A	68.5%	74.6%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	N/A	65.4%	75.4%	N/A	N/A	81.6%	84.1%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing <sup>a, b</sup>	N/A	N/A	99.8%	94.9%	N/A	N/A	93.3%	95.5%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	N/A	65.1%	61.0%	N/A	N/A	85.0%	92.6%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	N/A	59.8%	58.0%	N/A	N/A	80.7%	75.4%
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection <sup>a, b</sup>	N/A	N/A	0.0%	100.0%	N/A	N/A	0.0%	100.0%
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy) <sup>a, b</sup>	N/A	N/A	0.0%	100.0%	N/A	N/A	0.0%	100.0%
235	Hypertension (HTN): Plan of Care	N/A	N/A	45.4%	52.5%	N/A	N/A	79.1%	75.8%
236	Hypertension (HTN): Controlling High Blood Pressure <sup>a, b</sup>	N/A	N/A	0.0%	100.0%	N/A	N/A	0.0%	66.8%
237	Hypertension (HTN): Blood Pressure Measurement <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	0.0%	95.8%



Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
238	Drugs to be Avoided in the Elderly <sup>a, b, e</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	3.5%	8.1%
239	Weight Assessment and Counseling for Children and Adolescents <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	57.1%	0.0%
240	Childhood Immunization Status <sup>a, b</sup>	N/A	N/A	100.0%	100.0%	N/A	N/A	0.0%	0.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	89.4%	N/A	N/A	N/A	49.7%
242	Coronary Artery Disease (CAD): Symptom Management <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	0.0%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
244	Hypertension: Blood Pressure Management <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	61.9%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	N/A	N/A	N/A	30.5%	N/A	N/A	N/A	87.4%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	N/A	N/A	N/A	28.9%	N/A	N/A	N/A	77.6%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	N/A	78.1%	N/A	N/A	N/A	95.9%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	N/A	60.9%	N/A	N/A	N/A	88.0%
249	Barrett's Esophagus	N/A	N/A	N/A	81.2%	N/A	N/A	N/A	98.8%
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	N/A	89.1%	N/A	N/A	N/A	99.1%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	N/A	79.0%	N/A	N/A	N/A	97.5%
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	N/A	88.0%	N/A	N/A	N/A	84.8%
253	Pregnancy Test for Female Abdominal Pain Patients	N/A	N/A	N/A	82.9%	N/A	N/A	N/A	68.6%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	N/A	99.5%	N/A	N/A	N/A	74.7%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	100.0%
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR) <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB) <sup>a</sup>	N/A	N/A	N/A	55.1%	N/A	N/A	N/A	81.3%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) <sup>a</sup>	N/A	N/A	N/A	83.2%	N/A	N/A	N/A	54.4%
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2) <sup>a</sup>	N/A	N/A	N/A	80.4%	N/A	N/A	N/A	74.0%
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2) <sup>a</sup>	N/A	N/A	N/A	90.7%	N/A	N/A	N/A	85.5%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	N/A	43.4%	N/A	N/A	N/A	81.4%
262	Image Confirmation of Successful Excision of Image-Localized Breast Lesion	N/A	N/A	N/A	88.1%	N/A	N/A	N/A	97.1%
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	N/A	85.7%	N/A	N/A	N/A	98.4%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	95.1%
265	Biopsy Follow-Up <sup>a</sup>	N/A	N/A	N/A	99.7%	N/A	N/A	N/A	92.5%

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	N/A	44.7%	N/A	N/A	N/A	95.4%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	N/A	44.3%	N/A	N/A	N/A	95.2%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	N/A	52.4%	N/A	N/A	N/A	89.8%
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	100.0%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	0.0%
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
307	Prenatal Care: Anti-D Immune Globulin <sup>a</sup>	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Measure Number	Measure Description	Average Percent of Instances Reported in 2009	Average Percent of Instances Reported in 2010	Average Percent of Instances Reported in 2011	Average Percent of Instances Reported in 2012	Average Performance Rate in 2009	Average Performance Rate in 2010	Average Performance Rate in 2011	Average Performance Rate in 2012
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	9.2%
309	Cervical Cancer Screening <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	41.7%
310	Chlamydia Screening for Women <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	93.7%
311	Use of Appropriate Medications for Asthma <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	89.1%
312	Low Back Pain: Use of Imaging Studies <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	38.0%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%) <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	58.2%
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL <sup>a</sup>	N/A	N/A	N/A	100.0%	N/A	N/A	N/A	52.8%
317	Preventive Care and Screening: Screening for High Blood Pressure	N/A	N/A	N/A	76.5%	N/A	N/A	N/A	87.2%

<sup>a</sup> Measure was not reportable via claims (e.g. registry only) during the 2012 program year.

<sup>b</sup> Measure was not reportable via claims (e.g. registry only) during the 2011 program year.

<sup>c</sup> Measure was not reportable via claims (e.g., registry only) during the 2010 program year.

<sup>d</sup> Measure was not reportable via claims (e.g., registry only) during the 2009 program year.

<sup>e</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

*Notes for Table A27: (1) Eligible professional-level results in this table do not include eligible professionals who belong to a group practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) We applied the following hierarchy if an eligible professional participated in multiple methods: EHR, Claims 12-month, Registry 12-month, and Registry 6-month. For example, if an EP participated in both claims and registry methods, the information from claims was used. (3) The percent of instances reported was calculated as the count of reported instances (numerator) divided by the count of eligible instances (denominator) from the method selected according to the hierarchy. (4) The performance rate was calculated as the count of reported instances where performance was met (numerator) divided by the total number of reported instances that excluded reported exclusions (i.e., performance denominator).*

**Table A28. Eligible Professional Individual Measure Reporting Consistency Across Program Years for the Physician Quality Reporting System (2009 to 2012)**

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	3,685	3,452	6,527	20,748	2.3	1.7
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	3,356	3,138	5,697	20,217	2.2	1.7
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	3,065	3,045	6,751	21,832	2.1	1.6
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	182	392	617	1,811	1.9	1.3
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	1,115	1,414	2,650	13,244	1.8	1.4
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	107	406	943	5,336	1.3	0.7
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	104	159	210	538	1.9	1.1
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	116	167	365	2,559	1.5	1.0
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	1,705	1,845	2,280	2,865	3.3	1.8
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	1,725	1,487	2,254	3,669	3.4	1.9

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	1,790	1,614	2,284	2,778	3.5	1.9
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	1,172	964	1,578	5,616	2.8	2.0
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	510	547	1,000	1,442	3.2	1.9
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	673	556	808	1,356	3.2	1.9
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	800	687	817	1,237	3.5	1.9
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	590	580	688	1,129	3.3	1.9
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	665	704	778	1,152	3.4	1.9
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	64	67	125	271	2.9	1.9
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	1,477	1,929	3,625	8,747	2.5	1.7
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	6,984	5,667	7,535	9,772	3.3	1.8



Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	310	705	1,005	3,400	1.7	1.1
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	282	635	908	2,159	2.0	1.4
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	1	144	150	359	1.7	0.8
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	118	301	515	4,936	1.3	0.8
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	326	543	779	2,121	1.9	1.2
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	1,475	1,438	3,029	22,329	1.5	1.0
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	88	72	402	952	1.7	1.2
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	313	389	611	1,434	2.3	1.6
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	212	158	208	231	3.5	1.8
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	203	120	183	224	3.3	1.8
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	160	99	146	191	3.1	1.7

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	0	59	247	1,044	1.3	0.5
47	Advance Care Plan	629	1,825	4,128	24,257	1.4	0.9
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	661	998	1,900	17,433	1.4	1.0
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	243	300	492	768	2.6	1.7
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	218	308	448	854	2.5	1.6
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	222	336	674	1,632	2.1	1.5
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	131	208	331	1,158	2.1	1.6
53	Asthma: Pharmacologic Therapy for Persistent Asthma	21	32	204	609	1.5	0.9
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	3,713	4,299	8,143	13,530	3.0	1.9
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	2,226	2,691	4,612	8,224	3.1	2.0
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	3,211	3,997	6,397	16,036	2.8	1.9
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	3,369	4,474	7,461	13,311	3.0	1.9
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	3,309	4,091	7,017	12,465	2.9	1.8

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	2,342	2,924	4,875	12,879	2.6	1.8
64	Asthma: Assessment of Asthma Control	17	22	95	3,669	1.1	0.3
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	0	0	8	871	1.0	0.1
66	Appropriate Testing for Children with Pharyngitis	0	0	0	0	N/A	N/A
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	207	168	194	274	3.3	1.8
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	234	110	136	223	3.1	1.7
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	277	164	247	305	3.4	1.8
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	245	163	280	291	3.4	1.8
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	144	221	259	581	2.9	1.9
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	159	205	215	380	3.0	1.8
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	2,674	3,698	3,176	4,813	2.6	1.4
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute	0	0	0	0	N/A	N/A

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute	0	0	0	1	1.0	0.0
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia	0	4	14	17	1.6	0.7
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	20	72	74	169	2.2	1.3
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	21	59	59	146	2.2	1.4
86	Hepatitis C: Antiviral Treatment Prescribed	12	53	71	143	2.0	1.2
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	16	59	35	91	2.2	1.2
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	30	124	130	360	1.9	1.2
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	3	17	25	45	1.9	1.1
91	Acute Otitis Externa (AOE): Topical Therapy	53	85	322	2,004	1.3	0.7
92	Acute Otitis Externa (AOE): Pain Assessment	33	74	334	1,666	1.3	0.7
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	43	71	265	1,676	1.3	0.7
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	420	406	451	786	3.6	1.6
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	328	342	386	629	3.6	1.6

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	96	68	111	185	2.4	1.4
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	112	71	102	193	2.5	1.4
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	65	103	162	247	2.4	1.4
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	109	122	147	502	1.9	1.2
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	125	149	171	668	1.9	1.2
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	129	155	261	896	1.9	1.3
109	Osteoarthritis (OA): Function and Pain Assessment	219	170	331	762	2.1	1.3
110	Preventive Care and Screening: Influenza Immunization	1,775	2,475	8,522	26,154	1.6	1.0
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	2,443	3,089	8,225	28,593	1.6	1.0
112	Preventive Care and Screening: Screening Mammography	2,016	1,870	4,697	24,996	1.5	0.9
113	Preventive Care and Screening: Colorectal Cancer Screening	2,165	2,081	5,825	26,984	1.5	0.9
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	5	23	61	256	1.4	0.7
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	2,712	2,349	3,951	21,031	1.9	1.4

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	12	23	77	532	1.3	0.8
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	1,674	1,139	2,758	17,429	1.5	1.1
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	103	65	138	777	1.6	1.1
122	Adult Kidney Disease: Blood Pressure Management	81	42	119	316	2.1	1.4
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	71	53	89	174	2.3	1.4
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	9,410	9,842	17,916	33,537	2.1	1.2
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	482	791	1,224	2,152	2.0	1.1
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	378	454	831	1,199	2.1	1.1
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	1,431	1,876	7,208	28,214	1.4	0.8
130	Documentation of Current Medications in the Medical Record	4,410	5,620	16,148	29,436	1.8	1.0
131	Pain Assessment and Follow-Up	1,108	1,012	2,260	6,900	2.0	1.3

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	61	150	187	1,916	1.3	0.8
137	Melanoma: Continuity of Care – Recall System	506	287	385	525	2.5	1.2
138	Melanoma: Coordination of Care	265	427	445	540	2.2	1.1
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	3,446	1,676	2,308	2,654	2.6	1.2
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	1,584	948	1,527	1,665	2.4	1.2
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	198	268	549	1,694	1.6	0.9
143	Oncology: Medical and Radiation – Pain Intensity Quantified	9	3	16	37	1.8	1.1
144	Oncology: Medical and Radiation – Plan of Care for Pain	4	2	15	28	1.6	0.9
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	4,825	2,865	2,975	3,894	2.6	1.2
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening	3,410	1,870	2,094	1,952	2.7	1.2
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	2,714	1,757	1,900	2,007	2.6	1.2
154	Falls: Risk Assessment	2,893	1,229	2,806	5,617	2.1	1.2
155	Falls: Plan of Care	1,312	742	1,748	2,975	2.1	1.1
156	Oncology: Radiation Dose Limits to Normal Tissues	128	71	131	191	2.3	1.2

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	12	2	12	14	2.3	1.2
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	125	113	115	110	2.5	1.1
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	28	16	19	15	2.7	1.1
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	22	8	2	4	3.3	1.0
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	17	13	14	8	2.8	1.1
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	24	13	9	9	2.9	1.1
163	Diabetes Mellitus: Foot Exam	979	1,047	2,605	19,425	1.3	0.7
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	1	0	1	4	1.7	1.2
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate	0	0	0	0	0.0	N/A
166	Coronary Artery Bypass Graft (CABG): Stroke	0	0	0	0	0.0	N/A
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure	0	0	0	4	1.0	0.0
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	1	0	3	2	2.0	1.1
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	1	0	3	1	2.2	1.1
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge	0	0	0	1	1.0	0.0



Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge	0	0	0	1	1.0	0.0
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	68	51	53	63	2.5	1.2
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	223	1,304	3,112	21,475	1.2	0.6
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	62	96	68	284	1.9	1.1
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	53	102	95	299	1.8	1.0
178	Rheumatoid Arthritis (RA): Functional Status Assessment	70	102	96	383	1.8	1.1
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	41	73	65	227	1.8	1.1
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	45	80	77	279	1.8	1.0
181	Elder Maltreatment Screen and Follow-Up Plan	3	1	7	256	1.1	0.4
182	Functional Outcome Assessment	72	104	279	3,082	1.2	0.6
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	60	66	96	260	1.8	1.1
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	66	52	83	259	1.8	1.1
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	315	175	261	242	2.6	1.2

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	8	25	77	257	1.4	0.7
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	N/A	1	0	7	1.3	0.7
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	N/A	0	0	4	1.0	0.0
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	N/A	2	5	9	1.6	0.7
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	N/A	16	31	175	1.3	0.6
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	N/A	41	51	77	1.8	0.8
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	N/A	26	30	55	1.7	0.8
193	Perioperative Temperature Management	N/A	10,595	8,532	9,320	2.0	0.8
194	Oncology: Cancer Stage Documented	N/A	629	604	795	1.9	0.8
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	N/A	7,828	2,670	3,859	2.3	0.9
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment	N/A	18	95	572	1.2	0.5
197	Coronary Artery Disease (CAD): Lipid Control	N/A	598	872	9,936	1.2	0.5
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	N/A	31	38	615	1.1	0.5

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	N/A	141	433	3,543	1.2	0.5
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	N/A	1,398	2,469	12,910	1.3	0.6
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	N/A	1,535	2,396	14,140	1.3	0.6
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	N/A	9	0	13	1.8	1.0
206	HIV/AIDS: Screening for High Risk Sexual Behaviors	N/A	4	4	8	1.8	0.9
207	HIV/AIDS: Screening for Injection Drug Use	N/A	4	3	9	1.7	0.9
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	N/A	9	0	12	1.9	1.0
209	Functional Communication Measure - Spoken Language Comprehension	N/A	1	8	4	1.8	0.6
210	Functional Communication Measure - Attention	N/A	2	3	5	1.7	0.8
211	Functional Communication Measure - Memory	N/A	2	3	4	1.8	0.8
212	Functional Communication Measure - Motor Speech	N/A	0	4	5	1.4	0.5
213	Functional Communication Measure - Reading	N/A	0	2	3	1.4	0.5
214	Functional Communication Measure - Spoken Language Expression	N/A	2	6	5	1.8	0.7
215	Functional Communication Measure - Writing	N/A	0	0	3	1.0	0.0
216	Functional Communication Measure - Swallowing	N/A	2	4	4	1.8	0.8
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	N/A	N/A	121	338	1.3	0.4

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	N/A	N/A	118	326	1.3	0.4
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	N/A	N/A	99	324	1.2	0.4
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	N/A	N/A	138	366	1.3	0.4
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	N/A	N/A	130	368	1.3	0.4
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	N/A	N/A	65	165	1.3	0.5
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	N/A	N/A	128	314	1.3	0.5
224	Melanoma: Overutilization of Imaging Studies in Melanoma	N/A	N/A	1,242	672	1.6	0.5
225	Radiology: Reminder System for Mammograms	N/A	N/A	4,374	2,068	1.7	0.5
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	N/A	N/A	22,554	40,518	1.4	0.5
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	N/A	N/A	11	30	1.3	0.4

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	N/A	N/A	41	131	1.2	0.4
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	N/A	N/A	20	79	1.2	0.4
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection	N/A	N/A	0	1	1.0	0.0
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy)	N/A	N/A	0	1	1.0	0.0
235	Hypertension (HTN): Plan of Care	N/A	N/A	417	1,889	1.2	0.4
236	Hypertension (HTN): Controlling High Blood Pressure	N/A	N/A	0	11,249	1.0	0.0
237	Hypertension (HTN): Blood Pressure Measurement	N/A	N/A	160	11,954	1.0	0.1
238	Drugs to be Avoided in the Elderly	N/A	N/A	356	18,212	1.0	0.1
239	Weight Assessment and Counseling for Children and Adolescents	N/A	N/A	1	114	1.0	0.1
240	Childhood Immunization Status	N/A	N/A	0	5	1.0	0.0
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	N/A	N/A	N/A	13,418	1.0	0.0
242	Coronary Artery Disease (CAD): Symptom Management	N/A	N/A	N/A	510	1.0	0.0
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting	N/A	N/A	N/A	N/A	N/A	N/A
244	Hypertension: Blood Pressure Management	N/A	N/A	N/A	81	1.0	0.0
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	N/A	N/A	N/A	273	1.0	0.0

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	N/A	N/A	N/A	337	1.0	0.0
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	N/A	N/A	N/A	49	1.0	0.0
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	N/A	N/A	N/A	120	1.0	0.0
249	Barrett's Esophagus	N/A	N/A	N/A	3,648	1.0	0.0
250	Radical Prostatectomy Pathology Reporting	N/A	N/A	N/A	2,155	1.0	0.0
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	N/A	N/A	N/A	2,635	1.0	0.0
252	Anticoagulation for Acute Pulmonary Embolus Patients	N/A	N/A	N/A	1,954	1.0	0.0
253	Pregnancy Test for Female Abdominal Pain Patients	N/A	N/A	N/A	5,266	1.0	0.0
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	N/A	N/A	N/A	94	1.0	0.0
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	N/A	N/A	N/A	2	1.0	0.0
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR)	N/A	N/A	N/A	N/A	N/A	N/A
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB)	N/A	N/A	N/A	21	1.0	0.0

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7)	N/A	N/A	N/A	15	1.0	0.0
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2)	N/A	N/A	N/A	21	1.0	0.0
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2)	N/A	N/A	N/A	28	1.0	0.0
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	N/A	N/A	N/A	90	1.0	0.0
262	Image Confirmation of Successful Excision of Image–Localized Breast Lesion	N/A	N/A	N/A	174	1.0	0.0
263	Preoperative Diagnosis of Breast Cancer	N/A	N/A	N/A	184	1.0	0.0
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer	N/A	N/A	N/A	139	1.0	0.0
265	Biopsy Follow-Up	N/A	N/A	N/A	389	1.0	0.0
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	N/A	N/A	N/A	283	1.0	0.0
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	N/A	N/A	N/A	211	1.0	0.0
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	N/A	N/A	N/A	56	1.0	0.0

Measure Number	Measure Description	Participating EPs Reporting Individually 2009 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2010 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2011 to 2012 <sup>a</sup>	Participating EPs Reporting Individually 2012 Only <sup>a</sup>	Average Number of Years EPs Reported the Measure <sup>b</sup>	Standard Deviation for Average Number of Years EPs Reported the Measure <sup>b</sup>
303	Cataracts: Improvement in Patient's Visual Function within 90 Days Following Cataract Surgery	N/A	N/A	N/A	0	N/A	N/A
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery	N/A	N/A	N/A	12	1.0	0.0
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement	N/A	N/A	N/A	1,694	1.0	0.0
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV)	N/A	N/A	N/A	N/A	N/A	N/A
307	Prenatal Care: Anti-D Immune Globulin	N/A	N/A	N/A	N/A	N/A	N/A
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies	N/A	N/A	N/A	19,184	1.0	0.0
309	Cervical Cancer Screening	N/A	N/A	N/A	17,128	1.0	0.0
310	Chlamydia Screening for Women	N/A	N/A	N/A	688	1.0	0.0
311	Use of Appropriate Medications for Asthma	N/A	N/A	N/A	2,972	1.0	0.0
312	Low Back Pain: Use of Imaging Studies	N/A	N/A	N/A	3,106	1.0	0.0
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%)	N/A	N/A	N/A	14,688	1.0	0.0
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL	N/A	N/A	N/A	17,369	1.0	0.0
317	Preventive Care and Screening: Screening for High Blood Pressure	N/A	N/A	N/A	20,265	1.0	0.0
Total	--	35,347	37,588	54,589	93,953	2.8	1.8



<sup>a</sup> This section describes continuous participation. Therefore, if an eligible professional participated in multiple years, but not continuously (e.g., 2009 and 2011, but not 2010) they were not included in this section.

<sup>b</sup> This section describes all EPs who participated in the measure in program year 2012.

Notes for Table A28: (1) Eligible professional-level results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model.

**Table A29. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Four Years for the Physician Quality Reporting System (2009 to 2012)**

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	9,272	11.3%	18.3%	18.6%	16.6%	-2.0%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	8,763	67.7%	59.2%	60.2%	59.4%	-4.3%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	8,092	59.5%	59.4%	73.2%	73.3%	7.2%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	383	95.7%	93.6%	94.5%	90.8%	-1.7%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	2,756	85.3%	86.6%	90.2%	83.1%	-0.8%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	145	60.2%	71.6%	81.8%	84.7%	12.0%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	111	90.8%	89.7%	93.0%	95.0%	1.5%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	221	93.5%	97.5%	96.4%	94.8%	0.5%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	5,453	65.7%	68.4%	68.2%	67.2%	0.7%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	6,423	96.7%	96.6%	96.7%	96.7%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	6,618	97.7%	97.0%	97.0%	96.8%	-0.3%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	4,442	98.4%	98.1%	98.1%	97.9%	-0.2%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	2,100	93.2%	93.3%	93.1%	93.1%	0.0%
20	Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician	2,160	95.4%	96.7%	95.7%	96.4%	0.3%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	2,666	93.8%	94.5%	94.2%	94.4%	0.2%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	1,968	95.6%	95.3%	94.8%	95.5%	-0.1%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	2,289	95.7%	96.2%	96.4%	96.6%	0.3%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	276	62.6%	59.3%	58.5%	57.7%	-2.7%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	5,323	80.7%	82.9%	84.5%	85.4%	1.9%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	18,904	91.7%	92.4%	93.5%	94.1%	0.9%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	480	91.9%	85.7%	85.7%	87.9%	-1.5%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	592	90.4%	89.1%	90.2%	86.9%	-1.3%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	1	100.0%	0.0%	100.0%	100.0%	0.0%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	220	90.2%	90.9%	92.9%	90.8%	0.2%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	489	74.0%	72.1%	75.1%	79.2%	2.3%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	2,252	60.9%	66.2%	65.6%	62.0%	0.6%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	168	55.3%	53.5%	53.4%	50.3%	-3.1%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	695	84.3%	84.4%	84.2%	82.3%	-0.8%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	576	98.1%	98.4%	98.4%	99.3%	0.4%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	457	91.1%	94.2%	95.8%	96.2%	1.8%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	323	99.2%	99.4%	99.5%	99.1%	0.0%
47	Advance Care Plan	1,210	69.9%	66.6%	68.2%	68.4%	-0.7%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	1,356	81.3%	83.4%	84.1%	85.0%	1.5%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	590	93.9%	97.0%	96.3%	96.8%	1.0%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	525	97.1%	97.8%	98.0%	97.9%	0.3%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	583	86.9%	86.8%	88.4%	89.6%	1.0%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	375	98.6%	98.6%	98.7%	98.2%	-0.1%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	38	95.1%	95.8%	100.0%	92.9%	-0.8%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	15,727	95.4%	95.9%	96.0%	95.9%	0.2%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	10,394	96.4%	96.7%	96.9%	97.0%	0.2%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	13,312	95.8%	96.5%	96.9%	97.3%	0.5%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	14,471	94.7%	95.6%	96.2%	96.9%	0.8%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	13,110	96.9%	97.6%	97.8%	98.0%	0.4%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	9,045	94.9%	95.0%	95.2%	95.7%	0.3%
64	Asthma: Assessment of Asthma Control	23	82.6%	86.4%	83.7%	67.2%	-6.6%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	545	94.3%	96.4%	97.7%	98.0%	1.3%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	401	99.0%	99.4%	99.1%	99.2%	0.1%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	673	90.7%	92.1%	92.6%	91.7%	0.4%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	701	95.5%	95.4%	96.9%	97.6%	0.7%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	577	98.2%	98.4%	98.5%	98.1%	0.0%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	448	98.5%	99.0%	99.2%	98.8%	0.1%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	4,751	79.9%	82.7%	86.1%	87.2%	3.0%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	59	98.6%	98.6%	98.3%	96.8%	-0.6%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	62	96.7%	99.8%	99.6%	98.0%	0.4%
86	Hepatitis C: Antiviral Treatment Prescribed	35	65.3%	72.3%	73.0%	72.5%	3.5%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	29	98.6%	82.1%	81.5%	85.7%	-4.6%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	66	82.7%	84.9%	89.4%	92.0%	3.6%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	8	60.0%	66.7%	75.0%	50.0%	-5.9%
91	Acute Otitis Externa (AOE): Topical Therapy	83	85.5%	88.4%	94.8%	94.6%	3.4%
92	Acute Otitis Externa (AOE): Pain Assessment	64	91.6%	90.6%	95.8%	91.8%	0.1%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	65	92.1%	88.3%	90.2%	89.2%	-1.1%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,582	97.0%	97.7%	97.2%	97.6%	0.2%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,027	97.5%	98.4%	98.3%	98.1%	0.2%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	134	70.2%	77.5%	93.9%	92.0%	9.5%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	164	81.4%	78.9%	93.3%	89.5%	3.2%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	165	85.8%	96.6%	99.2%	98.1%	4.5%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	127	90.1%	87.5%	90.1%	89.9%	-0.1%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	162	92.2%	95.3%	96.4%	95.9%	1.3%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	241	93.1%	94.7%	94.2%	92.9%	-0.1%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
109	Osteoarthritis (OA): Function and Pain Assessment	303	88.5%	88.3%	89.8%	89.0%	0.2%
110	Preventive Care and Screening: Influenza Immunization	2,770	50.0%	51.7%	53.0%	56.3%	4.0%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	3,522	54.2%	56.9%	66.3%	65.1%	6.3%
112	Preventive Care and Screening: Screening Mammography	2,467	53.9%	53.9%	59.2%	67.0%	7.5%
113	Preventive Care and Screening: Colorectal Cancer Screening	2,679	56.6%	57.9%	61.4%	71.0%	7.9%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	6	10.0%	40.0%	56.7%	50.0%	71.0%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	5,736	93.9%	94.5%	94.4%	94.5%	0.2%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	29	100.0%	50.0%	50.2%	45.9%	-22.9%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	2,422	74.0%	77.8%	78.3%	70.6%	-1.5%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	138	84.6%	83.0%	80.6%	65.6%	-8.1%
122	Adult Kidney Disease: Blood Pressure Management	143	91.6%	90.5%	90.8%	89.5%	-0.8%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	107	98.5%	96.5%	94.8%	22.7%	-7.7%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	12,860	99.4%	99.7%	99.8%	99.9%	0.2%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	586	90.7%	90.4%	92.7%	93.9%	1.2%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	445	84.5%	84.3%	88.7%	89.4%	1.9%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	1,956	59.5%	63.4%	65.0%	70.9%	6.0%
130	Documentation of Current Medications in the Medical Record	4,989	79.5%	80.0%	90.1%	89.7%	4.1%
131	Pain Assessment and Follow-Up	2,245	98.5%	98.5%	97.9%	93.5%	-1.7%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	95	93.6%	93.7%	95.2%	88.9%	-1.7%
137	Melanoma: Continuity of Care - Recall System	506	98.1%	95.3%	98.7%	99.1%	0.3%
138	Melanoma: Coordination of Care	265	98.3%	91.8%	97.3%	94.1%	-1.5%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	3,446	94.1%	94.1%	93.7%	93.9%	-0.1%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	1,584	94.1%	94.9%	95.6%	96.4%	0.8%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	198	84.6%	88.3%	89.0%	89.4%	1.9%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	9	56.1%	62.8%	56.0%	63.9%	4.5%
144	Oncology: Medical and Radiation - Plan of Care for Pain	4	98.8%	98.6%	100.0%	68.5%	-11.5%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	4,825	44.4%	53.1%	57.2%	62.8%	12.2%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	3,410	1.8%	0.5%	0.6%	0.5%	0.4%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	2,714	57.9%	58.2%	59.0%	61.5%	2.0%
154	Falls: Risk Assessment	2,893	91.8%	91.7%	92.7%	91.8%	0.0%
155	Falls: Plan of Care	1,312	85.2%	85.1%	86.1%	87.1%	0.7%
156	Oncology: Radiation Dose Limits to Normal Tissues	128	97.0%	97.4%	96.2%	97.4%	0.1%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	12	83.3%	91.3%	98.6%	100.0%	6.3%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	125	93.6%	95.2%	96.4%	95.6%	0.7%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	28	88.7%	92.0%	92.8%	95.7%	2.6%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	22	98.9%	96.0%	78.8%	87.9%	-3.9%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	17	100.0%	100.0%	99.5%	99.6%	-0.1%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	24	99.9%	96.3%	86.8%	95.7%	-1.4%
163	Diabetes Mellitus: Foot Exam	979	82.2%	84.4%	86.8%	80.2%	-0.8%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	1	7.7%	1.9%	0.0%	0.0%	2.7%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	1	7.7%	5.9%	0.0%	0.0%	2.7%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	1	100.0%	100.0%	100.0%	100.0%	0.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	68	97.7%	97.8%	97.7%	98.4%	0.2%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	223	69.9%	75.1%	74.9%	89.1%	8.4%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	62	90.7%	93.2%	96.8%	97.4%	2.4%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	53	79.9%	85.7%	85.2%	90.0%	4.0%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	70	77.2%	80.9%	79.5%	85.8%	3.6%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	41	81.6%	80.7%	84.2%	88.6%	2.8%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	45	99.0%	99.0%	99.8%	99.8%	0.3%
181	Elder Maltreatment Screen and Follow-Up Plan	3	66.7%	88.9%	92.5%	98.7%	14.0%
182	Functional Outcome Assessment	72	83.7%	80.8%	82.1%	81.8%	-0.8%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	60	89.8%	83.5%	85.7%	83.5%	-2.4%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	66	89.4%	89.1%	88.0%	87.1%	-0.9%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	315	97.8%	97.4%	98.0%	98.5%	0.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Four Years Continuously	Average Performance Rate per EP in 2009	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	8	85.2%	89.6%	96.4%	93.9%	3.3%

<sup>a</sup> Measure was not reportable via claims (e.g. registry only) during the 2012 program year.

<sup>b</sup> Measure was not reportable via claims (e.g. registry only) during the 2011 program year.

<sup>c</sup> Measure was not reportable via claims (e.g., registry only) during the 2010 program year.

<sup>d</sup> Measure was not reportable via claims (e.g., registry only) during the 2009 program year.

<sup>e</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A29: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) Results included the claims, registry and EHR methods. (3) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry. (4) The "Growth Rate" is the compound annual growth rate (i.e., CAGR).

**Table A30. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Three Years for the Physician Quality Reporting System (2010 to 2012)**

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	12,724	20.4%	20.1%	17.8%	1.6%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	11,901	57.6%	59.1%	58.7%	0.9%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	11,137	58.2%	72.6%	72.8%	11.8%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	775	91.7%	92.9%	87.9%	-2.1%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	4,170	85.4%	88.4%	80.5%	-2.9%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	551	78.0%	83.0%	80.7%	1.7%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	270	91.2%	92.4%	94.2%	1.7%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	388	94.5%	95.0%	93.9%	-0.3%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	7,298	67.7%	66.9%	66.1%	-1.2%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	7,910	96.2%	96.3%	96.3%	0.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	8,232	96.7%	96.8%	96.6%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	5,406	97.7%	97.7%	97.4%	-0.2%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	2,647	92.5%	92.5%	92.5%	0.0%
20	Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician	2,716	96.4%	95.7%	96.2%	-0.1%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	3,353	94.4%	94.4%	94.5%	0.0%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	2,548	95.7%	95.4%	96.0%	0.2%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	2,993	95.6%	96.0%	96.1%	0.3%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	343	59.6%	58.4%	58.3%	-1.1%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	7,252	83.5%	84.9%	85.5%	1.2%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	24,571	92.2%	93.2%	94.0%	1.0%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	1,185	83.4%	85.4%	87.1%	2.2%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	1,227	87.2%	89.4%	87.0%	-0.1%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	145	76.3%	85.1%	93.9%	10.9%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	521	91.8%	90.4%	88.9%	-1.6%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	1,032	71.5%	76.1%	80.1%	5.8%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	3,690	64.3%	64.7%	61.8%	-1.9%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	240	54.6%	56.5%	50.6%	-3.7%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	1,084	82.8%	83.9%	81.6%	-0.7%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	734	98.6%	98.6%	99.4%	0.4%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	577	94.4%	95.9%	96.3%	1.0%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	422	99.3%	99.5%	99.1%	-0.1%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	59	92.4%	89.2%	95.3%	1.6%
47	Advance Care Plan	3,035	59.6%	61.6%	59.7%	0.1%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	2,354	83.0%	83.7%	84.1%	0.7%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	890	95.4%	95.0%	95.9%	0.2%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	833	96.7%	97.2%	97.5%	0.4%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	919	81.3%	82.3%	82.6%	0.8%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	583	98.7%	98.5%	98.5%	-0.1%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	70	91.3%	94.1%	86.1%	-2.9%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	20,026	95.8%	96.0%	95.8%	0.0%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	13,085	96.7%	97.0%	97.0%	0.1%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	17,309	96.5%	96.9%	97.2%	0.3%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	18,945	95.3%	96.0%	96.7%	0.8%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	17,201	97.6%	98.0%	98.2%	0.3%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	11,969	94.4%	94.6%	95.3%	0.5%
64	Asthma: Assessment of Asthma Control	45	64.2%	64.7%	54.4%	-7.9%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	713	94.1%	94.6%	95.6%	0.8%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	511	97.3%	98.4%	96.8%	-0.3%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	837	90.6%	91.1%	91.2%	0.3%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	864	94.7%	95.6%	96.6%	1.0%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	798	93.3%	93.9%	93.5%	0.1%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	653	95.4%	95.5%	95.5%	0.0%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	8,449	79.0%	82.6%	84.7%	3.5%
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	4	100.0%	50.0%	87.5%	-6.5%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	131	88.5%	90.2%	92.8%	2.4%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	121	88.2%	93.6%	96.7%	4.7%
86	Hepatitis C: Antiviral Treatment Prescribed	88	67.7%	68.1%	66.4%	-1.0%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	88	80.0%	88.9%	90.2%	6.2%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	190	73.1%	77.6%	75.4%	1.5%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	25	57.1%	73.3%	60.0%	2.5%
91	Acute Otitis Externa (AOE): Topical Therapy	168	86.3%	91.2%	92.7%	3.7%
92	Acute Otitis Externa (AOE): Pain Assessment	138	86.5%	88.9%	87.9%	0.8%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	136	88.9%	90.4%	89.5%	0.3%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,988	97.7%	97.2%	97.5%	-0.1%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,369	98.3%	98.2%	98.1%	-0.1%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	202	81.9%	95.1%	92.9%	6.6%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	235	81.9%	92.4%	91.2%	5.5%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	268	97.4%	99.4%	98.7%	0.7%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	249	89.1%	92.4%	92.4%	1.9%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	311	93.5%	95.4%	95.4%	1.0%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	396	93.8%	93.4%	92.9%	-0.5%
109	Osteoarthritis (OA): Function and Pain Assessment	473	85.2%	87.8%	86.2%	0.6%
110	Preventive Care and Screening: Influenza Immunization	5,245	54.6%	55.7%	56.8%	2.1%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	6,611	57.3%	64.3%	65.0%	6.5%
112	Preventive Care and Screening: Screening Mammography	4,337	54.5%	58.7%	66.4%	10.4%
113	Preventive Care and Screening: Colorectal Cancer Screening	4,760	58.8%	62.1%	68.5%	7.9%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	29	37.6%	31.3%	39.2%	2.2%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	8,085	92.6%	92.3%	92.5%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	52	61.5%	69.8%	55.4%	-5.1%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	3,561	76.4%	78.8%	74.6%	-1.2%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	203	83.8%	82.1%	68.0%	-9.9%
122	Adult Kidney Disease: Blood Pressure Management	185	90.2%	90.7%	89.5%	-0.4%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	160	94.8%	93.7%	23.0%	-9.9%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	22,702	99.7%	99.8%	99.9%	0.1%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	1,377	89.1%	91.2%	91.5%	1.3%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	899	88.0%	91.1%	91.0%	1.7%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	3,832	61.2%	66.7%	71.2%	7.9%
130	Documentation of Current Medications in the Medical Record	10,609	81.9%	89.9%	89.7%	4.6%
131	Pain Assessment and Follow-Up	3,257	98.0%	96.6%	92.8%	-2.7%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	245	90.3%	89.5%	87.6%	-1.5%
137	Melanoma: Continuity of Care - Recall System	793	92.9%	97.2%	98.3%	2.9%
138	Melanoma: Coordination of Care	692	91.6%	96.3%	93.8%	1.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	5,122	93.5%	93.4%	93.7%	0.1%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	2,532	95.2%	95.9%	96.6%	0.7%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	466	79.2%	80.2%	80.1%	0.6%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	12	66.8%	59.0%	68.8%	1.5%
144	Oncology: Medical and Radiation - Plan of Care for Pain	6	97.6%	100.0%	68.5%	-16.2%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	7,690	49.4%	54.6%	59.9%	10.2%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	5,280	0.5%	0.9%	0.6%	0.0%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	4,471	55.8%	56.6%	58.6%	2.5%
154	Falls: Risk Assessment	4,122	92.2%	92.2%	91.4%	-0.4%
155	Falls: Plan of Care	2,054	87.6%	88.0%	88.5%	0.5%
156	Oncology: Radiation Dose Limits to Normal Tissues	199	98.3%	97.5%	97.5%	-0.4%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	14	90.1%	98.8%	100.0%	5.3%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	238	96.3%	97.2%	96.6%	0.2%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	44	94.3%	94.2%	96.4%	1.1%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	30	90.4%	75.1%	81.9%	-4.8%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	30	99.8%	99.5%	99.8%	0.0%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	37	97.0%	89.9%	95.2%	-0.9%
163	Diabetes Mellitus: Foot Exam	2,026	83.0%	84.6%	81.3%	-1.0%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	1	1.9%	0.0%	0.0%	1.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	1	5.9%	0.0%	0.0%	3.1%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	1	100.0%	100.0%	100.0%	0.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	119	96.1%	97.0%	97.2%	0.6%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	1,527	70.7%	85.0%	84.0%	9.0%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	158	89.6%	94.7%	91.9%	1.3%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	155	89.0%	87.9%	89.1%	0.1%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	172	85.8%	86.3%	86.6%	0.5%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	114	88.0%	88.8%	89.7%	1.0%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	125	99.4%	99.3%	99.8%	0.2%
181	Elder Maltreatment Screen and Follow-Up Plan	4	91.7%	81.9%	90.7%	-0.5%
182	Functional Outcome Assessment	176	75.0%	75.1%	77.0%	1.3%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	126	69.2%	67.4%	68.5%	-0.5%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	118	80.3%	76.8%	79.1%	-0.7%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	490	96.5%	97.3%	97.9%	0.7%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	33	88.8%	91.2%	89.6%	0.4%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	1	100.0%	100.0%	100.0%	0.0%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	2	100.0%	100.0%	87.5%	-6.5%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	16	92.0%	98.1%	93.2%	0.7%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	41	94.3%	95.2%	95.3%	0.6%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	26	9.6%	8.7%	1.5%	4.4%
193	Perioperative Temperature Management	10,595	86.3%	88.7%	91.5%	3.0%
194	Oncology: Cancer Stage Documented	629	92.4%	92.9%	92.9%	0.3%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	7,828	60.6%	61.3%	66.2%	4.5%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment	18	36.6%	75.7%	77.0%	45.1%
197	Coronary Artery Disease (CAD): Lipid Control	598	76.7%	81.5%	72.1%	-3.0%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	31	79.6%	86.1%	86.5%	4.3%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	141	72.6%	64.6%	64.6%	-5.7%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	1,398	76.5%	73.8%	73.1%	-2.3%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Three Years Continuously	Average Performance Rate per EP in 2010	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	1,535	72.7%	84.8%	66.3%	-4.5%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	9	59.9%	71.8%	79.6%	15.3%
206	HIV/AIDS: Screening for High Risk Sexual Behaviors	4	50.0%	99.5%	97.7%	39.8%
207	HIV/AIDS: Screening for Injection Drug Use	4	96.9%	99.5%	100.0%	1.6%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	9	61.0%	60.5%	69.3%	6.6%
209	Functional Communication Measure - Spoken Language Comprehension	1	33.3%	62.5%	100.0%	73.2%
210	Functional Communication Measure - Attention	2	100.0%	57.5%	83.3%	-8.7%
211	Functional Communication Measure - Memory	2	87.5%	45.2%	58.3%	-18.4%
214	Functional Communication Measure - Spoken Language Expression	2	16.7%	78.6%	58.3%	87.1%
216	Functional Communication Measure - Swallowing	2	100.0%	66.7%	66.7%	-18.4%

<sup>a</sup> Measure was not reportable via claims (e.g. registry only) during the 2012 program year.

<sup>b</sup> Measure was not reportable via claims (e.g. registry only) during the 2011 program year.

<sup>c</sup> Measure was not reportable via claims (e.g., registry only) during the 2010 program year.

<sup>d</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A30: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry. (3) The "Growth Rate" is the compound annual growth rate (i.e., CAGR).

**Table A31. Individual Measure Performance Information Among Eligible Professionals who Participated Continuously in the Measure for Two Years for the Physician Quality Reporting System (2011 to 2012)**

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus	19,251	23.5%	20.0%	4.6%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	17,598	56.6%	56.3%	-0.4%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	17,888	72.1%	72.3%	0.3%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	1,392	92.8%	88.6%	-4.5%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	6,820	87.3%	79.9%	-8.5%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)	1,494	81.0%	73.8%	-8.9%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	480	92.6%	92.9%	0.3%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	753	90.1%	87.8%	-2.6%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	9,578	66.1%	65.7%	-0.6%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	10,164	95.9%	96.2%	0.2%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	10,516	96.3%	96.2%	0.0%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	6,984	97.1%	97.3%	0.2%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	3,647	92.4%	92.6%	0.2%
20	Perioperative Care: Timing of Antibiotic Prophylaxis - Ordering Physician	3,524	95.1%	95.7%	0.7%
21	Perioperative Care: Selection of Prophylactic Antibiotic - First OR Second Generation Cephalosporin	4,170	93.7%	93.9%	0.2%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	3,236	95.2%	95.8%	0.6%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	3,771	95.4%	95.5%	0.1%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	468	61.1%	60.8%	-0.6%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	10,877	85.4%	86.0%	0.7%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	32,106	93.3%	94.1%	0.8%
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	2,190	83.7%	84.9%	1.5%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	2,135	86.9%	85.9%	-1.2%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge	295	83.2%	92.5%	11.2%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	1,036	88.0%	84.6%	-3.9%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	1,811	72.6%	78.7%	8.4%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	6,719	59.2%	57.2%	-3.5%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	642	72.1%	64.5%	-10.5%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	1,695	83.8%	80.9%	-3.5%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	942	98.7%	99.4%	0.7%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	760	95.9%	96.4%	0.6%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	568	99.0%	98.9%	-0.1%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	306	97.2%	98.9%	1.7%
47	Advance Care Plan	7,163	58.5%	59.9%	2.3%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	4,254	81.4%	82.7%	1.6%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	1,382	90.6%	91.3%	0.8%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	1,281	96.7%	97.4%	0.7%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	1,593	78.4%	78.7%	0.4%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	914	98.8%	98.9%	0.1%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	274	91.0%	91.6%	0.6%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	28,169	95.7%	95.6%	-0.1%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	17,697	96.9%	96.9%	0.1%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	23,706	96.9%	97.1%	0.2%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	26,406	95.8%	96.6%	0.8%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	24,218	98.0%	98.2%	0.2%
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	16,844	94.6%	95.2%	0.6%
64	Asthma: Assessment of Asthma Control	140	55.6%	53.4%	-3.9%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	8	97.9%	84.1%	-14.2%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	907	94.8%	95.3%	0.6%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	647	98.2%	96.4%	-1.8%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	1,084	91.0%	91.1%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	1,144	95.5%	96.3%	0.9%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	1,057	93.6%	93.2%	-0.4%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	868	95.1%	94.9%	-0.3%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	11,625	81.7%	84.1%	2.9%
83	Hepatitis C: Testing for Chronic Hepatitis C - Confirmation of Hepatitis C Viremia	18	92.3%	90.6%	-1.9%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	205	89.5%	93.2%	4.2%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	180	94.1%	97.1%	3.2%
86	Hepatitis C: Antiviral Treatment Prescribed	159	66.4%	63.2%	-4.8%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	123	84.9%	91.0%	7.2%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	320	76.1%	74.6%	-2.0%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	50	82.6%	75.0%	-9.2%
91	Acute Otitis Externa (AOE): Topical Therapy	490	87.4%	87.6%	0.2%
92	Acute Otitis Externa (AOE): Pain Assessment	472	85.6%	84.2%	-1.6%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy - Avoidance of Inappropriate Use	401	78.9%	72.4%	-8.2%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	3,439	96.9%	97.5%	0.6%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	2,755	97.9%	97.8%	-0.1%
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	313	95.5%	93.0%	-2.6%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	337	93.8%	91.5%	-2.5%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	430	98.8%	99.1%	0.3%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	396	91.3%	91.7%	0.4%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	482	94.4%	94.7%	0.3%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	657	84.7%	84.8%	0.1%
109	Osteoarthritis (OA): Function and Pain Assessment	804	86.2%	84.4%	-2.1%
110	Preventive Care and Screening: Influenza Immunization	13,767	51.1%	51.9%	1.6%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	14,836	58.8%	61.9%	5.2%
112	Preventive Care and Screening: Screening Mammography	9,034	58.3%	65.3%	12.1%
113	Preventive Care and Screening: Colorectal Cancer Screening	10,585	55.6%	59.5%	7.0%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	90	24.5%	40.9%	66.6%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	12,036	87.9%	91.2%	3.7%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	129	67.0%	63.2%	-5.6%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	6,319	79.8%	76.4%	-4.3%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	341	84.1%	70.6%	-16.0%
122	Adult Kidney Disease: Blood Pressure Management	304	90.4%	88.4%	-2.2%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL	249	95.2%	19.5%	-15.5%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	40,618	99.5%	99.7%	0.2%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy - Neurological Evaluation	2,601	91.6%	92.1%	0.6%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention - Evaluation of Footwear	1,730	90.9%	91.0%	0.2%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	11,040	62.3%	65.6%	5.2%
130	Documentation of Current Medications in the Medical Record	26,757	88.0%	87.8%	-0.2%
131	Pain Assessment and Follow-Up	5,517	95.7%	92.0%	-3.9%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	432	84.8%	82.1%	-3.2%
137	Melanoma: Continuity of Care - Recall System	1,178	97.2%	98.1%	1.0%
138	Melanoma: Coordination of Care	1,137	95.9%	94.4%	-1.6%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	7,430	92.9%	93.3%	0.4%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	4,059	95.7%	95.8%	0.1%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	1,015	84.2%	84.4%	0.2%
143	Oncology: Medical and Radiation - Pain Intensity Quantified	28	79.0%	85.1%	7.6%
144	Oncology: Medical and Radiation - Plan of Care for Pain	21	98.1%	89.8%	-8.4%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	10,665	54.2%	60.0%	10.8%
146	Radiology: Inappropriate Use of "Probably Benign" Assessment Category in Mammography Screening	7,374	1.1%	0.7%	0.4%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	6,371	56.4%	59.3%	5.2%
154	Falls: Risk Assessment	6,928	91.0%	90.3%	-0.8%
155	Falls: Plan of Care	3,802	90.3%	91.1%	0.9%
156	Oncology: Radiation Dose Limits to Normal Tissues	330	98.1%	97.0%	-1.1%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	26	95.1%	90.9%	-4.4%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	353	94.7%	95.8%	1.2%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage	63	94.7%	96.0%	1.4%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis	32	75.0%	81.4%	8.5%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy	44	98.7%	99.0%	0.3%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy	46	92.0%	96.2%	4.6%
163	Diabetes Mellitus: Foot Exam	4,631	79.4%	81.8%	3.1%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation	2	0.0%	0.0%	0.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration	4	0.0%	3.4%	-3.4%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge	4	100.0%	100.0%	0.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	172	96.6%	96.5%	0.0%
173	Preventive Care and Screening: Unhealthy Alcohol Use - Screening	4,639	85.3%	86.3%	1.1%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	226	91.2%	91.2%	0.0%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	250	91.2%	92.1%	1.0%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	268	88.9%	90.2%	1.5%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	179	90.3%	90.6%	0.3%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	202	99.0%	99.8%	0.8%
181	Elder Maltreatment Screen and Follow-Up Plan	11	93.4%	86.3%	-7.6%
182	Functional Outcome Assessment	455	78.7%	81.4%	3.4%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	222	65.8%	67.6%	2.7%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	201	76.0%	77.9%	2.4%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps - Avoidance of Inappropriate Use	751	96.9%	97.5%	0.6%



Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	110	92.5%	91.9%	-0.6%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy	1	100.0%	100.0%	0.0%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	7	100.0%	87.5%	-12.5%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	47	86.1%	97.4%	13.1%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery	92	95.9%	95.3%	-0.6%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures	56	4.5%	1.4%	3.2%
193	Perioperative Temperature Management	19,127	88.3%	90.9%	2.9%
194	Oncology: Cancer Stage Documented	1,233	93.4%	94.2%	0.8%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	10,498	61.7%	66.7%	8.2%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment	113	63.6%	46.8%	-26.3%
197	Coronary Artery Disease (CAD): Lipid Control	1,470	80.9%	57.6%	-28.7%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment	69	49.6%	55.4%	11.7%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation	574	32.0%	56.8%	77.5%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	3,867	76.8%	74.7%	-2.8%
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	3,931	82.3%	70.8%	-14.1%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea	9	71.8%	79.6%	10.9%
206	HIV/AIDS: Screening for High Risk Sexual Behaviors	8	96.8%	96.4%	-0.4%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
207	HIV/AIDS: Screening for Injection Drug Use	7	96.3%	95.7%	-0.6%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis	9	60.5%	69.3%	14.5%
209	Functional Communication Measure - Spoken Language Comprehension	9	76.0%	89.6%	17.9%
210	Functional Communication Measure - Attention	5	66.3%	68.6%	3.4%
211	Functional Communication Measure - Memory	5	73.1%	67.3%	-7.9%
212	Functional Communication Measure - Motor Speech	4	87.5%	100.0%	14.3%
213	Functional Communication Measure - Reading	2	100.0%	100.0%	0.0%
214	Functional Communication Measure - Spoken Language Expression	8	75.5%	55.0%	-27.1%
216	Functional Communication Measure - Swallowing	6	71.5%	75.0%	4.9%
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments	121	70.1%	83.7%	19.3%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments	118	71.1%	74.0%	4.0%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments	99	61.0%	76.8%	25.9%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments	138	68.9%	73.9%	7.3%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments	130	66.9%	75.3%	12.6%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments	65	71.0%	71.0%	0.0%

Measure Number	Measure Description	Eligible Professionals who Reported the Measure Two Years Continuously	Average Performance Rate per EP in 2011	Average Performance Rate per EP in 2012	Growth Rate
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments	128	61.2%	71.7%	17.1%
224	Melanoma: Overutilization of Imaging Studies in Melanoma	1,242	95.1%	99.2%	4.3%
225	Radiology: Reminder System for Mammograms	4,374	69.3%	74.7%	7.8%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	22,554	83.4%	91.0%	9.1%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing	11	97.6%	97.7%	0.1%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	41	97.2%	95.4%	-1.8%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	20	95.0%	72.0%	-24.2%
235	Hypertension (HTN): Plan of Care	417	96.6%	95.1%	-1.5%
237	Hypertension (HTN): Blood Pressure Measurement	160	0.0%	99.5%	0.0%
238	Drugs to be Avoided in the Elderly	356	4.9%	6.2%	-1.4%
239	Weight Assessment and Counseling for Children and Adolescents	1	0.0%	0.0%	0.0%

<sup>a</sup> Measure was not reportable via claims (e.g. registry only) during the 2012 program year.

<sup>b</sup> Measure was not reportable via claims (e.g. registry only) during the 2011 program year.

<sup>c</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A31: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry.

**Table A32. Percent of Eligible Professionals who Participated by Individual Measures for the Physician Quality Reporting System and had at Least a 90% Performance Rate (2012)**

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
1	Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>e</sup>	51.9%
2	Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	10.5%
3	Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus	19.2%
5	Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	52.6%
6	Coronary Artery Disease (CAD): Antiplatelet Therapy	36.3%
7	Coronary Artery Disease (CAD): Beta-Blocker Therapy - Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%) <sup>a, b, c, d</sup>	22.6%
8	Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	64.4%
9	Major Depressive Disorder (MDD): Antidepressant Medication During Acute Phase for Patients with MDD	37.8%
10	Stroke and Stroke Rehabilitation: Computed Tomography (CT) or Magnetic Resonance Imaging (MRI) Reports	31.2%
12	Primary Open Angle Glaucoma (POAG): Optic Nerve Evaluation	85.1%
14	Age-Related Macular Degeneration (AMD): Dilated Macular Examination	90.1%
18	Diabetic Retinopathy: Documentation of Presence or Absence of Macular Edema and Level of Severity of Retinopathy	70.1%
19	Diabetic Retinopathy: Communication with the Physician Managing On-going Diabetes Care	85.3%
20	Perioperative Care: Timing of Antibiotic Prophylaxis – Ordering Physician	90.9%
21	Perioperative Care: Selection of Prophylactic Antibiotic – First OR Second Generation Cephalosporin	86.1%
22	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Non-Cardiac Procedures)	89.8%
23	Perioperative Care: Venous Thromboembolism (VTE) Prophylaxis (When Indicated in ALL Patients)	90.7%
24	Osteoporosis: Communication with the Physician Managing On-going Care Post-Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	54.4%
28	Aspirin at Arrival for Acute Myocardial Infarction (AMI)	68.6%
30	Perioperative Care: Timely Administration of Prophylactic Parenteral Antibiotics	84.2%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
31	Stroke and Stroke Rehabilitation: Deep Vein Thrombosis (DVT) Prophylaxis for Ischemic Stroke or Intracranial Hemorrhage	69.2%
32	Stroke and Stroke Rehabilitation: Discharged on Antithrombotic Therapy	70.2%
33	Stroke and Stroke Rehabilitation: Anticoagulant Therapy Prescribed for Atrial Fibrillation (AF) at Discharge <sup>a, b, c, d</sup>	76.2%
35	Stroke and Stroke Rehabilitation: Screening for Dysphagia	26.7%
36	Stroke and Stroke Rehabilitation: Rehabilitation Services Ordered	61.0%
39	Screening or Therapy for Osteoporosis for Women Aged 65 Years and Older	11.6%
40	Osteoporosis: Management Following Fracture of Hip, Spine or Distal Radius for Men and Women Aged 50 Years and Older	57.6%
41	Osteoporosis: Pharmacologic Therapy for Men and Women Aged 50 Years and Older	57.0%
43	Coronary Artery Bypass Graft (CABG): Use of Internal Mammary Artery (IMA) in Patients with Isolated CABG Surgery	97.8%
44	Coronary Artery Bypass Graft (CABG): Preoperative Beta-Blocker in Patients with Isolated CABG Surgery	88.4%
45	Perioperative Care: Discontinuation of Prophylactic Antibiotics (Cardiac Procedures)	96.9%
46	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility <sup>d</sup>	92.4%
47	Advance Care Plan	17.8%
48	Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older	24.5%
49	Urinary Incontinence: Characterization of Urinary Incontinence in Women Aged 65 Years and Older	82.1%
50	Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older	92.6%
51	Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation	59.5%
52	Chronic Obstructive Pulmonary Disease (COPD): Bronchodilator Therapy	60.6%
53	Asthma: Pharmacologic Therapy for Persistent Asthma	58.8%
54	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Non-Traumatic Chest Pain	88.5%
55	Emergency Medicine: 12-Lead Electrocardiogram (ECG) Performed for Syncope	91.3%
56	Emergency Medicine: Community-Acquired Pneumonia (CAP): Vital Signs	93.1%
57	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Oxygen Saturation	91.0%
58	Emergency Medicine: Community-Acquired Pneumonia (CAP): Assessment of Mental Status	94.9%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
59	Emergency Medicine: Community-Acquired Pneumonia (CAP): Empiric Antibiotic	86.2%
64	Asthma: Assessment of Asthma Control	3.9%
65	Treatment for Children with Upper Respiratory Infection (URI): Avoidance of Inappropriate Use	36.2%
66	Appropriate Testing for Children with Pharyngitis	0.0%
67	Hematology: Myelodysplastic Syndrome (MDS) and Acute Leukemias: Baseline Cytogenetic Testing Performed on Bone Marrow	88.9%
68	Hematology: Myelodysplastic Syndrome (MDS): Documentation of Iron Stores in Patients Receiving Erythropoietin Therapy	75.1%
69	Hematology: Multiple Myeloma: Treatment with Bisphosphonates	75.4%
70	Hematology: Chronic Lymphocytic Leukemia (CLL): Baseline Flow Cytometry	88.9%
71	Breast Cancer: Hormonal Therapy for Stage IC-IIIC Estrogen Receptor/Progesterone Receptor (ER/PR) Positive Breast Cancer	72.6%
72	Colon Cancer: Chemotherapy for Stage III Colon Cancer Patients	70.1%
76	Prevention of Catheter-Related Bloodstream Infections (CRBSI): Central Venous Catheter (CVC) Insertion Protocol	74.0%
81	Adult Kidney Disease: Hemodialysis Adequacy: Solute <sup>a, b, c, d</sup>	0.0%
82	Adult Kidney Disease: Peritoneal Dialysis Adequacy: Solute <sup>a, b, c, d</sup>	100.0%
83	Hepatitis C: Testing for Chronic Hepatitis C – Confirmation of Hepatitis C Viremia <sup>a, b, c</sup>	83.3%
84	Hepatitis C: Ribonucleic Acid (RNA) Testing Before Initiating Treatment	38.8%
85	Hepatitis C: HCV Genotype Testing Prior to Treatment	45.8%
86	Hepatitis C: Antiviral Treatment Prescribed	54.8%
87	Hepatitis C: HCV Ribonucleic Acid (RNA) Testing at Week 12 of Treatment	30.7%
89	Hepatitis C: Counseling Regarding Risk of Alcohol Consumption	77.0%
90	Hepatitis C: Counseling Regarding Use of Contraception Prior to Antiviral Therapy	30.6%
91	Acute Otitis Externa (AOE): Topical Therapy	78.1%
92	Acute Otitis Externa (AOE): Pain Assessment	82.8%
93	Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use	67.5%
99	Breast Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	90.3%
100	Colorectal Cancer Resection Pathology Reporting: pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade	93.6%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
102	Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low-Risk Prostate Cancer Patients	58.4%
104	Prostate Cancer: Adjuvant Hormonal Therapy for High-Risk Prostate Cancer Patients	63.6%
105	Prostate Cancer: Three-Dimensional (3D) Radiotherapy	94.8%
106	Major Depressive Disorder (MDD): Diagnostic Evaluation	67.2%
107	Major Depressive Disorder (MDD): Suicide Risk Assessment	70.9%
108	Rheumatoid Arthritis (RA): Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy	66.2%
109	Osteoarthritis (OA): Function and Pain Assessment	74.4%
110	Preventive Care and Screening: Influenza Immunization	13.5%
111	Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older	19.1%
112	Preventive Care and Screening: Screening Mammography	17.5%
113	Preventive Care and Screening: Colorectal Cancer Screening	17.0%
116	Antibiotic Treatment for Adults with Acute Bronchitis: Avoidance of Inappropriate Use	28.1%
117	Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient	75.8%
118	Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD) <sup>a, b, c</sup>	29.9%
119	Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients	50.1%
121	Adult Kidney Disease: Laboratory Testing (Lipid Profile)	47.6%
122	Adult Kidney Disease: Blood Pressure Management	78.8%
123	Adult Kidney Disease: Patients On Erythropoiesis-Stimulating Agent (ESA) - Hemoglobin Level > 12.0 g/dL <sup>e</sup>	79.3%
124	Health Information Technology (HIT): Adoption/Use of Electronic Health Records (EHR)	99.7%
126	Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation	79.2%
127	Diabetes Mellitus: Diabetic Foot and Ankle Care, Ulcer Prevention – Evaluation of Footwear	82.1%
128	Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up	23.2%
130	Documentation of Current Medications in the Medical Record	73.6%
131	Pain Assessment and Follow-Up	79.6%
134	Preventive Care and Screening: Screening for Clinical Depression and Follow-Up Plan	57.6%
137	Melanoma: Continuity of Care – Recall System <sup>a, b, c</sup>	93.9%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
138	Melanoma: Coordination of Care <sup>a, b, c</sup>	82.2%
140	Age-Related Macular Degeneration (AMD): Counseling on Antioxidant Supplement	85.4%
141	Primary Open-Angle Glaucoma (POAG): Reduction of Intraocular Pressure (IOP) by 15% OR Documentation of a Plan of Care	93.3%
142	Osteoarthritis (OA): Assessment for Use of Anti-Inflammatory or Analgesic Over-the-Counter (OTC) Medications	57.0%
143	Oncology: Medical and Radiation – Pain Intensity Quantified <sup>a, b, c</sup>	62.9%
144	Oncology: Medical and Radiation – Plan of Care for Pain <sup>a, b, c</sup>	80.0%
145	Radiology: Exposure Time Reported for Procedures Using Fluoroscopy	35.0%
146	Radiology: Inappropriate Use of “Probably Benign” Assessment Category in Mammography Screening <sup>e</sup>	99.1%
147	Nuclear Medicine: Correlation with Existing Imaging Studies for All Patients Undergoing Bone Scintigraphy	30.1%
154	Falls: Risk Assessment	51.6%
155	Falls: Plan of Care	85.4%
156	Oncology: Radiation Dose Limits to Normal Tissues	92.5%
157	Thoracic Surgery: Recording of Clinical Stage Prior to Lung Cancer or Esophageal Cancer Resection	81.3%
158	Carotid Endarterectomy: Use of Patch During Conventional Carotid Endarterectomy	88.5%
159	HIV/AIDS: CD4+ Cell Count or CD4+ Percentage <sup>a, b, c, d</sup>	87.8%
160	HIV/AIDS: Pneumocystis Jiroveci Pneumonia (PCP) Prophylaxis <sup>a, b, c, d</sup>	61.5%
161	HIV/AIDS: Adolescent and Adult Patients with HIV/AIDS Who Are Prescribed Potent Antiretroviral Therapy <sup>a, b, c, d</sup>	98.4%
162	HIV/AIDS: HIV RNA Control After Six Months of Potent Antiretroviral Therapy <sup>a, b, c, d</sup>	76.3%
163	Diabetes Mellitus: Foot Exam	23.2%
164	Coronary Artery Bypass Graft (CABG): Prolonged Intubation <sup>a, b, c, d, e</sup>	57.1%
165	Coronary Artery Bypass Graft (CABG): Deep Sternal Wound Infection Rate <sup>a, b, c, d, e</sup>	50.0%
166	Coronary Artery Bypass Graft (CABG): Stroke <sup>a, b, c, d, e</sup>	75.0%
167	Coronary Artery Bypass Graft (CABG): Postoperative Renal Failure <sup>a, b, c, d, e</sup>	75.0%
168	Coronary Artery Bypass Graft (CABG): Surgical Re-exploration <sup>a, b, c, d, e</sup>	100.0%
169	Coronary Artery Bypass Graft (CABG): Antiplatelet Medications at Discharge <sup>a, b, c, d</sup>	100.0%
170	Coronary Artery Bypass Graft (CABG): Beta-Blockers Administered at Discharge <sup>a, b, c, d</sup>	100.0%



Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
171	Coronary Artery Bypass Graft (CABG): Anti-Lipid Treatment at Discharge <sup>a, b, c, d</sup>	100.0%
172	Hemodialysis Vascular Access Decision-Making by Surgeon to Maximize Placement of Autogenous Arterial Venous (AV) Fistula	86.0%
173	Preventive Care and Screening: Unhealthy Alcohol Use – Screening	22.9%
176	Rheumatoid Arthritis (RA): Tuberculosis Screening	38.6%
177	Rheumatoid Arthritis (RA): Periodic Assessment of Disease Activity	88.4%
178	Rheumatoid Arthritis (RA): Functional Status Assessment	88.4%
179	Rheumatoid Arthritis (RA): Assessment and Classification of Disease Prognosis	84.7%
180	Rheumatoid Arthritis (RA): Glucocorticoid Management	99.8%
181	Elder Maltreatment Screen and Follow-Up Plan	77.6%
182	Functional Outcome Assessment	72.6%
183	Hepatitis C: Hepatitis A Vaccination in Patients with HCV	47.8%
184	Hepatitis C: Hepatitis B Vaccination in Patients with HCV	52.9%
185	Endoscopy & Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use	92.6%
186	Chronic Wound Care: Use of Compression System in Patients with Venous Ulcers	90.3%
187	Stroke and Stroke Rehabilitation: Thrombolytic Therapy <sup>a, b, c</sup>	25.0%
188	Referral for Otologic Evaluation for Patients with Congenital or Traumatic Deformity of the Ear	75.0%
189	Referral for Otologic Evaluation for Patients with History of Active Drainage from the Ear Within the Previous 90 Days	12.5%
190	Referral for Otologic Evaluation for Patients with a History of Sudden or Rapidly Progressive Hearing Loss	26.1%
191	Cataracts: 20/40 or Better Visual Acuity within 90 days Following Cataract Surgery <sup>a, b, c</sup>	80.2%
192	Cataracts: Complications within 30 Days Following Cataract Surgery Requiring Additional Surgical Procedures <sup>a, b, c, e</sup>	95.2%
193	Perioperative Temperature Management	69.6%
194	Oncology: Cancer Stage Documented	86.9%
195	Radiology: Stenosis Measurement in Carotid Imaging Reports	41.6%
196	Coronary Artery Disease (CAD): Symptom and Activity Assessment <sup>a, b, c</sup>	18.8%
197	Coronary Artery Disease (CAD): Lipid Control <sup>a, b, c</sup>	8.5%
198	Heart Failure: Left Ventricular Ejection Fraction (LVEF) Assessment <sup>a, b, c</sup>	24.2%
200	Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation <sup>a, b, c</sup>	19.7%
201	Ischemic Vascular Disease (IVD): Blood Pressure Management Control	19.5%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
204	Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic	25.4%
205	HIV/AIDS: Sexually Transmitted Disease Screening for Chlamydia and Gonorrhea <sup>a, b, c</sup>	36.4%
206	HIV/AIDS: Screening for High Risk Sexual Behaviors <sup>a, b, c</sup>	62.5%
207	HIV/AIDS: Screening for Injection Drug Use <sup>a, b, c</sup>	62.5%
208	HIV/AIDS: Sexually Transmitted Disease Screening for Syphilis <sup>a, b, c</sup>	23.8%
209	Functional Communication Measure - Spoken Language Comprehension <sup>a, b, c</sup>	46.2%
210	Functional Communication Measure - Attention <sup>a, b, c</sup>	60.0%
211	Functional Communication Measure - Memory <sup>a, b, c</sup>	33.3%
212	Functional Communication Measure - Motor Speech <sup>a, b, c</sup>	77.8%
213	Functional Communication Measure - Reading <sup>a, b, c</sup>	100.0%
214	Functional Communication Measure - Spoken Language Expression <sup>a, b, c</sup>	23.1%
215	Functional Communication Measure - Writing <sup>a, b, c</sup>	66.7%
216	Functional Communication Measure - Swallowing <sup>a, b, c</sup>	30.0%
217	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Knee Impairments <sup>a, b</sup>	49.5%
218	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Hip Impairments <sup>a, b</sup>	36.5%
219	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lower Leg, Foot or Ankle Impairments <sup>a, b</sup>	32.2%
220	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Lumbar Spine Impairments <sup>a, b</sup>	28.2%
221	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Shoulder Impairments <sup>a, b</sup>	36.3%
222	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Elbow, Wrist or Hand Impairments <sup>a, b</sup>	37.4%
223	Functional Deficit: Change in Risk-Adjusted Functional Status for Patients with Neck, Cranium, Mandible, Thoracic Spine, Ribs, or Other General Orthopedic Impairments <sup>a, b</sup>	31.4%
224	Melanoma: Overutilization of Imaging Studies in Melanoma <sup>a, b</sup>	97.5%
225	Radiology: Reminder System for Mammograms	65.1%
226	Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention	60.2%
228	Heart Failure (HF): Left Ventricular Function (LVF) Testing <sup>a, b</sup>	82.9%
231	Asthma: Tobacco Use: Screening - Ambulatory Care Setting	87.8%
232	Asthma: Tobacco Use: Intervention - Ambulatory Care Setting	28.3%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
233	Thoracic Surgery: Recording of Performance Status Prior to Lung or Esophageal Cancer Resection <sup>a, b</sup>	100.0%
234	Thoracic Surgery: Pulmonary Function Tests Before Major Anatomic Lung Resection (Pneumonectomy, Lobectomy, or Formal Segmentectomy) <sup>a, b</sup>	100.0%
235	Hypertension (HTN): Plan of Care	37.1%
236	Hypertension (HTN): Controlling High Blood Pressure <sup>a, b</sup>	9.1%
237	Hypertension (HTN): Blood Pressure Measurement <sup>a, b</sup>	84.2%
238	Drugs to be Avoided in the Elderly <sup>a, b, e</sup>	67.9%
239	Weight Assessment and Counseling for Children and Adolescents <sup>a, b</sup>	0.0%
240	Childhood Immunization Status <sup>a, b</sup>	0.0%
241	Ischemic Vascular Disease (IVD): Complete Lipid Panel and Low Density Lipoprotein (LDL-C) Control	8.9%
242	Coronary Artery Disease (CAD): Symptom Management <sup>a</sup>	0.0%
243	Cardiac Rehabilitation Patient Referral from an Outpatient Setting <sup>a</sup>	0.0%
244	Hypertension: Blood Pressure Management <sup>a</sup>	17.3%
245	Chronic Wound Care: Use of Wound Surface Culture Technique in Patients with Chronic Skin Ulcers	83.2%
246	Chronic Wound Care: Use of Wet to Dry Dressings in Patients with Chronic Skin Ulcers	70.0%
247	Substance Use Disorders: Counseling Regarding Psychosocial and Pharmacologic Treatment Options for Alcohol Dependence	95.9%
248	Substance Use Disorders: Screening for Depression Among Patients with Substance Abuse or Dependence	83.3%
249	Barrett's Esophagus	95.8%
250	Radical Prostatectomy Pathology Reporting	95.1%
251	Immunohistochemical (IHC) Evaluation of Human Epidermal Growth Factor Receptor 2 Testing (HER2) for Breast Cancer Patients	81.9%
252	Anticoagulation for Acute Pulmonary Embolus Patients	78.3%
253	Pregnancy Test for Female Abdominal Pain Patients	43.6%
254	Ultrasound Determination of Pregnancy Location for Pregnant Patients with Abdominal Pain	67.0%
255	Rh Immunoglobulin (Rhogam) for Rh-Negative Pregnant Women at Risk of Fetal Blood Exposure	50.0%
256	Surveillance after Endovascular Abdominal Aortic Aneurysm Repair (EVAR) <sup>a</sup>	0.0%
257	Statin Therapy at Discharge after Lower Extremity Bypass (LEB) <sup>a</sup>	52.4%

Measure Number	Measure Description	Percent of Eligible Professionals Who Had a Performance Rate of At Least 90 Percent
258	Rate of Open Elective Repair of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #7) <sup>a</sup>	46.7%
259	Rate of Elective Endovascular Aortic Repair (EVAR) of Small or Moderate Abdominal Aortic Aneurysms (AAA) without Major Complications (Discharged to Home by Post-Operative Day #2) <sup>a</sup>	52.4%
260	Rate of Carotid Endarterectomy (CEA) for Asymptomatic Patients, without Major Complications (Discharged to Home Post-Operative Day #2) <sup>a</sup>	71.4%
261	Referral for Otologic Evaluation for Patients with Acute or Chronic Dizziness	46.7%
262	Image Confirmation of Successful Excision of Image–Localized Breast Lesion	94.8%
263	Preoperative Diagnosis of Breast Cancer	97.8%
264	Sentinel Lymph Node Biopsy for Invasive Breast Cancer <sup>a</sup>	79.1%
265	Biopsy Follow-Up <sup>a</sup>	84.8%
266	Epilepsy: Seizure Type(s) and Current Seizure Frequency(ies)	90.8%
267	Epilepsy: Documentation of Etiology of Epilepsy or Epilepsy Syndrome	91.9%
268	Epilepsy: Counseling for Women of Childbearing Potential with Epilepsy	78.6%
303	Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery <sup>a</sup>	0.0%
304	Cataracts: Patient Satisfaction within 90 Days Following Cataract Surgery <sup>a</sup>	100.0%
305	Initiation and Engagement of Alcohol and Other Drug Dependence Treatment: (a) Initiation, (b) Engagement <sup>a</sup>	0.0%
306	Prenatal Care: Screening for Human Immunodeficiency Virus (HIV) <sup>a</sup>	0.0%
307	Prenatal Care: Anti-D Immune Globulin <sup>a</sup>	0.0%
308	Smoking and Tobacco Use Cessation, Medical assistance: a. Advising Smokers and Tobacco Users to Quit, b. Discussing Smoking and Tobacco Use Cessation Medications, c. Discussing Smoking and Tobacco Use Cessation Strategies <sup>a</sup>	0.0%
309	Cervical Cancer Screening <sup>a</sup>	2.1%
310	Chlamydia Screening for Women <sup>a</sup>	28.2%
311	Use of Appropriate Medications for Asthma <sup>a</sup>	60.1%
312	Low Back Pain: Use of Imaging Studies <sup>a</sup>	2.0%
313	Diabetes Mellitus: Hemoglobin A1c Testing (<8%) <sup>a</sup>	5.8%
316	Preventive Care and Screening: Cholesterol – Fasting Low Density Lipoprotein (LDL) Test Performed AND Risk-Stratified Fasting LDL <sup>a</sup>	6.3%
317	Preventive Care and Screening: Screening for High Blood Pressure	15.5%

<sup>a</sup> Measure was not reportable via claims (e.g. registry only) during the 2012 program year.

<sup>b</sup> Measure was an inverse measure where a lower performance rate indicates better performance.

Notes for Table A32: (1) Results in this table do not include eligible professionals who were part of a practice that participated under the GPRO or eligible professionals within ACOs reporting under the Medicare Shared Savings Program and Pioneer ACO Model. (2) If an eligible professional participated in multiple methods, we used performance information in accordance with the following hierarchy: EHR, claims, and registry.

**Table A33. Performance Information for Measures Reported by Practices Participating in the Small Group Practice Reporting Option for the Physician Quality Reporting System (2012)**

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) +(D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Care Coordination/Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	8	0	927	1,032	1,959	245	1,959	58.7%
Care-2	Falls: Screening for Future Fall Risk	8	7	965	1,343	2,315	289	2,308	45.6%
<b>Chronic Obstructive Pulmonary Disease (COPD)</b>	--	--	--	--	--	--	--	--	--
COPD-1	Bronchodilator Therapy	8	0	148	14	162	20	162	92.8%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
CAD-1	Antiplatelet Therapy	8	32	1,894	260	2,186	273	2,154	88.4%
CAD-2	Lipid Control	8	22	1,546	618	2,186	273	2,164	73.2%
CAD-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	8	35	772	187	994	124	959	81.7%

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) +(D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	8	0	341	1,873	2,214	277	2,214	15.6%
DM-3	High Blood Pressure Control in Diabetes Mellitus	8	0	1,633	581	2,214	277	2,214	73.8%
DM-5	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	8	0	1,283	931	2,214	277	2,214	58.7%
DM-7	Dilated Eye Exam in Diabetic Patient	8	0	1,178	1,036	2,214	277	2,214	56.0%
DM-8	Foot Exam	8	12	1,768	434	2,214	277	2,202	81.3%
DM-10	Hemoglobin A1c Control (<8%)	8	0	1,648	566	2,214	277	2,214	74.2%
DM-11	Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease	8	42	533	78	653	82	611	88.1%
DM-12	Tobacco Non Use	8	0	1,811	403	2,214	277	2,214	81.0%

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) +(D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Heart Failure (HF)</b>	--	--	--	--	--	--	--	--	--
HF-1	Left Ventricular Ejection Fraction (LVEF) Assessment	8	0	680	626	1,306	163	1,306	65.2%
HF-2	Left Ventricular Function (LVF) Testing	8	0	490	99	589	74	589	86.6%
HF-5	Patient Education	8	0	749	557	1,306	163	1,306	65.3%
HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	8	6	178	26	210	26	204	88.8%
HF-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	8	22	135	53	210	26	188	73.0%
<b>Hypertension (HTN)</b>	--	--	--	--	--	--	--	--	--
HTN-2	Controlling High Blood Pressure	8	10	1,710	630	2,350	294	2,340	72.5%
<b>Ischemic Vascular Disease (IVD)</b>	--	--	--	--	--	--	--	--	--
IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	8	0	1,218	960	2,178	272	2,178	57.2%
IVD-2	Use of Aspirin or Another Antithrombotic	8	0	1,870	308	2,178	272	2,178	87.0%



GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Preventive Care</b>	--	--	--	--	--	--	--	--	--
Prev-5	Screening Mammography	8	11	1,523	784	2,318	290	2,307	66.7%
Prev-6	Colorectal Cancer Screening	8	1	1,473	938	2,412	302	2,411	61.7%
Prev-7	Influenza Immunization	8	64	1,398	940	2,402	300	2,338	60.8%
Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	8	2	1,559	822	2,383	298	2,381	66.2%
Prev-9	Body Mass Index (BMI) Screening and Follow-Up	8	5	1,682	727	2,414	302	2,409	70.6%
Prev-10	Tobacco Use: Screening and Cessation Intervention	8	0	2,281	132	2,413	302	2,413	94.8%
Prev-11	Screening for High Blood Pressure	8	560	1,576	246	2,382	298	1,822	88.7%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

Notes for Table A33: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).

**Table A34. Performance Information for Measures Reported by Practices Participating in the Large Group Practice Reporting Option for the Physician Quality Reporting System (2012)**

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) +(D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Care Coordination/Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	58	0	20,567	4,451	25,018	431	25,018	82.0%
Care-2	Falls: Screening for Future Fall Risk	58	80	11,737	15,073	26,890	464	26,810	44.5%
<b>Chronic Obstructive Pulmonary Disease (COPD)</b>	--	--	--	--	--	--	--	--	--
COPD-1	Bronchodilator Therapy	55	0	3,935	205	4,140	75	4,140	94.5%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
CAD-1	Antiplatelet Therapy	58	730	23,098	2,268	26,096	450	25,366	91.2%
CAD-2	Lipid Control	58	411	20,155	5,530	26,096	450	25,685	78.3%
CAD-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)	58	939	10,777	1,989	13,705	236	12,766	84.0%

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	58	0	4,965	21,116	26,081	450	26,081	19.2%
DM-3	High Blood Pressure Control in Diabetes Mellitus	58	0	18,373	7,708	26,081	450	26,081	70.3%
DM-5	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	58	0	14,612	11,469	26,081	450	26,081	56.1%
DM-7	Dilated Eye Exam in Diabetic Patient	58	0	14,842	11,239	26,081	450	26,081	57.2%
DM-8	Foot Exam	58	75	17,387	8,619	26,081	450	26,006	68.1%
DM-10	Hemoglobin A1c Control (<8%)	58	0	18,580	7,501	26,081	450	26,081	71.2%
DM-11	Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease	58	644	6,882	1,277	8,803	152	8,159	83.2%
DM-12	Tobacco Non Use	58	0	21,162	4,919	26,081	450	26,081	80.2%

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) + (D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Heart Failure (HF)</b>	--	--	--	--	--	--	--	--	--
HF-1	Left Ventricular Ejection Fraction (LVEF) Assessment	58	0	18,910	4,314	23,224	400	23,224	81.2%
HF-2	Left Ventricular Function (LVF) Testing	58	19	7,995	1,442	9,456	163	9,437	84.9%
HF-5	Patient Education	58	0	17,413	5,811	23,224	400	23,224	74.3%
HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	58	565	5,217	613	6,395	110	5,830	88.3%
HF-7	Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)	58	692	4,898	805	6,395	110	5,703	85.4%
<b>Hypertension (HTN)</b>	--	--	--	--	--	--	--	--	--
HTN-2	Controlling High Blood Pressure	58	213	19,116	8,732	28,061	484	27,848	68.6%
<b>Ischemic Vascular Disease (IVD)</b>	--	--	--	--	--	--	--	--	--
IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	58	0	15,217	11,164	26,381	455	26,381	58.1%
IVD-2	Use of Aspirin or Another Antithrombotic	58	0	21,933	4,448	26,381	455	26,381	83.5%

GPRO measures	Measure Description	(A) GPRO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per GPRO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Preventive Care</b>	--	--	--	--	--	--	--	--	--
Prev-5	Screening Mammography	58	187	18,713	9,119	28,019	483	27,832	67.2%
Prev-6	Colorectal Cancer Screening	58	170	17,464	10,693	28,327	488	28,157	62.4%
Prev-7	Influenza Immunization	58	1,184	15,247	11,963	28,394	490	27,210	56.7%
Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	58	90	19,077	9,335	28,502	491	28,412	67.2%
Prev-9	Body Mass Index (BMI) Screening and Follow-Up	58	501	16,578	11,243	28,322	488	27,821	59.7%
Prev-10	Tobacco Use: Screening and Cessation Intervention	58	0	24,749	4,061	28,810	497	28,810	86.9%
Prev-11	Screening for High Blood Pressure	58	14,272	12,080	2,753	29,105	502	14,833	80.4%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

Notes for Table A34: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).

**Table A35. Performance Information for Measures Reported by ACOs Reporting Under the Medicare Shared Savings Program and Pioneer ACO Model (2012)**

ACO measures	Measure Description	(A) ACO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) +(D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per ACO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Care Coordination/Patient Safety Module</b>	--	--	--	--	--	--	--	--	--
ACO-Care-1	Medication Reconciliation: Reconciliation After Discharge from an Inpatient Facility	144	0	41,889	16,098	57,987	403	57,987	73.9%
ACO-Care-2	Falls: Screening for Future Fall Risk	144	665	20,770	52,536	73,971	514	73,306	28.5%
<b>Coronary Artery Disease (CAD)</b>	--	--	--	--	--	--	--	--	--
ACO-CAD-2	Lipid Control	144	1,017	40,505	16,021	57,543	400	56,526	70.2%
ACO-CAD-7	Diabetes/LVSD and ACE-I/ARB	144	997	17,786	7,561	26,344	183	25,347	70.2%
<b>Diabetes Mellitus (DM)</b>	--	--	--	--	--	--	--	--	--
ACO-DM-2	Hemoglobin A1c Poor Control in Diabetes Mellitus <sup>a</sup>	144	0	17,177	49,112	66,289	460	66,289	26.1%
ACO-DM-13	High Blood Pressure Control in Diabetes Mellitus	144	0	44,127	22,162	66,289	460	66,289	66.5%
ACO-DM-14	Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus	144	0	35,552	30,737	66,289	460	66,289	53.4%
ACO-DM-15	Hemoglobin A1c Control (< 8%)	144	0	43,125	23,164	66,289	460	66,289	64.9%
ACO-DM-16	Daily Aspirin Use for Patients with Diabetes and Ischemic Vascular Disease	144	745	13,033	5,365	19,143	133	18,398	73.8%
ACO-DM-17	Tobacco Non Use	144	0	47,945	18,344	66,289	460	66,289	72.2%

ACO measures	Measure Description	(A) ACO Count	(B) Perfor- mance Exclusion count	(C) Perfor- mance Met count	(D) Perfor- mance not met count	(E)=(B)+(C) + (D) Total Denom- inator Instances	(F)=(E)/ (A) Average Denom- inator Instances per ACO	(G)=(C)+ (D) Total Numer- ator Instances	Average Perfor- mance Rate
<b>Heart Failure (HF)</b>	--	--	--	--	--	--	--	--	--
ACO-HF-6	Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)	144	471	7,922	1,726	10,119	70	9,648	82.5%
<b>Hypertension (HTN)</b>	--	--	--	--	--	--	--	--	--
ACO-HTN-2	Controlling High Blood Pressure	144	86	38,035	21,618	59,739	415	59,653	63.7%
<b>Ischemic Vascular Disease (IVD)</b>	--	--	--	--	--	--	--	--	--
ACO-IVD-1	Complete Lipid Profile and Low Density Lipoprotein (LDL-C) Control	144	0	31,695	28,011	59,706	415	59,706	52.4%
ACO-IVD-2	Use of Aspirin or Another Antithrombotic	144	0	43,657	16,049	59,706	415	59,706	73.1%
<b>Preventive Care</b>	--	--	--	--	--	--	--	--	--
ACO-Prev-5	Screening Mammography	144	755	45,404	26,857	73,016	507	72,261	62.7%
ACO-Prev-6	Colorectal Cancer Screening	144	924	36,075	35,461	72,460	503	71,536	50.6%
ACO-Prev-7	Influenza Immunization	144	2,705	36,941	36,082	75,728	526	73,023	50.9%
ACO-Prev-8	Pneumonia Vaccination for Patients 65 Years and Older	144	901	36,968	38,179	76,048	528	75,147	49.0%
ACO-Prev-9	Body Mass Index (BMI) Screening and Follow-Up	144	729	39,595	33,393	73,717	512	72,988	54.3%
ACO-Prev-10	Tobacco Use: Screening and Cessation Intervention	144	0	60,016	14,561	74,577	518	74,577	80.7%
ACO-Prev-11	Screening for High Blood Pressure	144	21,957	41,332	12,446	75,735	526	53,778	72.1%
ACO-Prev-12	Depression Screening	144	5,887	15,674	52,880	74,441	517	68,554	22.6%

<sup>a</sup> Measure that was an inverse measure where a lower performance rate indicates better performance (DM-2).

*Notes for Table A35: Denominator instances reflect counts of performance met, performance not met, and performance exclusions. Numerator instances reflect counts of performance met and performance not met. Performance rate is the performance met as a percent of (performance met + performance not met).*



**Table A36. Physician Quality Reporting System Incentive Eligibility and Incentive Payments for Group Reporting, Including ACOs Reporting Under the Medicare Shared Savings Program and Pioneer ACO Model (2012)**

GPRO	Number of TINs Participating	Number of TINs Qualifying For Incentive	Percent of Participating TINs who Qualify for Incentive	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount
Small GPRO	8	8	100.0%	\$16,577	\$30,795	\$36,082	\$62,292	\$288,660
Large GPRO	58	58	100.0%	\$13,122	\$161,435	\$203,041	\$697,987	\$11,776,382
MSSP ACO	112	109	97.3%	\$1,201	\$89,249	\$153,355	\$1,139,954	\$16,715,672
Pioneer ACO	32	32	100.0%	\$10,297	\$310,994	\$501,599	\$1,918,688	\$16,051,155

*Note for Table A36: Incentive amounts do not include MOCP.*

## 2012 ERX INCENTIVE PROGRAM APPENDIX TABLES

**Table A37. Distribution of Incentive Amounts for the eRx Incentive Program, by Specialty (2012)**

Specialty	Eligible Professionals who Received an Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Maximum Incentive Amount	Total Incentive Amount	Percent of National Total
<b>MD/DO</b>	<b>182,217</b>	<b>69.0%</b>	<b>35.3%</b>	<b>\$0.01</b>	<b>\$1,021</b>	<b>\$1,632</b>	<b>\$87,298</b>	<b>\$297,360,423</b>	<b>88.7%</b>
Allergy/Immunology	1,188	63.2%	31.8%	\$0.50	\$551	\$823	\$13,821	\$978,285	0.3%
Anesthesiology	2,484	78.5%	28.6%	\$0.09	\$465	\$906	\$12,463	\$2,251,016	0.7%
Cardiology	13,378	74.9%	54.9%	\$0.08	\$2,530	\$3,135	\$28,107	\$41,945,242	12.5%
Colon/Rectal Surgery	273	48.5%	22.3%	\$2.13	\$1,248	\$1,382	\$4,542	\$377,384	0.1%
Critical Care	527	68.3%	38.7%	\$0.69	\$1,204	\$1,648	\$9,694	\$868,754	0.3%
Dermatology	4,795	65.5%	42.0%	\$0.50	\$2,025	\$2,931	\$87,298	\$14,052,599	4.2%
Emergency Medicine	2,545	76.4%	27.3%	\$0.08	\$356	\$539	\$18,019	\$1,371,097	0.4%
Endocrinology	2,883	73.8%	50.1%	\$0.50	\$788	\$1,042	\$9,609	\$3,002,965	0.9%
Family Practice	41,571	76.1%	45.5%	\$0.09	\$585	\$835	\$14,779	\$34,724,209	10.4%
Gastroenterology	5,692	65.1%	43.9%	\$0.11	\$1,497	\$1,729	\$15,805	\$9,842,252	2.9%
General Practice	930	65.4%	17.5%	\$7.64	\$750	\$1,185	\$13,192	\$1,101,713	0.3%
General Surgery	2,450	39.3%	11.2%	\$0.21	\$906	\$1,167	\$13,431	\$2,858,013	0.9%
Geriatrics	1,596	74.2%	38.9%	\$1.69	\$1,130	\$1,601	\$18,694	\$2,555,499	0.8%
Hand Surgery	296	36.4%	16.6%	\$0.08	\$1,518	\$1,725	\$9,105	\$510,465	0.2%
Infectious Disease	1,295	50.2%	24.8%	\$0.49	\$770	\$1,272	\$19,654	\$1,647,737	0.5%
Internal Medicine	36,518	77.0%	44.0%	\$0.01	\$973	\$1,368	\$19,973	\$49,947,456	14.9%
Interventional Radiologist	131	72.4%	12.8%	\$0.11	\$766	\$852	\$2,744	\$111,677	0.0%
Nephrology	3,514	61.9%	42.1%	\$0.72	\$2,561	\$2,689	\$15,839	\$9,447,536	2.8%
Neurology	5,563	69.3%	41.2%	\$0.47	\$1,052	\$1,435	\$18,457	\$7,983,116	2.4%
Neurosurgery	702	43.0%	14.9%	\$0.10	\$1,248	\$1,539	\$12,308	\$1,080,659	0.3%
Nuclear Medicine	118	82.5%	37.8%	\$1.52	\$1,458	\$2,131	\$15,336	\$251,499	0.1%
Obstetrics/Gynecology	4,476	37.2%	13.8%	\$0.10	\$226	\$420	\$7,871	\$1,882,076	0.6%
Oncology/Hematology	5,359	71.8%	43.7%	\$0.48	\$1,822	\$2,401	\$27,348	\$12,866,494	3.8%
Ophthalmology	9,650	72.1%	47.9%	\$0.45	\$3,340	\$4,080	\$38,188	\$39,372,748	11.7%

Specialty	Eligible Professionals who Received an Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Maximum Incentive Amount	Total Incentive Amount	Percent of National Total
Oral/Maxillofacial Surgery	21	47.7%	5.2%	\$1.10	\$225	\$595	\$5,321	\$12,487	0.0%
Orthopaedic Surgery	5,002	47.2%	22.6%	\$0.27	\$2,034	\$2,402	\$24,710	\$12,015,404	3.6%
Other MD/DO	1,425	64.7%	18.1%	\$0.17	\$1,025	\$1,727	\$20,322	\$2,461,063	0.7%
Otolaryngology	3,734	67.6%	40.3%	\$0.12	\$1,218	\$1,455	\$14,062	\$5,433,985	1.6%
Pathology	859	97.4%	67.9%	\$0.12	\$370	\$537	\$9,182	\$461,125	0.1%
Pediatrics	1,366	68.9%	18.8%	\$0.07	\$7	\$138	\$3,377	\$189,105	0.1%
Physical Medicine	1,722	57.0%	22.1%	\$0.47	\$1,281	\$1,706	\$15,096	\$2,938,187	0.9%
Plastic Surgery	332	43.2%	7.2%	\$0.34	\$617	\$1,013	\$14,591	\$336,376	0.1%
Psychiatry	4,144	67.3%	13.9%	\$0.05	\$325	\$592	\$10,397	\$2,451,738	0.7%
Pulmonary Disease	4,391	71.0%	47.1%	\$0.09	\$1,891	\$2,280	\$16,669	\$10,010,696	3.0%
Radiation Oncology	327	38.9%	6.7%	\$0.80	\$999	\$1,438	\$13,255	\$470,201	0.1%
Radiologist	2,140	95.8%	36.8%	\$0.08	\$419	\$644	\$9,835	\$1,378,004	0.4%
Rheumatology	2,708	78.5%	57.8%	\$0.75	\$1,049	\$1,491	\$22,307	\$4,037,443	1.2%
Thoracic/Cardiac Surgery	369	44.8%	10.0%	\$0.11	\$1,131	\$1,568	\$21,248	\$578,723	0.2%
Urology	5,327	77.8%	54.4%	\$0.19	\$2,084	\$2,339	\$24,588	\$12,459,736	3.7%
Vascular Surgery	416	34.5%	13.0%	\$0.80	\$2,164	\$2,634	\$15,039	\$1,095,660	0.3%
<b>Other Eligible Professionals</b>	<b>45,145</b>	<b>56.2%</b>	<b>17.2%</b>	<b>\$0.07</b>	<b>\$311</b>	<b>\$840</b>	<b>\$46,978</b>	<b>\$37,910,843</b>	<b>11.3%</b>
Agencies/ Hospitals/Nursing and Treatment Facilities	220	63.2%	16.7%	\$0.38	\$591	\$971	\$8,080	\$213,687	0.1%
Audiologist	211	96.8%	49.4%	\$0.20	\$33	\$56	\$651	\$11,727	0.0%
Certified Nurse Midwives	181	34.6%	10.4%	\$0.20	\$3	\$22	\$869	\$4,034	0.0%
Chiropractor	27	79.4%	27.0%	\$0.25	\$102	\$444	\$2,436	\$11,981	0.0%
Clinical Nurse Specialists	389	59.8%	17.3%	\$0.62	\$212	\$311	\$3,041	\$121,008	0.0%
Counselor/Psychologist	632	81.0%	1.9%	\$0.19	\$86	\$158	\$2,062	\$99,816	0.0%
Dentist	105	79.5%	3.4%	\$0.36	\$51	\$197	\$4,122	\$20,691	0.0%
Dietitian/Nutritionist	226	85.6%	29.1%	\$0.23	\$20	\$45	\$977	\$10,114	0.0%
Nurse Anesthetist	1,499	99.6%	91.5%	\$0.55	\$125	\$141	\$3,419	\$212,067	0.1%
Nurse Practitioner	15,098	55.8%	25.2%	\$0.07	\$202	\$327	\$5,985	\$4,940,048	1.5%

Specialty	Eligible Professionals who Received an Incentive	Percent of Participating EPs Incentive Eligible	Percent of all EPs Incentive Eligible	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Maximum Incentive Amount	Total Incentive Amount	Percent of National Total
Optometry	2,577	36.5%	7.6%	\$0.41	\$773	\$1,042	\$25,875	\$2,685,605	0.8%
Other Eligible Professional	8,216	61.3%	26.0%	\$0.50	\$1,628	\$2,299	\$46,978	\$18,890,214	5.6%
Physical/Occupational Therapy	571	90.8%	69.8%	\$0.19	\$128	\$276	\$5,510	\$157,466	0.0%
Physician Assistant	10,280	56.8%	26.3%	\$0.08	\$192	\$339	\$9,165	\$3,487,731	1.0%
Podiatrist	4,239	49.2%	23.5%	\$0.56	\$1,408	\$1,632	\$15,143	\$6,919,841	2.1%
Registered Nurse	337	57.5%	16.5%	\$0.32	\$167	\$295	\$4,536	\$99,556	0.0%
Social Worker	337	71.9%	1.0%	\$0.15	\$45	\$75	\$532	\$25,257	0.0%
Unknown/Missing	85	46.4%	10.8%	\$0.77	\$453	\$705	\$3,683	\$59,950	0.0%
<b>Total (Unduplicated)</b>	<b>227,447</b>	<b>66.0%</b>	<b>29.2%</b>	<b>\$0.01</b>	<b>\$857</b>	<b>\$1,474</b>	<b>\$87,298</b>	<b>\$335,331,216</b>	<b>100.0%</b>

*Notes for Table A37: Results include eligible professionals who were part of a practice that participated under the GPRO.*

**Table A38. Potential Incentives and Participation Information for the eRx Incentive Program, by Specialty (2012)**

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
<b>MD/DO</b>	<b>\$1,125</b>	<b>51.2%</b>
Allergy/Immunology	\$554	50.4%
Anesthesiology	\$822	36.5%
Cardiology	\$2,452	73.2%
Colon/Rectal Surgery	\$1,078	46.1%
Critical Care	\$1,345	56.7%
Dermatology	\$2,466	64.1%
Emergency Medicine	\$410	35.7%
Endocrinology	\$785	67.9%
Family Practice	\$614	59.8%
Gastroenterology	\$1,341	67.5%
General Practice	\$552	26.8%
General Surgery	\$916	28.6%
Geriatrics	\$1,148	52.4%
Hand Surgery	\$1,133	45.7%
Infectious Disease	\$1,156	49.4%
Internal Medicine	\$1,048	57.2%
Interventional Radiologist	\$2,405	17.7%
Nephrology	\$2,504	68.1%
Neurology	\$983	59.4%
Neurosurgery	\$1,385	34.5%
Nuclear Medicine	\$1,837	45.8%
Obstetrics/Gynecology	\$190	37.1%
Oncology/Hematology	\$1,471	60.9%
Ophthalmology	\$2,656	66.4%
Oral/Maxillofacial Surgery	\$182	10.9%
Orthopaedic Surgery	\$1,497	47.8%
Other MD/DO	\$1,044	27.9%
Otolaryngology	\$1,044	59.6%
Pathology	\$792	69.7%
Pediatrics	\$75	27.3%
Physical Medicine	\$1,199	38.8%
Plastic Surgery	\$656	16.6%
Psychiatry	\$342	20.6%
Pulmonary Disease	\$1,761	66.3%
Radiation Oncology	\$3,633	17.3%
Radiologist	\$1,493	38.4%
Rheumatology	\$1,133	73.6%
Thoracic/Cardiac Surgery	\$1,590	22.2%
Urology	\$1,719	70.0%
Vascular Surgery	\$2,586	37.6%

Specialty	Average Potential Incentive per Eligible Professional	% of Eligible Professionals who Participated
<b>Other Eligible Professionals</b>	<b>\$414</b>	<b>30.7%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	\$622	26.4%
Audiologist	\$163	51.1%
Certified Nurse Midwives	\$16	30.1%
Chiropractor	\$284	34.0%
Clinical Nurse Specialists	\$219	28.9%
Counselor/Psychologist	\$194	2.4%
Dentist	\$105	4.3%
Dietitian/Nutritionist	\$78	34.0%
Nurse Anesthetist	\$170	91.9%
Nurse Practitioner	\$217	45.2%
Optometry	\$309	20.8%
Other Eligible Professional	\$1,414	42.5%
Physical/Occupational Therapy	\$631	76.9%
Physician Assistant	\$220	46.4%
Podiatrist	\$1,081	47.8%
Registered Nurse	\$214	28.8%
Social Worker	\$89	1.4%
Unknown/Missing	\$423	23.3%
<b>Total (Unduplicated)</b>	<b>\$885</b>	<b>44.3%</b>

*Notes for Table A38: Results include eligible professionals who are part of a practice that participated under the GPRO.*

**Table A39. Eligible Professional Information for the eRx Incentive Program, by Specialty (2011 to 2012)**

Specialty	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals who Participated in 2011	Eligible Professionals who Participated in 2012	Participation Percent in 2011	Participation Percent in 2012
<b>MD/DO</b>	<b>502,024</b>	<b>515,904</b>	<b>219,907</b>	<b>264,114</b>	<b>43.8%</b>	<b>51.2%</b>
Allergy/Immunology	3,590	3,732	1,479	1,881	41.2%	50.4%
Anesthesiology	8,363	8,676	2,651	3,164	31.7%	36.5%
Cardiology	23,850	24,382	15,611	17,856	65.5%	73.2%
Colon/Rectal Surgery	1,172	1,222	470	563	40.1%	46.1%
Critical Care	1,441	1,362	689	772	47.8%	56.7%
Dermatology	11,054	11,428	6,335	7,326	57.3%	64.1%
Emergency Medicine	8,742	9,324	2,377	3,331	27.2%	35.7%
Endocrinology	5,499	5,757	3,226	3,909	58.7%	67.9%
Family Practice	89,424	91,318	44,808	54,596	50.1%	59.8%
Gastroenterology	12,540	12,965	7,345	8,748	58.6%	67.5%
General Practice	5,365	5,305	1,020	1,423	19.0%	26.8%
General Surgery	21,191	21,818	5,132	6,240	24.2%	28.6%
Geriatrics	3,940	4,104	1,726	2,151	43.8%	52.4%
Hand Surgery	1,658	1,780	697	813	42.0%	45.7%
Infectious Disease	4,923	5,226	1,985	2,580	40.3%	49.4%
Internal Medicine	82,137	82,948	40,398	47,454	49.2%	57.2%
Interventional Radiologist	893	1,025	114	181	12.8%	17.7%
Nephrology	7,910	8,339	4,693	5,679	59.3%	68.1%
Neurology	13,049	13,508	6,738	8,028	51.6%	59.4%
Neurosurgery	4,664	4,727	1,312	1,633	28.1%	34.5%
Nuclear Medicine	297	312	129	143	43.4%	45.8%
Obstetrics/Gynecology	31,687	32,375	9,437	12,025	29.8%	37.1%
Oncology/Hematology	11,639	12,256	6,281	7,462	54.0%	60.9%
Ophthalmology	19,738	20,159	12,117	13,393	61.4%	66.4%
Oral/Maxillofacial Surgery	380	403	27	44	7.1%	10.9%
Orthopaedic Surgery	21,507	22,131	9,505	10,587	44.2%	47.8%

Specialty	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals who Participated in 2011	Eligible Professionals who Participated in 2012	Participation Percent in 2011	Participation Percent in 2012
Other MD/DO	7,381	7,894	1,681	2,204	22.8%	27.9%
Otolaryngology	9,033	9,274	4,550	5,527	50.4%	59.6%
Pathology	1,164	1,266	708	882	60.8%	69.7%
Pediatrics	6,766	7,272	1,484	1,984	21.9%	27.3%
Physical Medicine	7,515	7,790	2,453	3,019	32.6%	38.8%
Plastic Surgery	4,498	4,631	659	769	14.7%	16.6%
Psychiatry	29,434	29,821	3,983	6,158	13.5%	20.6%
Pulmonary Disease	9,030	9,327	5,135	6,187	56.9%	66.3%
Radiation Oncology	4,588	4,849	674	841	14.7%	17.3%
Radiologist	5,296	5,808	1,656	2,233	31.3%	38.4%
Rheumatology	4,501	4,684	2,905	3,448	64.5%	73.6%
Thoracic/Cardiac Surgery	3,516	3,705	666	823	18.9%	22.2%
Urology	9,586	9,790	5,999	6,850	62.6%	70.0%
Vascular Surgery	3,063	3,211	1,052	1,207	34.3%	37.6%
<b>Other Eligible Professionals</b>	<b>245,657</b>	<b>262,215</b>	<b>62,368</b>	<b>80,379</b>	<b>25.4%</b>	<b>30.7%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	1,246	1,316	261	348	20.9%	26.4%
Audiologist	380	427	160	218	42.1%	51.1%
Certified Nurse Midwives	1,538	1,738	369	523	24.0%	30.1%
Chiropractor	84	100	26	34	31.0%	34.0%
Clinical Nurse Specialists	2,100	2,255	441	651	21.0%	28.9%
Counselor/Psychologist	32,108	32,724	526	780	1.6%	2.4%
Dentist	3,241	3,101	101	132	3.1%	4.3%
Dietitian/Nutritionist	669	776	198	264	29.6%	34.0%
Nurse Anesthetist	1,335	1,638	1,200	1,505	89.9%	91.9%
Nurse Practitioner	52,078	59,913	19,142	27,057	36.8%	45.2%
Optometry	32,651	33,936	6,071	7,054	18.6%	20.8%
Other Eligible Professional	32,592	31,567	12,305	13,413	37.8%	42.5%



Specialty	Eligible Professionals in 2011	Eligible Professionals in 2012	Eligible Professionals who Participated in 2011	Eligible Professionals who Participated in 2012	Participation Percent in 2011	Participation Percent in 2012
Physical/Occupational Therapy	605	818	373	629	61.7%	76.9%
Physician Assistant	33,964	39,048	13,110	18,107	38.6%	46.4%
Podiatrist	17,877	18,026	7,281	8,609	40.7%	47.8%
Registered Nurse	2,077	2,037	449	586	21.6%	28.8%
Social Worker	31,112	32,795	355	469	1.1%	1.4%
Unknown/Missing	674	785	107	183	15.9%	23.3%
<b>Total (Unduplicated)</b>	<b>748,355</b>	<b>778,904</b>	<b>282,382</b>	<b>344,676</b>	<b>37.7%</b>	<b>44.3%</b>

*Note for Table A39: Results include eligible professionals who were part of a practice that participated under the GPRO.*

**Table A40. Eligible Professionals who Qualified for an Incentive from the eRx Incentive Program, by Specialty (2011 to 2012)**

Specialty	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligible EPs as a Percent of EPs who Participated in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligible EPs as a Percent of EPs who Participated in 2012
<b>MD/DO</b>	<b>142,337</b>	<b>64.7%</b>	<b>182,217</b>	<b>69.0%</b>
Allergy/Immunology	849	57.4%	1,188	63.2%
Anesthesiology	1,996	75.3%	2,484	78.5%
Cardiology	10,912	69.9%	13,378	74.9%
Colon/Rectal Surgery	213	45.3%	273	48.5%
Critical Care	459	66.6%	527	68.3%
Dermatology	3,937	62.1%	4,795	65.5%
Emergency Medicine	1,817	76.4%	2,545	76.4%
Endocrinology	2,264	70.2%	2,883	73.8%
Family Practice	31,811	71.0%	41,571	76.1%
Gastroenterology	4,184	57.0%	5,692	65.1%
General Practice	636	62.4%	930	65.4%
General Surgery	1,798	35.0%	2,450	39.3%
Geriatrics	1,235	71.6%	1,596	74.2%
Hand Surgery	245	35.2%	296	36.4%
Infectious Disease	902	45.4%	1,295	50.2%
Internal Medicine	29,843	73.9%	36,518	77.0%
Interventional Radiologist	80	70.2%	131	72.4%
Nephrology	2,613	55.7%	3,514	61.9%
Neurology	4,293	63.7%	5,563	69.3%
Neurosurgery	505	38.5%	702	43.0%
Nuclear Medicine	101	78.3%	118	82.5%
Obstetrics/Gynecology	3,127	33.1%	4,476	37.2%
Oncology/Hematology	4,305	68.5%	5,359	71.8%
Ophthalmology	8,555	70.6%	9,650	72.1%
Oral/Maxillofacial Surgery	18	66.7%	21	47.7%
Orthopaedic Surgery	3,983	41.9%	5,002	47.2%
Other MD/DO	965	57.4%	1,425	64.7%
Otolaryngology	2,758	60.6%	3,734	67.6%
Pathology	663	93.6%	859	97.4%
Pediatrics	1,002	67.5%	1,366	68.9%
Physical Medicine	1,247	50.8%	1,722	57.0%
Plastic Surgery	274	41.6%	332	43.2%
Psychiatry	2,467	61.9%	4,144	67.3%
Pulmonary Disease	3,336	65.0%	4,391	71.0%
Radiation Oncology	237	35.2%	327	38.9%
Radiologist	1,518	91.7%	2,140	95.8%
Rheumatology	2,239	77.1%	2,708	78.5%
Thoracic/Cardiac Surgery	291	43.7%	369	44.8%

Specialty	Eligible Professionals who Qualified for an Incentive in 2011	Incentive Eligible EPs as a Percent of EPs who Participated in 2011	Eligible Professionals who Qualified for an Incentive in 2012	Incentive Eligible EPs as a Percent of EPs who Participated in 2012
Urology	4,330	72.2%	5,327	77.8%
Vascular Surgery	329	31.3%	416	34.5%
<b>Other Eligible Professionals</b>	<b>31,810</b>	<b>51.0%</b>	<b>45,145</b>	<b>56.2%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	170	65.1%	220	63.2%
Audiologist	151	94.4%	211	96.8%
Certified Nurse Midwives	143	38.8%	181	34.6%
Chiropractor	16	61.5%	27	79.4%
Clinical Nurse Specialists	236	53.5%	389	59.8%
Counselor/Psychologist	395	75.1%	632	81.0%
Dentist	87	86.1%	105	79.5%
Dietitian/Nutritionist	169	85.4%	226	85.6%
Nurse Anesthetist	1,176	98.0%	1,499	99.6%
Nurse Practitioner	9,566	50.0%	15,098	55.8%
Optometry	2,119	34.9%	2,577	36.5%
Other Eligible Professional	7,000	56.9%	8,216	61.3%
Physical/Occupational Therapy	329	88.2%	571	90.8%
Physician Assistant	6,660	50.8%	10,280	56.8%
Podiatrist	3,133	43.0%	4,239	49.2%
Registered Nurse	230	51.2%	337	57.5%
Social Worker	230	64.8%	337	71.9%
Unknown/Missing	42	39.3%	85	46.4%
<b>Total (Unduplicated)</b>	<b>174,189</b>	<b>61.7%</b>	<b>227,447</b>	<b>66.0%</b>

Notes for Table A40: Results include eligible professionals who are part of a practice that participated under the GPRO.

**Table A41. Eligible Professional Characteristics for the eRx Incentive Program (2012)**

Eligible Professional (EP) Characteristics	Number of EPs	Number of EPs Participating	Participation Rate	Number of EPs who were Incentive Eligible	Incentive Eligibility Rate
Participation Mechanism/Option	--	--	--	--	--
Claims	731,199	292,367	40.0%	175,096	59.9%
Registry	731,199	11,033	1.5%	9,222	83.6%
EHR	731,199	7,858	1.1%	6,028	76.7%
Small GPRO	752	650	86.4%	650	100.0%
Large GPRO	46,953	46,088	98.2%	45,638	99.0%
Geography (Regions)	--	--	--	--	--
1 – Boston	56,926	22,398	39.3%	14,525	64.8%
2 - New York	91,941	32,286	35.1%	20,199	62.6%
3 – Philadelphia	80,356	36,199	45.0%	23,437	64.7%
4 – Atlanta	135,984	64,443	47.4%	41,958	65.1%
5 – Chicago	142,594	68,388	48.0%	45,648	66.7%
6 – Dallas	74,116	34,687	46.8%	23,229	67.0%
7 - Kansas City	34,771	17,024	49.0%	11,090	65.1%
8 – Denver	26,516	10,868	41.0%	6,998	64.4%
9 - San Francisco	88,277	31,562	35.8%	18,866	59.8%
10 - Seattle	31,665	13,230	41.8%	8,481	64.1%
Unknown	15,515	15,224	98.1%	14,301	93.9%
Practice Size (# of NPIs)	--	--	--	--	--
Individual Participants	--	--	--	--	--
1	162,133	43,746	27.0%	28,146	64.3%
2-4	105,186	45,322	43.1%	27,336	60.3%
5-10	88,695	39,369	44.4%	24,203	61.5%
11-24	78,752	33,192	42.1%	20,087	60.5%
25-50	61,288	25,996	42.4%	15,856	61.0%
51-99	57,489	28,730	50.0%	17,980	62.6%
100-199	58,542	29,358	50.1%	18,448	62.8%
200+	119,114	52,225	43.8%	29,103	55.7%
GPRO	--	--	--	--	--
1-24	22	22	100.0%	0	0.0%
25-50	70	70	100.0%	45	64.3%
51-99	452	452	100.0%	325	71.9%
100-199	508	406	79.9%	406	100.0%
200+	46,653	45,788	98.1%	45,512	99.4%
Beneficiary Volume	--	--	--	--	--
Individual Participants	--	--	--	--	--
1 – 25	229,089	19,596	8.6%	690	3.5%
26 – 100	164,642	55,029	33.4%	19,987	36.3%
101 – 200	120,287	65,085	54.1%	39,866	61.3%
> 200	216,224	157,399	72.8%	120,616	76.6%
Unknown	957	829	86.6%	0	0.0%

Eligible Professional (EP) Characteristics	Number of EPs	Number of EPs Participating	Participation Rate	Number of EPs who were Incentive Eligible	Incentive Eligibility Rate
<b>GPRO</b>	--	--	--	--	--
1 – 25	9,739	9,525	97.8%	9,403	98.7%
26 – 100	8,736	8,584	98.3%	8,464	98.6%
101 – 200	6,792	6,594	97.1%	6,533	99.1%
> 200	7,880	7,640	97.0%	7,587	99.3%
Unknown	14,558	14,395	98.9%	14,301	99.3%
<b>Specialty</b>	--	--	--	--	--
<b>MD/DO</b>	--	--	--	--	--
Primary Care	186,843	105,457	56.4%	80,385	76.2%
Surgery	63,628	22,679	35.6%	9,861	43.5%
Other Specialties	265,433	135,978	51.2%	91,971	67.6%
<b>Other eligible professionals</b>	--	--	--	--	--
Physicians	37,137	7,220	19.4%	2,709	37.5%
Physician Assistant	39,048	18,107	46.4%	10,280	56.8%
Nurse Practitioner	59,913	27,057	45.2%	15,098	55.8%
Podiatrists	18,026	8,609	47.8%	4,239	49.2%
Other Eligible Professionals	108,876	19,569	18.0%	12,904	65.9%
<b>Total (Unduplicated)</b>	<b>778,904</b>	<b>344,676</b>	<b>44.3%</b>	<b>227,447</b>	<b>66.0%</b>

*Notes for Table A41: (1) Eligible professional-level results in this table include eligible professionals who belong to a practice that participated under the GPRO. (2) Sums across participation methods do not equal totals due to participation in multiple methods. (3) Eligible Professionals in the Unknown categories include Registry and EHR data where a match in claims was not found.*

**Table A42. Eligible Professional Information for the eRx Incentive Program, by State (2012)**

State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received Incentive	Incentive Eligibility Rate
Alaska	1,789	424	23.7%	239	56.4%
Alabama	9,083	4,464	49.1%	2,894	64.8%
Arkansas	6,011	3,416	56.8%	2,589	75.8%
Arizona	13,953	5,783	41.4%	3,169	54.8%
California	67,113	23,573	35.1%	14,416	61.2%
Colorado	11,775	3,987	33.9%	2,168	54.4%
Connecticut	11,938	4,271	35.8%	2,586	60.5%
District of Columbia	2,694	1,177	43.7%	908	77.1%
Delaware	2,486	1,090	43.8%	738	67.7%
Florida	43,362	20,006	46.1%	12,756	63.8%
Georgia	18,655	8,926	47.8%	6,394	71.6%
Hawaii	2,804	885	31.6%	546	61.7%
Iowa	7,904	4,472	56.6%	3,530	78.9%
Idaho	3,611	1,342	37.2%	791	58.9%
Illinois	32,497	14,899	45.8%	10,183	68.3%
Indiana	15,957	7,301	45.8%	4,465	61.2%
Kansas	7,349	3,250	44.2%	2,006	61.7%
Kentucky	11,136	4,724	42.4%	2,930	62.0%
Louisiana	9,856	3,613	36.7%	2,086	57.7%
Massachusetts	29,028	11,663	40.2%	7,548	64.7%
Maryland	16,128	6,206	38.5%	3,924	63.2%
Maine	5,686	1,830	32.2%	1,031	56.3%
Michigan	30,774	15,065	49.0%	10,673	70.8%
Minnesota	19,492	9,944	51.0%	6,891	69.3%
Missouri	15,008	7,570	50.4%	4,827	63.8%
Mississippi	6,068	2,595	42.8%	1,731	66.7%
Montana	2,777	1,084	39.0%	724	66.8%
North Carolina	23,908	13,275	55.5%	9,063	68.3%
North Dakota	2,860	1,850	64.7%	1,552	83.9%
Nebraska	5,106	2,262	44.3%	1,294	57.2%
New Hampshire	5,316	3,056	57.5%	2,467	80.7%
New Jersey	23,752	9,411	39.6%	6,104	64.9%
New Mexico	4,843	2,396	49.5%	1,719	71.7%
Nevada	4,610	1,817	39.4%	1,054	58.0%
New York	64,093	23,518	36.7%	15,010	63.8%
Ohio	31,916	16,123	50.5%	11,255	69.8%
Oklahoma	8,059	3,937	48.9%	2,553	64.8%
Oregon	9,978	4,626	46.4%	3,083	66.6%
Pennsylvania	38,080	17,902	47.0%	11,490	64.2%
Puerto Rico	5,762	498	8.6%	165	33.1%
Rhode Island	3,640	1,309	36.0%	759	58.0%

State or Territory	Eligible Professionals	Eligible Professionals who Participated	Participation Rate	Eligible Professionals who Received Incentive	Incentive Eligibility Rate
South Carolina	9,362	4,704	50.2%	3,123	66.4%
South Dakota	2,731	1,438	52.7%	793	55.1%
Tennessee	16,335	7,143	43.7%	4,396	61.5%
Texas	45,713	22,934	50.2%	16,118	70.3%
Utah	5,906	2,783	47.1%	2,206	79.3%
Virginia	18,052	9,036	50.1%	6,275	69.4%
Virgin Islands	141	43	30.5%	24	55.8%
Vermont	2,337	1,131	48.4%	983	86.9%
Washington	17,305	7,531	43.5%	5,039	66.9%
Wisconsin	17,477	9,765	55.9%	6,632	67.9%
West Virginia	4,407	1,964	44.6%	1,179	60.0%
Wyoming	1,273	405	31.8%	239	59.0%
Other	223	76	34.1%	44	57.9%
Unknown/Missing	785	183	23.3%	85	46.4%
<b>Total (Unduplicated)</b>	<b>778,904</b>	<b>344,676</b>	<b>44.3%</b>	<b>227,447</b>	<b>66.0%</b>

*Notes for Table A42: Results include eligible professionals who were part of a practice that participated under the GPRO.*

**Table A43. Eligible Professionals who Successfully met Reporting Criteria but did not Receive an Incentive Because they did not have at Least 10% of their MPFS Charges from Instances for the eRx Measure (i.e., Incentive Eligibility Threshold) for the eRx Incentive Program (2011 to 2012)**

Specialty	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2011	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2011	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012
<b>MD/DO</b>	<b>1,787</b>	<b>0.4%</b>	<b>2,228</b>	<b>0.4%</b>
Allergy/Immunology	2	0.1%	3	0.1%
Anesthesiology	6	0.1%	7	0.1%
Cardiology	202	0.8%	188	0.8%
Colon/Rectal Surgery	4	0.3%	3	0.2%
Critical Care	12	0.8%	17	1.2%
Dermatology	265	2.4%	315	2.8%
Emergency Medicine	7	0.1%	17	0.2%
Endocrinology	1	0.0%	3	0.1%
Family Practice	115	0.1%	168	0.2%
Gastroenterology	106	0.8%	131	1.0%
General Practice	3	0.1%	3	0.1%
General Surgery	39	0.2%	64	0.3%
Geriatrics	5	0.1%	6	0.1%
Hand Surgery	0	0.0%	0	0.0%
Infectious Disease	59	1.2%	89	1.7%
Internal Medicine	186	0.2%	256	0.3%
Interventional Radiologist	1	0.1%	1	0.1%
Nephrology	377	4.8%	498	6.0%
Neurology	13	0.1%	26	0.2%
Neurosurgery	28	0.6%	24	0.5%
Nuclear Medicine	0	0.0%	3	1.0%
Obstetrics/Gynecology	2	0.0%	9	0.0%
Oncology/Hematology	5	0.0%	7	0.1%
Ophthalmology	37	0.2%	27	0.1%
Oral/Maxillofacial Surgery	0	0.0%	0	0.0%



Specialty	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2011	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2011	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012
Orthopaedic Surgery	34	0.2%	42	0.2%
Other MD/DO	22	0.3%	24	0.3%
Otolaryngology	4	0.0%	7	0.1%
Pathology	0	0.0%	0	0.0%
Pediatrics	16	0.2%	0	0.0%
Physical Medicine	23	0.3%	33	0.4%
Plastic Surgery	8	0.2%	9	0.2%
Psychiatry	14	0.0%	22	0.1%
Pulmonary Disease	87	1.0%	98	1.1%
Radiation Oncology	37	0.8%	46	0.9%
Radiologist	1	0.0%	5	0.1%
Rheumatology	5	0.1%	2	0.0%
Thoracic/Cardiac Surgery	24	0.7%	32	0.9%
Urology	5	0.1%	6	0.1%
Vascular Surgery	32	1.0%	37	1.2%
<b>Other Eligible Professionals</b>	<b>319</b>	<b>0.1%</b>	<b>392</b>	<b>0.1%</b>
Agencies/Hospitals/Nursing and Treatment Facilities	4	0.3%	2	0.2%
Audiologist	0	0.0%	1	0.2%
Certified Nurse Midwives	2	0.1%	0	0.0%
Chiropractor	0	0.0%	0	0.0%
Clinical Nurse Specialists	1	0.0%	1	0.0%
Counselor/Psychologist	0	0.0%	2	0.0%
Dentist	0	0.0%	0	0.0%
Dietitian/Nutritionist	0	0.0%	0	0.0%
Nurse Anesthetist	0	0.0%	0	0.0%
Nurse Practitioner	80	0.2%	118	0.2%
Optometry	1	0.0%	0	0.0%
Other Eligible Professional	107	0.3%	149	0.5%

Specialty	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2011	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2011	Number of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012	Percent of Successful Reporters (EPs) Not Meeting 10% Threshold in 2012
Physical/Occupational Therapy	1	0.2%	0	0.0%
Physician Assistant	91	0.3%	89	0.2%
Podiatrist	30	0.2%	26	0.1%
Registered Nurse	2	0.1%	4	0.2%
Social Worker	0	0.0%	0	0.0%
Unknown/Missing	3	0.4%	4	0.5%
<b>Total (Unduplicated)</b>	<b>2,109</b>	<b>0.3%</b>	<b>2,624</b>	<b>0.3%</b>

*Notes for Table A43: (1) Eligible professional-level results in this table do not include eligible professionals who participated within a GPRO. (2) Results included the claims, registry, and EHR mechanisms.*

**Table A44. Eligible Professionals Subject to the 2012 and 2013 eRx Payment Adjustment, by Specialty**

Specialty	Number of EPs Subject to Payment Adjustment in 2012	Percent of EPs Subject to Payment Adjustment in 2012	Number of EPs Subject to Payment Adjustment in 2013	Percent of EPs Subject to Payment Adjustment in 2013
<b>MD/DO</b>	<b>115,829</b>	<b>85.2%</b>	<b>48,165</b>	<b>80.3%</b>
Allergy/Immunology	800	0.6%	426	0.7%
Anesthesiology	1,314	1.0%	650	1.1%
Cardiology	5,917	4.4%	1,833	3.1%
Colon/Rectal Surgery	242	0.2%	100	0.2%
Critical Care	216	0.2%	84	0.1%
Dermatology	3,158	2.3%	1,627	2.7%
Emergency Medicine	1,319	1.0%	815	1.4%
Endocrinology	1,513	1.1%	557	0.9%
Family Practice	24,629	18.1%	9,218	15.4%
Gastroenterology	3,355	2.5%	1,156	1.9%
General Practice	1,762	1.3%	997	1.7%
General Surgery	3,304	2.4%	1,401	2.3%
Geriatrics	1,354	1.0%	590	1.0%
Hand Surgery	404	0.3%	159	0.3%
Infectious Disease	603	0.4%	267	0.4%
Internal Medicine	20,953	15.4%	7,980	13.3%
Interventional Radiologist	6	0.0%	5	0.0%
Nephrology	1,556	1.1%	494	0.8%
Neurology	2,936	2.2%	1,140	1.9%
Neurosurgery	798	0.6%	368	0.6%
Nuclear Medicine	33	0.0%	9	0.0%
Obstetrics/Gynecology	2,875	2.1%	1,410	2.4%
Oncology/Hematology	3,299	2.4%	1,325	2.2%
Ophthalmology	5,088	3.7%	1,879	3.1%
Oral/Maxillofacial Surgery	19	0.0%	8	0.0%
Orthopaedic Surgery	5,811	4.3%	2,428	4.0%
Other MD/DO	1,256	0.9%	605	1.0%
Otolaryngology	2,995	2.2%	1,214	2.0%
Pathology	45	0.0%	7	0.0%
Pediatrics	269	0.2%	103	0.2%
Physical Medicine	1,836	1.4%	880	1.5%
Plastic Surgery	410	0.3%	205	0.3%
Psychiatry	8,469	6.2%	5,559	9.3%
Pulmonary Disease	2,302	1.7%	812	1.4%
Radiation Oncology	282	0.2%	170	0.3%
Radiologist	104	0.1%	41	0.1%
Rheumatology	1,091	0.8%	400	0.7%

Specialty	Number of EPs Subject to Payment Adjustment in 2012	Percent of EPs Subject to Payment Adjustment in 2012	Number of EPs Subject to Payment Adjustment in 2013	Percent of EPs Subject to Payment Adjustment in 2013
Thoracic/Cardiac Surgery	221	0.2%	94	0.2%
Urology	2,648	1.9%	911	1.5%
Vascular Surgery	637	0.5%	238	0.4%
<b>Other Eligible Professionals<sup>a</sup></b>	<b>20,010</b>	<b>14.7%</b>	<b>11,665</b>	<b>19.5%</b>
Nurse Practitioner	9,087	6.7%	5,818	9.7%
Physician Assistant	4,566	3.4%	3,181	5.3%
Podiatrist	6,357	4.7%	2,666	4.4%
Other <sup>b</sup>	92	0.1%	125	0.2%
<b>Total (Unduplicated)</b>	<b>135,931</b>	<b>100.0%</b>	<b>59,955</b>	<b>100.0%</b>

<sup>a</sup> Table does not show the "Other Eligible Professionals" specialties that are not subject to the payment adjustment.

<sup>b</sup> "Other" includes eligible professionals who belong to a practice that participated under the GPRO. For these practices, there are no exemptions based on specialty, so these are the eligible professionals within those practices whose specialty is not MD/DO, Nurse Practitioner, Physician Assistant, or Podiatrist.

Notes for Table A44: Eligible professional-level results in this table include EPs who were part of a practice that participated under the GPRO. The April 2012 and September 2011 NPPES files were used to determine specialty, to be consistent with file used for payment adjustment.

**Table A45. GPRO Incentive Eligibility and Incentive Payments for the eRx Incentive Program, by GPRO Size (2012)**

GPRO	Number of TINs Participating	Number of TINs Qualifying For Incentive	Percent of Participating TINs who Qualify for Incentive	Minimum Incentive Amount	Median Incentive Amount	Mean Incentive Amount	Max Incentive Amount	Total Incentive Amount
Small GPRO	7	7	100.0%	\$47,266	\$63,929	\$80,243	\$124,584	\$561,703
Large GPRO	59	56	94.9%	\$18,746	\$321,652	\$383,443	\$1,395,974	\$21,472,790
<b>Total (Unduplicated)</b>	<b>66</b>	<b>63</b>	<b>95.5%</b>	<b>\$18,746</b>	<b>\$286,279</b>	<b>\$349,754</b>	<b>\$1,395,974</b>	<b>\$22,034,493</b>

## ABBREVIATIONS

**Table A46. Abbreviations**

Abbreviation	Meaning
ACO	Accountable Care Organization
CMS	Centers for Medicare & Medicaid Services
CSP	Communication Support Page
EHR	Electronic Health Record
eRx	Electronic Prescribing Program
EP	Eligible Professional
FFS	Fee for Service
GPRO	Group Practice Reporting Option
HCPCS	Healthcare Common Procedure Coding System
HCV	Hepatitis C Virus
HIC	Health Insurance Claim Number
HIV/AIDS	Human Immunodeficiency Virus / Acquired Immunodeficiency Syndrome
MAV	Measure Applicability Validation
MD/DO	Doctor of Medicine or Doctor of Osteopathy
MOCP	Maintenance of Certification Program
MPFS	Medicare Physician Fee Schedule
NPPES	National Plan and Provider Enumeration System
NPI	National Provider Identifier
PQRS	Physician Quality Reporting System
QDC	Quality Data Code
QRUR	Quality Resource Use Reports
RRB	Railroad Retirement Board
TIN	Taxpayer Identification Number